WO2008021388A1 - Dérivés hétéroaryles en tant qu'inhibiteurs des cytokines - Google Patents

Dérivés hétéroaryles en tant qu'inhibiteurs des cytokines Download PDF

Info

Publication number
WO2008021388A1
WO2008021388A1 PCT/US2007/018049 US2007018049W WO2008021388A1 WO 2008021388 A1 WO2008021388 A1 WO 2008021388A1 US 2007018049 W US2007018049 W US 2007018049W WO 2008021388 A1 WO2008021388 A1 WO 2008021388A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
compound
group
substituted
unsubstituted
Prior art date
Application number
PCT/US2007/018049
Other languages
English (en)
Inventor
Erik Boman
Justin Ernst
Antonio Garrido Montalban
Christopher Larson
Christopher Lum
Yazhong Pei
Lubomir Sebo
Jan Urban
Zhijun Wang
Jay Zhu
Original Assignee
Kemia, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kemia, Inc. filed Critical Kemia, Inc.
Publication of WO2008021388A1 publication Critical patent/WO2008021388A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18—Bridged systems

Definitions

  • the present invention relates to low molecular weight compounds and compositions thereof, useful as, e.g., cytokine inhibitors, and their preparation.
  • the present invention relates to methods of treating, preventing, modifying and managing a variety of conditions, including cytokine-mediated disorders or related disorders, which comprise the administration of a cytokine inhibitor, alone or in combination with known therapeutics.
  • the invention also relates to pharmaceutical compositions and dosing regimens using the disclosed compounds, optionally in conjunction with other therapies, for the treatment of a variety of conditions, including autoimmune diseases, inflammatory diseases, cardiovascular ⁇ diseases, cancer, and the like.
  • cytokines The functioning of the immune system is finely balanced by the activities of pro-inflammatory and anti-inflammatory mediators or cytokines.
  • Some cytokines promote inflammation and are called pro-inflammatory cytokines, whereas other cytokines suppress the activity of pro-inflammatory cytokines and are referred to as anti-inflammatory cytokines.
  • IL-4, IL-10, and IL- 13 are potent activators of B lymphocytes, but are also potent anti-inflammatory agents. They are anti-inflammatory cytokines by virtue of their ability to suppress genes for pro-inflammatory cytokines such as IL-I , TNF, and chemokines (CA. Dinarello, Chest. 2000, 118, 503).
  • autoimmune diseases arise when immune system cells (lymphocytes, macrophages) become sensitized against the "self. Lymphocytes as well as macrophages are usually under control in this system. However, a misdirection of the system toward the body's own tissues may happen in response to still unexplained triggers.
  • lymphocytes recognize an antigen which mimics the "self and a cascade of activation of different components of the immune system takes place, ultimately leading to tissue destruction. Genetic predisposition has also been postulated to be responsible for autoimmune disorders.
  • Tumor necrosis factor-or (TNF- a) and interleukin-1 (IL-I) are pro-inflammatory cytokines that mediate inflammatory responses associated with infectious agents and other cellular stresses.
  • Overproduction of cytokines such as IL-I and TNF- ⁇ is believed to underlie the progression of many inflammatory diseases including rheumatoid arthritis (RA), Crohn's disease, inflammatory bowel disease, multiple sclerosis, endotoxin shock, osteoporosis, Alzheimer's disease, congestive heart failure, and psoriasis among others (Dinarello, CA. et al., Rev. Infect. Diseases 1984, 6, 51; Salituro et al., Curr. Med.
  • RA rheumatoid arthritis
  • Crohn's disease inflammatory bowel disease
  • multiple sclerosis multiple sclerosis
  • endotoxin shock osteoporosis
  • Alzheimer's disease congestive heart failure
  • TNF- ⁇ pro-inflammatory cytokines
  • IL-Ib interleukin-1 ⁇
  • the present invention provides low molecular weight compounds and pharmaceutical compositions thereof.
  • compounds of the invention are useful for a variety of applications including, e.g., as cytokine release inhibitory agents.
  • methods for the preparation of such compounds and for the use of these compounds alone, in mixtures thereof, or in mixtures with other therapeutic agents, in the preparation of medicaments for use in treating various disease states are provided.
  • methods for the use of compounds of the invention in the prevention and treatment of various disorders mediated by cytokines such as inflammatory, cardiovascular, and autoimmune disorders, cancer, pain, and others.
  • a compound comprising: a targeting moiety, TM, comprising an amide NH and carbonyl, the targeting moiety capable of forming one or more hydrogen bonds with a target protein; a pocket-expanding moiety, PEM, directly attached to the carbonyl or the NH of the targeting moiety, the pocket-expanding moiety comprising a planar moiety attached to a bulky non-planar hydrophobic moiety, wherein the non-planar moiety is capable of forming hydrophobic interactions with a target protein; an orienting moiety, OM, comprising a 6-membered heteroaryl ring and attached to the NH or the carbonyl of the targeting moiety, wherein the orienting moiety is capable of forming hydrophobic interactions with a target protein; a linker moiety, L, attached to a different atom of the orienting moiety than the targeting moiety, wherein the linker moiety comprises a 6-
  • cytokine inhibitors have the structure PEM-TM-
  • the targeting moiety can hydrogen bond to residues at the binding site of the target protein.
  • the targeting moiety is an amide group.
  • the pocket-expanding moiety is of sufficient size to force a conformational change in the target protein, resulting in an expanded binding pocket therein.
  • Such moieties include 6-membered aryl and heteroaryl groups, for example, phenyl, pyridyl, or the like, substituted by bulky moieties.
  • Bulky moieties fill a large volume of space in comparison to, for example, a methyl group, and include groups such as substituted or unsubstituted C2-4 alkyl groups, for example substituted or unsubstituted isopropyl, tert-butyl, isobutyl, or sec-butyl groups; substituted or unsubsituted C 3 .
  • cycloalkyl groups for example substituted or unsubstituted cyclohexyl or norbornyl groups; or substituted or unsubstituted heterocyclyl groups, such as substituted or unsubstituted morpholinyl, pyrrolidinyl, piperidinyl, or thiomorpholinyl groups.
  • the orienting moiety by binding to a hydrophobic pocket on the target protein, provides the proper orientation of the targeting moiety and pocket-expanding moiety for binding of the cytokine inhibitor to its target protein.
  • Such moieties include, for example, pyridyl, pyridyl-N-oxide or pyridazinyl, substituted by small hydrophobic moieties, exemplified by halogens, methyl, trifluoromethyl, and the like.
  • the linker moiety, L comprises a phenyl, pyridyl, pyrimidyl, or pyridazinyl group, for example, L is a phenyl, 2-pyridyl, 3 -pyridyl or 4-pyridyl group.
  • the anchoring moiety is a hydrogen bond acceptor.
  • the anchoring bond moiety comprises both a hydrogen bond donor and acceptor.
  • the anchoring moiety may comprise an amide, amine, carbonyl, alkoxy, urethane, sulfoxide, sulfonamide, or OC(O) group, and may further comprise a substituted or unsubstituted methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, sec-butyl, isobutyl, neopentyl, phenyl, benzyl, phenethyl, 2-pyridyl, (CH 2 )-2-pyridyl, (CH 2 )2-2-pyridyl, (CH 2 ) 3 -2-pyridyl, 3-pyridyl, (CH 2 )-3 -pyridyl, (CH
  • the invention provides for compounds of Formula I:
  • X is CH 3 N, or NO
  • Y is CH, N, or NO, provided that X and Y are not both CH or NO;
  • A is F, Cl, Br, I, NR 2 , or a C 1 . 3 alkyl or -0(C 1-3 alkyl) group, wherein the alkyl group is optionally partially or fully halogenated;
  • G is an aryl or heteroaryl group, wherein G is substituted by one or more R 1 , R 2 or R 3 ;
  • Ar is a 6-membered aryl or heteroaryl group
  • L 1 is -C(O)NH-
  • L 2 is a covalent bond, (CR' 2 ) S , (CR' 2 ) n O(CR' 2 ) t , (CR' 2 ) n NR(CR' 2 ) t , (CR' 2 ) n C(NOR), (CR' 2 ) n SO 2 NR(CR' 2 )t, (CR' 2 ) n C(O)(CR' 2 ) t , O(CR' 2 ) t C(O)(CR' 2 ) n , O(CR' 2 )sNR(CR' 2 ) n , O(CR' 2 )nC(O)NR(CR' 2 )t, O(CR' 2 ) s NRC(O)(CR' 2 )n, (CR' 2 ) n C(O)NR(CR' 2 ) t , (CR' 2 ) n C(O)NRNR(CR' 2 ) t , or (CR' 2 ) n NRC
  • Q is a substituted or unsubstituted alkyl, cycloalkyl, aryl, heterocyclyl, cycloalkylalkyl, aralkyl, or heterocyclylalkyl group; each R 1 is independently F, Cl, Br, I, -NR 2 , -CN, or a substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heterocyclyl, or heterocyclylalkyl group; each R 2 is independently F, Cl, Br, I, -CN, -NO 2 , a substituted or unsubstituted alkyl or heterocyclylalkyl group, -OR', -C(O)R', -C(O)OR', -C(O)NR' 2 , -C(NR)NR 2 , -C(NR)NROR, -NR' 2 , -(CR
  • Ax is phenyl, pyridyl, pyrimidyl, or pyridazinyl.
  • Ar is phenyl, 2-pyridyl, 3-pyridyl or 4-pyridyl.
  • the compound of Formula I is N-AX [0017] In some embodiments, the compound of Formula I is N-AX [0017] In some embodiments, the compound of Formula I is N-AX [0017] In some embodiments, the compound of Formula I is N-AX [0017] In some embodiments, the compound of Formula I is N-AX [0017] In some embodiments, the compound of Formula I is N-AX [0017] In some embodiments, the compound of Formula I is N-AX
  • the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • A is F, -CH 3 , or -CF 3 .
  • G is a phenyl, pyrimidyl, pyridyl, oxazolyl, isoxazolyl, pyrazolyl, or furanyl group.
  • G is
  • L 2 is a covalent bond
  • L 2 is a covalent bond, O, OC(O), C(NOH), SO 2 NH 3 OCH 2 C(O), C(O), C(O)CH 2 , C(O)CH 2 CH 2 , C(O)NHNH, or C(O)NH.
  • Q is a substituted or unsubstituted alkyl, cycloalkyl, (C 0 - 4 alkyl)phenyl, (C0-4 alkyl)pyridyl, (Co-4 alkyl)pyrimidinyl, (C0-4 alkyl)mo ⁇ holinyl, (Co -4 alkyl)thiomorpholinyl, (Co-4 alkyl)quinuclidinyl, (Q M alkyl)(10-oxa-4-aza-tricycIo[5.2.1.0 2 ' 6 ]decanyl), (Co-4 alkyI)(8-oxa-3-aza-bicyclo[3.2.1]octanyl), (C 0-4 alkyl)tetrahydropyranyl, (Co- 4 alkyl)tetrahydrofuranyl, (C 0 - 4 alkyl)pyrrolidinyl, (Co -4 alkyl)pipe
  • Q is a substituted or unsubstituted methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, sec-butyl, isobutyl, neopentyl, cyclopropyl, (CH 2 )-cyclopropyl, (CHbVcyclopropyl, (CH2) 3 -cyclopropyl, cyclobutyl, (CH 2 )-cyclobutyl, (CH 2 ) 2 -cyclobutyl, (CH 2 ) 2 -cyclobutyl, (CH 2 ) 3 -cyclobutyl, cyclopentyl, (CH 2 )-cyclopentyl, (CH 2 ) 2 -cyclopentyl, (CH2) 3 -cyclopentyl, cyclohexyl, (CH2)-cyclohexyl, (CH2)-cyclohexyl, (CH 2 )2-cycl
  • R 1 is F, -CN, -NR 2 , or a substituted or unsubstituted Ci -4 alkyl, C 3 - 9 cycloalkyl, heterocyclyl or heterocyclylalkyl group.
  • R 1 is F, -CN, -N(Ci O alkyl) 2 wherein each Ci -3 alkyl group is independently substituted or unsubstituted; or R 1 is a substituted or unsubstituted methyl, isopropyl, tert-butyl, isobutyl, sec-butyl, neopentyl, cyclohexyl, pyrrolidinyl, imidazolyl, pyrazolyl, triazolyl, oxodiazolyl, isoxazolyl, 2,3-dihydroisoxazolyl, piperidinyl, piperazinyl, oxazepanyl, morpholinyl, thiomorpholinyl, (CH 2 )-pyrrolidinyl, (CH 2 )-piperidinyl, (CH 2 )-oxazepanyl, (CH 2 )-morpholinyl > or (CH 2 )-pi ⁇
  • R 2 is a substituted or unsubstituted (Ci-6 alkyl) or heterocyclylalkyl group, F, Cl, -CN, -NO 2 , -OR', -C(O)OR', -C(O)NR' 2 , -(CH 2 ) t NRR", -C(NR)NR 2 , -C(NR)NROR, -NRC(O)R", -NRC(O)OR", -NR'SO 2 R", -NR'C(O)NR * 2 , or -SO 2 NR' 2 .
  • R 2 is F, -CN, -CF 3 , -NO 2 , -0(C -6 alkyl), -C(O)O(Ci -6 alkyl), -C(O)NH 2 , -C(O)NH(Cu 6 alkyl), -C(O)NH(C 3 .
  • R 3 is a substituted or unsubstituted Ci -4 alkyl or
  • -O(Ci- 4 alkyl) group or is a.partially or fully halogenated -O(Ci_ 2 alkyl) group.
  • G is phenyl and R 1 is F, Cl,
  • R 1 is a substituted or unsubstituted morpholinyl, thiomorpholinyl, pyrrolidinyl, imidazolyl, pyrazolyl, triazolyl, oxodiazolyl, isoxazolyl, 2,3-dihydroisoxazolyl, piperidinyl, piperazinyl, oxazepanyl, (CH 2 )-pyrrolidinyl, (CH 2 )-piperidinyl, (CH 2 )-oxazepanyl, (CH 2 )-morpholinyl, (CH 2 )-piperazinyl, methyl, isopropyl, tert-butyl, iso-butyl, sec-butyl, neopentyl, or cyclohexyl group.
  • R 1 is F, Cl, a substituted or unsubstituted morpholinyl, pyrrolidinyl, imidazolyl, pyrazolyl, triazolyl, oxodiazolyl, isoxazolyl, 2,3-dihydroisoxazolyl, piperidinyl, (CH 2 )-pyrrolidinyl, (CH 2 )- piperidinyl, (CH 2 )-morpholinyl, (CH 2 )-piperazinyl, methyl, tert-butyl, or cyclohexyl group.
  • R 2 is F, -CN, -CF 3 , -NO 2 , -0(Ci -6 alkyl), -C(O)O(Ci -6 alkyl), -C(O)NH 2 , -C(O)NH(Ci -6 alkyl), -C(O)NH(C 3-6 cycloalkyl), -C(0)NH(cycloalkylalkyl), -C(O)NH(aralkyl), -NHC(O)(Ci -6 alkyl), -NHC(O)(C 3-6 cycloalkyl), -NHC(O)(cycloalkylalkyl),-NHC(O)(aryl), -NHC(O)(aralkyl), -(CH 2 )NH(Ci -6 alkyl), -(CH 2 )NH(aralkyl), -(CH 2 )NH(heterocyclylalkyl), -NHSO 2 (C) (
  • each Ci- ⁇ alkyl, C 3 - 6 cycloalkyl, cycloalkylalkyl aryl, and aralkyl group is substituted or unsubstituted.
  • F F, -CN, -CF 3 , -C(O)NH 2 , -C(O)NH(C 1-6 alkyl), -C(O)NH(C 3-6 cycloalkyl), -C(O)NH(cycloalkylalkyl), -(CH 2 )NH(C 1-6 alkyl), -(CH 2 )NH(heterocyclylalkyl), -NHSO 2 (C 1-6 alkyl), or -S ⁇ 2 NH(Ci. 6 alkyl), wherein each Ci_ ⁇ alkyl group is substituted or unsubstituted.
  • R 3 is a substituted or unsubstituted Cj -4 alkyl or -0(Ci -4 alkyl) group, or is a partially or folly halogenated -O(Ci-2 alkyl) group.
  • L 2 is O, OC(O), C(O),
  • G is a phenyl group.
  • the compound at a concentration of 10 ⁇ M inhibits induced TNFa-release from a cell by about 50% or greater than 50%.
  • Table 1 sets forth various combinations of substituents of Formula I as described herein.
  • combination 1025 describes those embodiments in which Ar is 2- ⁇ yridyl and G is phenyl.
  • Table 1 Exemplary combinations of G and Ar for Formula I.
  • Table 2 sets forth various combinations of substituents L and Q of Formula I.
  • combination 4311 describes those embodiments in which L is C(O) and Q is morpholinyl.
  • a combination of substituents is permissible only if such a combination results in a chemically stable compound, and that any combination from Table 1 , describing Ar and G, may be combined with any combination from Table 2, describing L 2 and Q.
  • combination 1025 from Table 1 and combination 4311 from Table 2 describe those embodiments of Formula I in which Ar is 2-pyridyl, G is phenyl, L 2 is C(O) and Q is morpholinyl.
  • Each G and Q in the tables is understood to be optionally substituted as described herein.
  • each value of A (-F, Cl, Br, I, NR 2 , or C ]-3 alkyl or — O(C 1-3 )alkyl group) may be combined with any combination from Table 1 or Table 2 or any pair of combinations from the two tables.
  • combination 4311 describes those embodiments in which A is -F, L 2 is C(O) and Q is morpholinyl, as well as those where A is -CH3, L 2 is C(O) and Q is morpholinyl, etc.
  • X is CH 5 N, or NO
  • Y is CH 5 N 5 or NO, provided that X and Y are not both CH or NO;
  • A is F 5 Cl 5 Br, I, NR 2 , or a Cj -3 alkyl or -O(Ci_ 3 alkyl) group, wherein the alkyl group is optionally partially or fully halogenated;
  • B and D are each independently CR or N;
  • G is an aryl or heteroaryl group, wherein G is substituted by one or more R 1 , R 2 or R 3 ;
  • L 1 is -C(O)NH-
  • L 2 is a covalent bond, CR' 2 O, (CR' 2 ) m C(O)(CR'2) «, (CR' 2 ) m C(O)NR(CR' 2 )t, (CR' 2 ) m C(O)NRNR(CR' 2 ) t , (CR' 2 ) m C(NOR) (CR' 2 ) t , or (CR' 2 ) m NRC(O)O(CR' 2 ) t group;
  • Q is a substituted or unsubstituted alkyl, cycloalkyl, aryl, heterocyclyl, cycloalkylalkyl, aralkyl, or heterocyclylalkyl group; each R 1 is independently F, Cl, Br, I, -NR 2 , -CN, or a substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heterocyclyl, or heterocyclylalkyl group; each R 2 is independently F, Cl, Br, I, -CN, -NO 2 , a substituted or unsubstituted alkyl or heterocyclylalkyl group, -OR', -C(O)R', -C(O)OR', -C(O)NR' 2 , -NR' 2 , -(CR' 2 ) t NRR', -NRC(O)R",
  • the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • B is N.
  • D is N.
  • A is F, -CH 3 , or -CF 3 .
  • G is a phenyl, pyrimidyl or pyridyl group. In others, G is
  • L 2 is a covalent bond, C(O), CH 2 O 3 C(O)NHNH,
  • Q is a substituted or unsubstituted alkyl, cycloalkyl, 10- oxa-4-aza-tricyclo[5.2.1.0 2>6 ]decanyl, 8-oxa-3-aza-bicyclo[3.2.1 ]octanyl, (Co ⁇ alkyl)cycloalkyl, (Co -4 alkyl)phenyl, (C 0-4 alkyl)pyridyl, (C 0 ⁇ alkyl)pyrimidinyl,
  • Q is a substituted or unsubstituted methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, sec-butyl, isobutyl, neopentyl, cyclopropyl, (CH 2 )-cyclopropyl, (CH 2 ) 2 -cyclopropyl, (CH 2 ) 3 -cyclopropyl, cyclobutyl, (CH 2 )-cyclobutyl, (CH 2 ) 2 -cyclobutyl, (CH 2 ) 3 -cyclobutyl, cyclopentyl, (CH2)-cyclopentyl, (CH 2 ) 2 -cyclopentyl, (CH 2 ) 3 -cyclopentyl, cyclohexyl, (CH 2 )
  • R 1 is F, -CN, -NR 2 , or a substituted or unsubstituted Cj -4 alkyl, C 3 .. 9 cycloalkyl, heterocyclyl, or heterocyclylalkyl group.
  • R 1 is F 5 -CN, -N(Ci -3 alkyl) 2 wherein each C1.
  • R 1 is a substituted or unsubstituted methyl, isopropyl, tert-butyl, isobutyl, sec-butyl, neopentyl, cyclohexyl, pyrrolidinyl, imidazolyl, pyrazolyl, triazolyl, oxodiazolyl, isoxazolyl, 2,3-dihydroisoxazolyl, piperidinyl, piperazinyl, oxazepanyl, morpholinyl, thiomorpholinyl, (CH 2 )-pyrrolidinyl, (CH 2 )-piperidinyl, (CH 2 )- oxazepanyl, (CH 2 )-morpholinyl, or (CH 2 )-piperazinyl group.
  • R 2 is a substituted or unsubstituted (Ci- ⁇ alkyl) or heterocyclylalkyl group, F, Cl 5 -CN, -NO 2 , -OR', -C(O)OR', -C(O)NR" 2 , -(CH 2 ) t NRR", - NRC(O)R', -NRC(O)OR", -NR'SO 2 R", -NR'C(O)NR' 2 , or -SO 2 NR' 2 .
  • R 2 is F, -CN, -CF 3 , -NO 2 , -O(C,.6 alkyl), -C(O)O(C 1-6 alkyl), -C(O)NH 2 , -C(O)NH(C 6 alkyl), -C(O)NH(C 3-6 cycloalkyl), -C(0)NH(cycloalkylalkyl), -C(O)NH(aralkyl), -(CH 2 )NH(C 6 alkyl), -(CH 2 )NH(aralkyl), -(CH 2 )NH(heterocyclylalkyl), -NHC(O)(C L6 alkyl), -NHC(O)(C 3-6 cycloalkyl), -NHC(O)(cycloalkylalkyl), -NHC(O)(aryl), -NHC(O)(aralkyl), -NHSO 2 (C 1-6 alkyl),
  • R 3 is a substituted or unsubstituted Ci ⁇ alkyl or -
  • O(C]- 4 alkyl) group or is a partially or fully halogenated -O(Ci-2 alkyl) group.
  • G is phenyl and R 1 is F, Cl, -CN, -N(Ci -3 alkyl) 2 wherein each Cu 3 alkyl group is independently substituted or unsubstituted; or R 1 a substituted or unsubstituted morpholinyl, thiomorpholinyl, pyrrolidinyl, imidazolyl, pyrazolyl, triazolyl, oxodiazolyl, isoxazolyl, 2,3-dihydroisoxazolyl, piperidinyl, piperazinyl, oxazepanyl, (CH 2 )-pyrrolidinyl, (CH 2 )-piperidinyl, (CH 2 )-oxazepanyl, (CH 2 )-morpholinyl, (CH 2 )-piperazinyl, methyl, isopropyl, tert-butyl, iso-butyl, sec-
  • R 1 is F, Cl, a substituted or unsubstituted morpholinyl, pyrrolidinyl, imidazolyl, pyrazolyl, triazolyl, oxodiazolyl, isoxazolyl, 2,3-dihydroisoxazolyl, piperidinyl, (CH 2 )-pyrrolidinyl, (CH 2 )-piperidinyl, (CH 2 )-morpholinyl, (CH 2 )-piperazinyl, methyl, tert- butyl, or cyclohexyl group.
  • R 2 is F, -CN, -CF 3 , -NO 2 , -0(Ci -6 alkyl), -C(O)O(Ci -6 alkyl), -C(O)NH 2 , -C(O)NH(Ci -6 alkyl), -C(O)NH(C 3-6 cycloalkyl), -C(O)NH(cycloalkylalkyl), -C(O)NH(aralkyl), -NHC(O)(C 1-6 alkyl), -NHC(O)(C 3-6 cycloalkyl), -NHC(O)(cycloalkylalkyl), -NHC(O)(aryl), -NHC(O)(aralkyl), -(CH 2 )NH(Ci -6 alkyl), -(CH 2 )NH(aralkyl), -(CH 2 )NH(heterocyclylalkyl), -NHSO 2
  • R 2 is F, -CN, -CF 3 , -C(O)NH 2 , -C(O)NH(Ci -6 alkyl), -C(O)NH(C 3-6 cycloalkyl), -C(O)NH(cycloalkylalkyl), -(CH 2 )NH(Ci -6 alkyl), -(CH 2 )NH(heterocyclylalkyl), -NHSO 2 (Ci -6 alkyl), or -SO 2 NH(Cj -6 alkyl), wherein each Ci -6 alkyl group is substituted or unsubstituted.
  • R 3 is a substituted or unsubstituted C] -4 alkyl or -0(C M alkyl) group, or is a partially or fully halogenated -Q(Ci -2 alkyl) group.
  • L 2 is a bond, CH 2 O, C(O),
  • B and D are N. In some other such embodiments,
  • G is a. phenyl group.
  • the compound at a concentration of 10 ⁇ M inhibits induced TNFa-release from a cell by about 50% or greater than 50%.
  • Table 3 sets forth various combinations of G and the B, D-containing ring of Formula II as described herein, while Table 4 describes various combinations of L 2 and Q. [0051 ] Table 3: Exemplary combinations of G and the B, D-containing ring for
  • Formula IHA with (i) G-COOH in the presence of a coupling agent and a base; or with (ii) G-CO-Z in the presence of abase, wherein said contacting occurs under conditions suitable to provide a compound of Formula I, wherein A, X, Y, R 3 L 2 , Q and G are as defined in Formula I, and Z is an activating moiety, which may be displaced by, e.g., an amine.
  • Formula IHC with G-NH 2 in the presence of a base wherein said contacting occurs under conditions suitable to provide a compound of Formula I, wherein A 5 X, Y, R, L 2 , Q and G are as defined in Formula I, and Z is an activating moiety, which may be displaced by, e.g., an amine.
  • Formula IVA with (i) G-COOH in the presence of a coupling agent and a base; or with (ii) G-CO-Z in the presence of a base; wherein said contacting occurs under conditions suitable to provide a compound of Formula II; wherein A, B, D, X, Y, R, L 2 , Q and G are as defined in Formula II, and Z is an activating moiety, which may be displaced by, e.g., an amine.
  • Formula IVC with G-NH 2 in the presence of a base wherein said contacting occurs under conditions suitable to provide a compound of Formula II; wherein A, B, D, X, Y, R, L 2 , Q and G are as defined in Formula II, and Z is an activating moiety, which may be displaced by, e.g., an amine.
  • Typical coupling agents include DCC, EDC, CDI, BOP, PyBOP, HATU,
  • the activating moiety is typically F, Cl, Br, I, N 3 , N-hydroxysuccinirnido, 1 -hydroxybenzotriazole, 1 -hydroxy-7- azabenzotriazole, pentafluorophenoxy, pentachlorophenoxy, para-nitrophenoxy, or -OC(O)-OR y , wherein R y is a substituted or unsubstituted C ⁇ alkyl group.
  • Suitable bases include sodium bicarbonate or a suitable organoamine, such as pyridine, N-methylmorpholine, diisopropylethylamine or triethylamine.
  • Ar' is a phenyl, triazolyl, pyrrolyl, or imidazolyl group.
  • the reaction is typically carried out in the presence of ammonium acetate, in for example EtOH/H 2 O solvent mixtures, and typically at temperatures between about 5O 0 C and about 8O 0 C.
  • ammonium acetate in for example EtOH/H 2 O solvent mixtures, and typically at temperatures between about 5O 0 C and about 8O 0 C.
  • Formula VII 5 wherein Hal is Cl, Br, or I; T is O or (CBb) n ; Rm is H or a substituted or unsubstituted alkyl, aralkyl or heterocyclalkyl group; and n is 0, 1 or 2.
  • T is O or (CH 2 ) n ;
  • U is F, Cl, Br, CN, -SO 2 NR' 2 , -C(O)NR' 2j or -NR'SO 2 R";
  • V is -0(C 1-6 alkyl);
  • T is an (C 2-6 )alkyl or cycloalkyl group, optionally partially or fully halogenated;
  • U is -CN, -SO 2 NR' 2 , or -NR'SO 2 R"; each R' is independently hydrogen, or a substituted or unsubstituted alkyl, aralkyl, heterocyclyl, or heterocyclylalkyl group; and each R" is independently a substituted or unsubstituted alkyl, aryl, heterocyclyl, aralkyl or heterocyclylalkyl group; and P N is H or an amine protecting group.
  • compositions comprising a compound as described herein and a pharmaceutically acceptable carrier.
  • the invention provides methods of treating disorders mediated by cytokines, including but not limited to inflammatory disorders, autoimmune disorders, cardiovascular disorders, cancer and pain.
  • the methods include administering to a subject in need of such treatment a therapeutically effective amount of a compound as described herein.
  • the cytokine-mediated disorder is a p38 MAPK-mediated disorder.
  • the cytokine is selected from TNFa, IL-I, IL-6, IL-8, GM-CSF, and IFN-gamma, or a combination of any two or more thereof.
  • the cytokine is TNFa or IL-I .
  • the method further includes administration of additional therapeutic ingredients (hereafter referred to as ingredient A), as described herein.
  • Cytokine-mediated disorders include rheumatoid arthritis, osteoarthritis,
  • cytokine-mediated disorders are stroke, chronic heart failure, endotoxemia, reperfusion injury, ischemia reperfusion, myocardial ischemia, restenosis, thrombosis, angiogenesis, coronary heart disease, coronary artery disease, acute coronary syndrome, Takayasu arteritis, cardiac failure such as heart failure, cardiomyopathy, myocarditis, vasculitis, vascular restenosis, valvular disease or coronary artery bypass; hypercholesteremia, diseases or conditions related to blood coagulation or fibrinolysis, such as for example, acute venous thrombosis, pulmonary embolism, thrombosis during pregancy, hemorrhagic skin necrosis, acute or chronic disseminated intravascular coagulation (DIC), clot formation from surgery, long bed rest or long periods of immobilization, venous thrombosis, fulminant meningococcemia, acute thrombotic strokes, acute coronary o
  • cytokine mediated disorders are allergic conjunctivitis, uveitis, glaucoma, optic neuritis, retinal ischemia, diabetic retinopathy, laser induced optic damage, or surgery or trauma-induced proliferative vitreoretinopathy.
  • Cytokine-mediated disorders further include allergic rhinitis, asthma, adult respiratory distress syndrome, chronic pulmonary inflammation, chronic obstructive pulmonary disease, obliterative bronchiolitis, emphysema, bronchitis, mucus hypersecretion, silicosis, SARS infection and respiratory tract inflammation.
  • cytokine-mediated disorders are Guillain-Barre syndrome, Parkinson's disease, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis and other demyelinating diseases, viral and bacterial meningitis, CNS trauma, spinal cord injury, seizures, convulsions, olivopontocerebellar atrophy, AIDS dementia complex, MERRF and MELAS syndromes, Leber's disease, Wernicke's encephalopathy, Rett syndrome, homocysteinuria, hyperprolinemia, hyperhomocysteinemia, nonketotic hyperglycinemia, hydroxybutyric aminoaciduria, sulfite oxidase deficiency, combined systems disease, lead encephalopathy, Tourett's syndrome, hepatic encephalopathy,
  • the cytokine-mediated disorders include bone resorption diseases such as osteopetrosis, osteoporosis, or osteoarthritis. Also included are diabetes, systemic cachexia, cachexia secondary to infection or malignancy, cachexia secondary to acquired immune deficiency syndrome (AIDS), obesity, anorexia or bulimia nervosa.
  • bone resorption diseases such as osteopetrosis, osteoporosis, or osteoarthritis.
  • diabetes systemic cachexia, cachexia secondary to infection or malignancy, cachexia secondary to acquired immune deficiency syndrome (AIDS), obesity, anorexia or bulimia nervosa.
  • the cytokine-mediated disease can be sepsis, HIV infection, HCV infection, malaria, infectious arthritis, leishmaniasis, Lyme disease, cancer, including but not limited to breast cancer, colon cancer, lung cancer, prostatic cancer, multiple myeloma, acute myelogenous leukemia, myelodysplastic syndrome, non-Hodgkins lymphoma, osteosarcoma or follicular lymphoma, Castleman's disease, or drug resistance.
  • the cytokine-mediated disorder is rheumatoid arthritis, osteoarthritis, Crohn's Disease, ulcerative colitis, inflammatory bowel disease, diabetes, psoriatic arthritis, psoriasis, pemphigus, chronic obstructive pulmonary disease, pain, atherosclerosis, ischemia reperfusion, restenosis, acute coronary syndrome, heart failure, multiple myeloma, follicular lymphoma or osteosarcoma.
  • the cytokine mediated disorder is a neutrophil-mediated disorder, such as, for example, bronchial asthma, rhinitis, influenza, stroke, myocardial infarction, thermal injury, adult respiratory distress syndrome (ARDS), multiple organ injury secondary to trauma, acute glomerulonephritis, dermatoses with acute inflammatory components, acute purulent meningitis, hemodialysis, leukopheresis, granulocyte transfusion associated syndromes, or necrotizing enterocolitis.
  • ARDS adult respiratory distress syndrome
  • the disorder is or results from abnormal bleeding, an abscess, actinic reticuloid syndrome, acute confusional migraine, acute . confusional senile dementia, acute hepatocellular injury, acute tubular necrosis, adenohypophyseal diseases, adenovirus infections, adhesions, adhesive capsulitis, adnexitis, agammaglobulinemia, allergy, alopecia, fibrosing alveolitis, amyloidosis, angioplasty, angor pectoris, antiphospholipid syndrome, arteriosclerotic dementia, arteritis temporal, arthropod- borne encephalitis, asphyxia, atopic hypersensitivity, atrial fibrillation, beaver fever, biliary cirrhosis, bone loss, bronchiolitis, cancer of endocrine gland, cancer of larynx, candidiasis, small cell lung carcinoma, cardiac hypertrophy, cardiac surgery, cardio
  • a cytokine inhibitor in another aspect of the invention, there are provided methods of reducing levels of a cytokine in a subject.
  • the methods comprise administering to a subject, such as a subject in need thereof, an amount of a compound, such as a cytokine inhibitor, effective to reduce a level of a cytokine relative to the level prior to administration of the compound, wherein the compound is as described herein, or a stereoisomer, tautomer, solvate, prodrug, or pharmaceutically acceptable salt thereof.
  • the reduction in cytokine levels is at least 10%, at least 30%, at least 50%, at least 70%, or at least 90%.
  • the subject suffers from, or is at risk for a cytokine-mediated disorder, as described herein.
  • the cytokine is selected from TNFa, IL-I, IL-6, IL- 8, GM-CSF, IFN-gamma, or a combination of any two or more thereof.
  • the cytokine is TNFa or IL-I .
  • the cytokine level is measured in the subject or samples from the subject, e.g., tissue or bodily fluids such as the subject's blood.
  • cytokine level is measured in the subject's synovium.
  • the cytokine level is measured in the subject's skin.
  • the method further includes administration of additional therapeutic ingredient(s) (hereafter referred to as ingredient(s) A), as described herein.
  • a cytokine released from a cell in response to a pro-inflammatory stimulus comprise exposing a cell to an amount of a compound, such as a cytokine inhibitor, effective to reduce the level of cytokine released from the cell in response to a proinflammatory stimulus relative to the level of released cytokine prior to contacting the cell with the compound, wherein the compound is as described herein, or a stereoisomer, tautomer, solvate, prodrug, or pharmaceutically acceptable salt thereof.
  • the reduction in cytokine levels is at least 10%, at least 30%, at least 50%, at least 70%, or at least 90%.
  • the pro-inflammatory stimulus results from the presence of TNFa, IL-I, IL-6, IL-8, GM-CSF, EFN-gamma, LPS, or a combination of any two or more thereof.
  • the cytokine level is the level of TNFa, IL-I, IL-6, IL-8, GM-CSF, IFN-gamma, or a combination of any two or more thereof.
  • the method further includes exposing the cell to additional therapeutic ingredient(s) (hereafter referred to as ingredient(s) A), as described herein.
  • methods of inhibiting - p38 activity comprise contacting p38 with an amount of a compound, such as a cytokine inhibitor, effective to inhibit p38 activity, the phosphorylation of p38, or both, wherein the compound is as described herein, or a stereoisomer, tautomer, solvate, prodrug, or pharmaceutically acceptable salt thereof.
  • a compound such as a cytokine inhibitor
  • the inhibition of p38 activity or phosphorylation of p38 is at least 10%, at least 30%, at least 50%, at least 70%, or at least 90%.
  • the p38 may be isolated such as in a cell-free in vitro system, a cellular preparation or it may be in a cell.
  • the p38 is in a subject.
  • the subject suffers from, or is at risk for, a cytokine-mediated disorder as described herein.
  • the method further includes administration of additional therapeutic ingredients (hereafter referred to as ingredient(s) A) to the subject, as described herein.
  • additional therapeutic ingredients hereafter referred to as ingredient(s) A
  • the methods comprise administering to a subject, such as a subject in need thereof, an amount of a compound, such as a cytokine inhibitor, effective to reduce the activity of a pro-inflammatory mediator relative to the activity prior to the administration of the compound, wherein the compound is as described herein, or a stereoisomer, tautomer, solvate, prodrug, or pharmaceutically acceptable salt thereof.
  • a compound such as a cytokine inhibitor
  • the reduction in pro-inflammatory mediator activity is at least 10%, at least 30%, at least 50%, at least 70%, or at least 90%.
  • the subject suffers from or is at risk for a cytokine-mediated disorder as described herein.
  • the reduction in activity results from a decrease in circulating levels of a proinflammatory mediator relative to the circulating levels prior to administration of the compound.
  • the decrease in circulating pro-inflammatory mediator level is at least 10%, at least 30%, at least 50%, at least 70%, or at least 90%.
  • the pro-inflammatory mediator is a prostaglandin or a leukotriene, or a combination of two ⁇ r more thereof.
  • the reduction in activity results from an inhibition of the production of a pro-inflammatory mediator.
  • the inhibition of pro-inflammatory mediator production is at least 10%, at least 30%, at least 50%, at least 70%, or at least 90%.
  • the proinflammatory mediator is a prostaglandin, leukotriene, COX-2, NO-synthase, or a combination of any two or more thereof.
  • the method further includes administration of additional therapeutic ingredients (hereafter referred to as ingredient(s) A), as described herein.
  • methods of reducing the circulating levels of C-Reactive Protein or Rheumatoid Factor, or both comprise administering to a subject, such as a subject in need thereof, an amount of a compound, such as a cytokine inhibitor, effective to reduce the circulating levels of C- Reactive Protein or Rheumatoid Factor, or both, in the subject's blood relative to the level prior to the administration of the compound, wherein the compound is as described herein, or a stereoisomer, tautomer, solvate, prodrug, or pharmaceutically acceptable salt thereof.
  • the circulating C-Reactive Protein levels before administration are higher than about 2.87 mg/1.
  • the reduction in circulating level is at least 10%, at least 30%, at least 50%, at least 70%, or at least 90%.
  • the subject suffers from, or is at risk for a cytokine-mediated disorder as described herein.
  • the method further includes administration of additional therapeutic ingredients (hereafter referred to as ingredient(s) A), as described herein, for example, the method further includes administration of methotrexate.
  • the methods comprise administering to a subject exhibiting one or more indicia of rheumatoid arthritis, an amount of a compound, such as a cytokine inhibitor, effective to reduce at least one of the indicia to a level below that which exists prior to the administration of the compound, wherein the indicia are selected from erythrocyte sedimentation rate (ESR), number of painful and tender joints, level of joint pain, Ritchie articular index, duration of morning stiffness, joint immobility, joint swelling, and/or circulating C-reactive protein level, and wherein the compound is as described herein, or a stereoisomer, tautomer, solvate, prodrug, or pharmaceutically acceptable salt thereof.
  • the method further includes administration of additional therapeutic ingredients (hereafter referred to as ingredient(s) A), as described herein
  • kits for reducing the number or severity of the clinical signs of psoriasis comprise administering to a subject exhibiting one or more clinical signs of psoriasis an amount of a compound, such as a cytokine inhibitor, effective to reduce the number or severity of the clinical signs of psoriasis relative to those present in the subject prior to the administration of the compound, wherein the clinical signs of psoriasis are.
  • a compound such as a cytokine inhibitor
  • BSA total body surface area
  • one or more of the clinical signs of psoriasis, especially BSA is reduced by at least 10%, by at least 30%, by at least 50%, by at least 70% or by at least 90%.
  • the method further includes administration of additional therapeutic ingredients (hereafter referred to as ingredient(s) A), as described herein.
  • ingredient(s) A additional therapeutic ingredients
  • Combination therapy with other therapeutic ingredients A in the methods of the invention provides a beneficial therapeutic effect, particularly an additive or over-additive effect or an overall reduction of side effects of therapy. Such a beneficial therapeutic effect is desirable in the treatment of cytokine-mediated disorders and other methods as described herein.
  • the invention provides methods that further include administering to a subject one or more, typically one, compound as described herein, for example a cytokine inhibitor, together with one or more, typically one, of the ingredients A described herein.
  • the methods are for treating cytokine-mediated disorders or conditions.
  • a combination of any two or more ingredients A are administered with a compound as described herein.
  • An additive or over-additive (e.g., synergistic) effect of the pharmaceutical combinations according to the invention provides for dose reduction, side-effect reduction and/or interval extension when compared to the individual compounds of the invention alone, or ingredient(s) A alone.
  • the effects mentioned above are observed both when the two substances are administered simultaneously in a single formulation and when they are administered successively in separate formulations.
  • ingredient(s) A being an injectable, especially a biological agent
  • other benefits of adding a compound as described herein, e.g., a cytokine inhibitor may be seen, such as, for example, cost reduction by way of interval and/or dose reduction.
  • both the compound(s) as described herein and ingredient(s) A are administered orally.
  • both compound(s) and ingredient(s) A are administered intravenously, subcutaneously or by inhalation.
  • compound(s) is administered orally and the ingredient(s) A is administered intravenously, subcutaneously, or by inhalation.
  • compound(s) may be administered intravenously, subcutaneously, or by inhalation and the ingredient(s) A may be administered orally.
  • Biological agents shall be understood to mean any natural or artificial/synthetic biological molecule or fragment thereof as known in the art, such as antibodies, proteins, fusion proteins, receptors, nucleic acids, lipids, carbohydrates, and the like. Therefore, ingredient(s) A includes biological agents, such as etanercept, infliximab, alefacept, adalimumab, efalizumab, anakinra, IL-IRA, alpha-interferon, interferon beta 1-B, CTLA-4, and other antibodies or receptor constructs directed against TNFa, IL-I and IL-6, LFA-I, or C5.
  • biological agents such as etanercept, infliximab, alefacept, adalimumab, efalizumab, anakinra, IL-IRA, alpha-interferon, interferon beta 1-B, CTLA-4, and other antibodies or receptor constructs directed against TNFa, IL-I and
  • NSAIDs non-steroidal anti-inflammatory drugs
  • NSAIDs include acetaminophen, aspirin, ibuprofen, choline magnesium salicylate, choline salicylate, diclofenac, diflunisal, etodolac, fenoprofen calcium, flurbiprofen, indomethacin, ketoprofen, carprofen, indoprofen, ketorolac tromethamine, magnesium salicylate, meclofenamate sodium, mefenamic acid, oxaprozin, piroxicam, sodium salicylate, sulindac, tolmetin, meloxicam, rofecoxib, celecoxib, etoricoxib, valdecoxib, nabumetone, naproxen
  • Angiogenesis inhibitors may serve as ingredient(s) A, such as VEGF inhibitors, taxol, pentoxyfylline and/or thalidomide.
  • ingredient(s) A are steroids, such as glucocorticoids, and vitamin D3 an,d analogs thereof (cholecalciferols), alone (the latter being used mostly for psoriasis) or in combination.
  • steroids such as glucocorticoids, and vitamin D3 an,d analogs thereof (cholecalciferols), alone (the latter being used mostly for psoriasis) or in combination.
  • Steroids include budesonide, dexamethasone, fluocinonide, hydrocortisone, betamethasone, halobetasol (ulobetasol), methylprednisolone, prednisolone, prednisone, clobetasone, deflazacort, fhiocinolone acetonide, fluticasone, triamcinolone acetonide, mometasone and diflucortolone.
  • vitamin D3 derivatives are calcipotriol, tacalcitol, maxacalcitol, and tacalitol, the calciotropic hormones, 1 o ⁇ 2,5- dihydroxyvitamin D3, and parathyroid hormone-related peptide.
  • cytokine inhibitors include hydroxychloroquine, D-penicillamine, sulfasalazine, auranofin, gold sodium thiomalate, minocycline, dapsone, chlorambucil, mercaptopurine, tacrolimus, sirolimus, pimecrolimus, mycophenolate mofetil, cyclosporine, leflunomide, methotrexate, azathioprine, cyclophosphamide, macrolides, ascomycin, hydroxyurea, 6-thioguanine, (Orfanos C E., 1999, Cutis 64(5), 347); alefacept, leflunomide, infliximab, etanercept, efalizumab, anti-CD4, anti- CD25, peptide T, LFA3TIP, alicafors
  • agents or therapies which act on other targets or immune mediated products are suitable as the ingredient(s) A.
  • agents or therapies which act on other targets or immune mediated products are suitable as the ingredient(s) A.
  • PTKs protein tyrosine kinases
  • EGFR epidermal growth factor receptor
  • E-selectin inhibitors and therapies widely used for psoriasis such as anthralin, coal tar, phototherapies including ultraviolet B (UVB) or psoralens ultraviolet A (PUVA), photodynamic therapy and laser therapy.
  • UVB ultraviolet B
  • PUVA psoralens ultraviolet A
  • Retinoid therapy can also be used as ingredient(s) A.
  • bexarotene, acitretin, etretinate, tazarotene, hydroxyurea, 6-thioguanine and phototherapies are suitable additional ingredients.
  • Ingredients A useful in the invention further include small molecule inhibitors directed against enzymes involved in signal transduction pathways or to cell adhesion molecules like LFA-I or ICAM-I.
  • Statins and HMG-CoA reductase inhibitors may also be employed as ingredients A including, e.g., atorvastatin (LIPITOR, TORVAST), fluvastatin (LESCOL), lovastatin (MEVACOR, ALTOCOR) 3 mevastatin, pitavastatin (LIVALO, PITAVA), pravastatin (PRAVACHOL, SELEKTINE, LIPOSTAT), rosuvastatin (CRESTOR), or simvastatin (ZOCOR, LIPEX).
  • atorvastatin LIPITOR, TORVAST
  • fluvastatin LESCOL
  • lovastatin MEVACOR, ALTOCOR
  • mevastatin mevastatin
  • pitavastatin LIVALO, PITAVA
  • pravastatin PRAVACHOL
  • SELEKTINE SELEKTINE
  • LIPOSTAT rosuvastatin
  • CRESTOR simvastatin
  • ZOCOR simvastatin
  • ingredients A contemplated for use in methods of the invention include fibrates, such as bezafibrate (e.g., BEZALIP), ciprofibrate (e.g., MODALIM), clofibrate, clinofibrate, gemfibrozil (e.g., LOPID), or fenofibrate; cholesterol absorption inhibitors, such as, ezetimibe (e.g., ZETIA); nicotinic acid; bile acid sequestrants, such as cholestyramine (QUESTRAN) and colestipol (COLESTID); and/or plant sterol- containing products and ⁇ 3-fatty acids.
  • fibrates such as bezafibrate (e.g., BEZALIP), ciprofibrate (e.g., MODALIM), clofibrate, clinofibrate, gemfibrozil (e.g., LOPID), or fenofibrate
  • Combination therapy with the above ingredients A is contemplated for use in any method of the invention including treatment of cytokine-mediated disorders and conditions.
  • combinations comprising ingredient(s) A and one or more compounds, as described herein, for example, cytokine inhibitors, typically in therapeutically effective amounts, for use as pharmaceutical compositions with anti-cytokine activity.
  • combinations comprising ingredient(s) A and a compound as described herein can be used for preparing a pharmaceutical composition for the treatment and/or prevention of a cytokine-mediated disorder or condition.
  • the pharmaceutical preparations, containing as the active substance one or more compound combinations comprising ingredient(s) A and the compound(s) as described herein further include pharmaceutically acceptable derivatives thereof, and may be optionally combined with a conventional excipient, carrier, or combination thereof.
  • UVB ultraviolet B
  • PUVA psoralens ultraviolet A
  • a typical combination for treating psoriasis includes a compound described herein in combination with immunotherapy drugs which include cyclosporine, pimecrolimus, tacrolimus, ascomycine, anti-CD4, ' anti-CD25, peptide T, LFA3TIP, DAB 389 , CTLA-4Ig, E- selectin inhibitors, alefacept, infliximab, etanercept, efalizumab, and those disclosed in Griffiths, Christopher E. M., 1998 Hospital Medicine, 59 No 7, and variants thereof.
  • Another typical combination for treating psoriasis is a compound as described herein with methotrexate (MTX).
  • MTX methotrexate
  • Another typical combination for treating psoriasis is a compound as described herein with cyclosporine, especially because of cyclosporine' s efficiency for induction of remission.
  • Another embodiment of the invention comprises administration in the following sequence: induction with a compound described herein and cyclosporine, followed by continuation with the compound after decrease of dosing and discontinuation of cyclosporine.
  • Another typical combination for treating psoriasis is a compound described herein in combination with retinoids.
  • Retinoids provide minimal efficacy with potential Cyt P450 interactions and risk of teratogenicity, and this would be alleviated by continuation of therapy with the compound.
  • Yet another typical combination for treating psoriasis is a compound described herein, in combination with ingredient(s) A selected from steroids, such as glucocorticosteroids, vitamin D analogs, retinoids and dithranol. In some such combination treatments, the steroids and retinoids can be administered topically.
  • a more typical combination for treating psoriasis is a compound as described herein with vitamin D derivatives, most typically calcipotriol or tacalcitol.
  • Another typical combination for treating psoriasis is a compound described herein in combination with macrolides, most typically with ascomycin analogues, administered topically, and even more typically with those available orally such as pimecrolimus.
  • Another typical combination for treating psoriasis is a compound described herein in combination with cell adhesion molecule inhibitors, such as anti-LFA3, and/or anti-LFAl .
  • Cell adhesion molecule inhibitors appear to provide an acceptable response rate with limited tolerability problems.
  • Combination with a compound described herein should avoid the disadvantage of their injectable form, with CAM inhibitors being used intermittently.
  • Another embodiment of the invention comprises administration in the following sequence: induction with compound as described herein and CAM inhibitor(s), followed by maintenance treatment with the compound alone and retreatment with CAM inhibitor(s) in case of significant relapse.
  • Another typical combination for treating psoriasis is a compound as described herein with another anti-TNFa ingredient.
  • a typical embodiment is one wherein the other anti-TNFa ingredient is selected from infliximab or etanercept, typically infliximab.
  • Another typical combination for treating psoriasis is a compound described herein with anti-CD4, a ⁇ ti-CD80 (IDEC-114 or ABX-IL8), DAB-IL-2, DAB 389 -IL-2 5 CTLA4-Ig, IL-10, IL-2 receptor inhibitors such as daclizumab (anti-TAC), or basiliximab.
  • DMARDs Disease Modifying Antirheumatic Drugs
  • SAARDs Slow Acting Antirheumatic Drugs
  • a typical combination for treating rheumatoid arthritis is a compound as described herein combined with one or more of the following immunosuppressive, immunomodulatory, or cytostatic drugs, such as, for example, hydroxychloroquine, D- penicillamine, sulfasalazine, auranofin, gold sodium thiomalate, minocycline, dapsone, chlorambucil, mercaptopurine, tacrolimus, sirolimus, mycophenolate mofetil, cyclosporine, leflunomide, methotrexate, azathioprine or cyclophosphamide.
  • immunosuppressive immunomodulatory
  • cytostatic drugs such as, for example, hydroxychloroquine, D- penicillamine, sulfasalazine, auranofin, gold sodium thiomalate, minocycline, dapsone, chlorambucil, mercaptopurine, tacrolimus, sirol
  • Another typical combination for treating rheumatoid arthritis is a compound as described herein combined with angiogenesis inhibitors, such as compounds directed against VEGF, taxol, pentoxyfylline, thalidomide, interferon beta- IB and alpha-interferon.
  • angiogenesis inhibitors such as compounds directed against VEGF, taxol, pentoxyfylline, thalidomide, interferon beta- IB and alpha-interferon.
  • Yet another typical combination for treating rheumatoid arthritis is a compound as described herein in combination with Inhibitors of cell adhesion, such as inhibitors of LFA-I or inhibitors of ICAM-I .
  • Another typical combination for treating rheumatoid arthritis is a compound as described herein combined with anti-TNFa antibodies or TNFa-receptor antagonists such as etanercept, infliximab, adalimumab (D2E7), or biological agents such as CTLA-4, or biological agents directed against targets such as CD-4, LFA-I, IL-6, ICAM-I, C5, or IL-I receptor.
  • a compound as described herein is combined with infliximab alone or infliximab and methotrexate.
  • Another typical combination for treating rheumatoid arthritis is a compound as described herein in combination with IL-I receptor antagonists, such as anakinra (KINERET).
  • IL-I receptor antagonists such as anakinra (KINERET).
  • NSAIDs including acetaminophen, aspirin, ibuprofen, choline magnesium salicylate, choline salicylate, diclofenac, diflunisal, etodolac, fenoprofen calcium, flurbiprofen, indomethacin, ketoprofen, carprofen, indoprofen, ketorolac tromethamine, magnesium salicylate, meclofenamate sodium, mefenamic acid, oxaprozin, piroxicam, sodium salicylate, sulindac, tolmetin, meloxicam, rofecoxib, celecoxib, etoricoxib, valde
  • Another typical combination for treating rheumatoid arthritis is a compound as described herein combined with steroids, such as glucocorticosteroids, for example, betamethasone, dexamethasone, methylprednisolone, prednisolone, and deflazacort.
  • steroids such as glucocorticosteroids, for example, betamethasone, dexamethasone, methylprednisolone, prednisolone, and deflazacort.
  • a compound as described herein the following groups of drugs may be combined with a compound as described herein: steroids such as budesonide, 5-ASA drugs like mesalamine, immunosuppressants, biological agents and adhesion molecule inhibitors.
  • steroids such as budesonide, 5-ASA drugs like mesalamine, immunosuppressants, biological agents and adhesion molecule inhibitors.
  • a typical combination for treating Crohn's disease is a compound as described herein with one or more of the following: steroids including all those listed herein, 5-ASA, methotrexate and azathioprine.
  • Another typical combination for treating Crohn's disease is a compound described herein combined with IL-I receptor antagonists, such as anakinra (KINERET).
  • Yet another typical combination for treating Crohn's disease is a compound described herein with anti-TNFa antibodies or TNFa-receptor antagonists, such as etanercept, infliximab, adalimumab (D2E7), or biological agents such as CTLA-4, or biological agents directed against targets such as CD-4, LFA-I, IL-6, ICAM-I, or C5.
  • a compound described herein is combined with infliximab and methotrexate. More typically, the compound is a cytokine inhibitor and is combined with infliximab.
  • Another typical combination for treating Crohn's disease is a compound described herein combined with IL- 10, alicaforsen (anti ICAM 1), or antegren (VCAM receptor antagonist).
  • the methods comprise administering to a subject, such as a subject in need thereof, an amount of a compound, such as a cytokine inhibitor, effective to increase the HDL-level of the subject relative to the level prior to the administration of the compound, wherein the compound is as described herein or a stereoisomer, tautomer, solvate, prodrug, or pharmaceutically acceptable salt thereof.
  • the compound is a p38 inhibitor.
  • the subject suffers from or is at risk for a cytokine- mediated disorder as described herein.
  • the HDL level prior to administration is less than about 70 mg/dl, less than about 65 mg/ml, less than about 60 mg/dl, less than about 55 mg/dl, less than about 50 mg/dl, less than about 45 mg/dl or less than about 40 mg/dl.
  • the HDL level prior to administration is less than about 55 mg/dl.
  • the HDL is HDL 2 , while in others it is HDL 3 .
  • the subject has an LDL level less than about 150 mg/ml.
  • the subject is at risk of a vascular event, for example, one or more of thrombotic disorder, myocardial infarction, angina, stroke, transient ischemic attack, thrombotic re-occlusion subsequent to a coronary intervention procedure and/or a disorder in which at least one major coronary artery exhibits greater than 50% stenosis.
  • the vascular event is a cardiovascular event or a cerebrovascular event.
  • a reduction of the occurrence or severity of the vascular event occurs, relative to a subject who is at risk of a vascular event who has not been administered the compound.
  • the subject is suffering from or is at risk of suffering from diabetes, insulin resistance, or metabolic syndrome.
  • the methods of increasing HDL-levels in a subject additionally comprise administration of statins or HMG-CoA reductase inhibitors, such as, atorvastatin (LIPITOR, TORVAST), fluvastatin (LESCOL), lovastatin (MEVACOR, ALTOCOR), mevastatin, pitavastatin (LIVALO, PITAVA), pravastatin (PRAVACHOL, SELEKTINE, LIPOSTAT), rosuvastatin (CRESTOR), or simvastatin (ZOCOR, LlPEX); fibrates, such as, gemfibrozil, fenofibrate, bezafibrate, ciprofibrate, clofibrate, or clinofibrate; bile acid sequestrants, such as, cholestyramine (QUESTRAN); cholesterol absorption inhibitors, such as colestipol (COLESTID), or ezetimibe (ZETIA); niacin
  • the HDL level of the subject is increased by at least about 5%, by at least about 7%, by at least about 10%, or by at least about 15%.
  • the HDL level of the subject is increased by at least about 12%.
  • the HDL level of the subject may be increased by about 5% to about 20%.
  • methods of increasing Apo-Al -levels of a subject comprise administering to a subject an amount of a compound, such as a cytokine inhibitor, effective to increase the Apo-Al -level of the subject relative to the level prior to the administration of the compound, wherein the compound is as described herein or a stereoisomer, tautomer, solvate, prodrug, or pharmaceutically acceptable salt thereof.
  • a compound such as a cytokine inhibitor
  • the Apo-Al -level is increased by at least about 5% or by at least about 10%.
  • the subject's HDL level prior to administration is less than about 70 mg/dl, less than about 65 mg/dl, less than about 60 mg/dl, less than about 55 mg/dl, less than about 50 mg/dl, less than about 45 mg/dl or less than about 40 mg/dl. In other embodiments, the HDL level prior to administration is less than about 55 mg/dl; or the subject's LDL level prior to administration is less than about 150 mg/ml.
  • the subject is at risk of a vascular event, for example, one or more of thrombotic disorder, myocardial infarction, angina, stroke, transient ischemic attack, thrombotic re-occlusion subsequent to a coronary intervention procedure and a disorder in which at least one major coronary artery exhibits greater than 50% stenosis.
  • a vascular event can be a cardiovascular event or a cerebrovascular event.
  • a reduction of the occurrence or severity of the vascular event occurs, relative to a subject who is at risk of a vascular event who has not been administered the cytokine inhibitor.
  • the subject is suffering from or is at risk of suffering from diabetes, insulin resistance, or metabolic syndrome.
  • the HDL level of the subject is increased by at least about 5%, by at least about 7%, by at least about 10%, or by at least about 15%.
  • the HDL level of the subject is increased by at least about 12%.
  • the HDL level of the subject may be increased by about 5% to about 20%.
  • methods of decreasing or preventing from increasing the systolic or diastolic blood pressure of a subject in need thereof comprise administering to a subject an amount of a compound effective to decrease or to prevent from increasing the systolic or diastolic blood pressure of the subject relative to the blood pressure prior to the administration of the compound, wherein the compound is as described herein or a stereoisomer, tautomer, solvate, prodrug, or pharmaceutically acceptable salt thereof.
  • the blood pressure is the systolic blood pressure. In others, the blood pressure is the diastolic blood pressure.
  • the subject's systolic blood pressure prior to administration is above 140 mm Hg, and the diastolic blood pressure prior to administration of the compound is above 90 mm Hg. In others, the diastolic blood pressure prior to administration of the compound is higher than 85 mm Hg. In some embodiments, the decrease in systolic or diastolic blood pressure, or both, is at least about 5 mm Hg, at least about 3 mm Hg or at least about 2 mm Hg.
  • the subject's HDL level prior to administration is less than about 70 mg/dl, less than about 65 mg/dl, less than about 60 mg/dl, less than about 55 mg/dl, less than about 50 mg/dl, less than about 45 mg/dl or less than about 40 mg/dl. In other embodiments, the HDL level prior to administration is less than about 55 mg/dl; or the subject's LDL level prior to administration is less than about 150 mg/ml.
  • the subject is at risk of a vascular event, for example, one or more of thrombotic disorder, myocardial infarction, angina, stroke, transient ischemic attack, thrombotic re-occlusion subsequent to a coronary intervention procedure and a disorder in which at least one major coronary artery exhibits greater than 50% stenosis.
  • a vascular event for example, one or more of thrombotic disorder, myocardial infarction, angina, stroke, transient ischemic attack, thrombotic re-occlusion subsequent to a coronary intervention procedure and a disorder in which at least one major coronary artery exhibits greater than 50% stenosis.
  • the vascular event may be a cardiovascular event or a cerebrovascular event.
  • the present methods produce a reduction of the occurrence or severity of the vascular event in the subject, relative to a subject who is at risk of a vascular event who has not been administered a compound described herein.
  • the subject is suffering from or is at risk of suffering from diabetes, insulin resistance, or metabolic syndrome.
  • the HDL level of the subject may be increased by at least about 5%, by at least about 7%, by at least about 10%, or by at least about 15%.
  • the HDL level of the subject is increased by at least about 12%.
  • the HDL level of the subject may be increased by about 5% to about 20%.
  • Compounds disclosed herein may be used in combination therapy with one or more anti-hypertensive agents, for example, ACE inhibitors, calcium channel blockers, aldosterone antagonists, angiotensin II antagonists, diuretics, benzothiazepine derivatives, beta blocking agents, dihydropyridine derivatives, potassium- sparing agents, urologicals, sulfonamides, or thiazides.
  • ACE inhibitors for example, ACE inhibitors, calcium channel blockers, aldosterone antagonists, angiotensin II antagonists, diuretics, benzothiazepine derivatives, beta blocking agents, dihydropyridine derivatives, potassium- sparing agents, urologicals, sulfonamides, or thiazides.
  • calcium channel blockers for example, calcium channel blockers, aldosterone antagonists, angiotensin II antagonists, diuretics, benzothiazepine derivatives, beta blocking agents, dihydropyridine derivatives, potassium-
  • Examples include benazepril, enalapril, lisinopril, quinapril, captopril, ramipril, spironolactone, olmesartan, valsartan, telmisartan, valsartan, losartan, irbesartan, diltiazem, verapamil, trandolapril, atenolol, bisoprolol, metoprolol, toprol, tenoretic, amlodipine, nifedipine, felodipine, nisoldipine, triamterene, furosemide, lasix, prazosin, propanolol, hydrochlorothiazide, or combinations of two or more thereof.
  • methods of decreasing or preventing an elevation in PAI-I levelsr comprise administering to a subject at risk for increased PAI-I levels (for example in a subject suffering from, or at risk of obesity, metabolic syndrome or inflammatory conditions) an amount of a compound effective to decrease or prevent an elevation in ' the PAI-I -level of the subject relative to the level in the untreated subject, wherein the compound is as described herein, or a stereoisomer, tautomer, solvate, prodrug, or pharmaceutically acceptable salt thereof.
  • methods of decreasing the triglyceride-level of a subject comprise administering to a subject, such as a subject in need thereof, an amount of a compound, such as a cytokine inhibitor, effective to decrease the triglyceride-level of the subject relative to the level prior to the administration of the compound, wherein the compound is as described herein, or a stereoisomer, tautomer, solvate, prodrug, or pharmaceutically acceptable salt thereof.
  • the triglyceride-level prior to administration is above 500 mg/dl, above 200 mg/dl, or above 150 mg/dl.
  • the triglyceride-level prior to administration is above 200 mg/dl.
  • the subject suffers from or is at risk for a cytokine-mediated disorder as described herein.
  • the subject is at risk of a vascular event, for example, one or more of thrombotic disorder, myocardial infarction, angina, stroke, transient ischemic attack, thrombotic re-occlusion subsequent to a coronary intervention procedure and a disorder in which at least one major coronary artery exhibits greater than 50% stenosis.
  • the vascular event is a cardiovascular event or a cerebrovascular event.
  • a reduction of the occurrence or severity of the vascular event occurs, relative to a subject who is at risk of a vascular event who has not been administered the compound.
  • the method additionally comprises administration of statins or HMG-CoA reductase inhibitors, such as, atorvastatin (LIPITOR, TORVAST), fluvastatin (LESCOL), lovastatin (MEVACOR, ALTOCOR), mevastatin, pitavastatin (LIVALO, PITAVA), pravastatin (PRAVACHOL, SELEKTINE, LIPOSTAT), rosuvastatin (CRESTOR), or simvastatin (ZOCOR, LIPEX); fibrates, such as, gemfibrozil, fenofibrate, bezafibrate, ciprofibrate, clofibrate, or clinofibrate; bile acid sequestrants, such as, cholestyramine (QUESTRAN); cholesterol
  • the subject is suffering from, or is at risk of suffering from diabetes, insulin resistance, or metabolic syndrome.
  • the subject is a primate, particularly a human.
  • the triglyceride level of the subject is reduced by at least about 10%. In others, the triglyceride level of the subject is reduced by at least about 20%.
  • methods of decreasing the fasting glucose-level in a subject comprise administering to a subject, such as a subject in need thereof, an amount of a compound, such as a cytokine inhibitor, effective to decrease the fasting glucose-level in a subject relative to the level prior to the administration of the compound, wherein the compound is as described herein, or a stereoisomer, tautomer, solvate, prodrug, or pharmaceutically acceptable salt thereof.
  • a compound such as a cytokine inhibitor
  • the subject suffers from, or is at risk for a cytokine-mediated disorder as described herein. In others, the subject suffers from, or is at risk of suffering from diabetes, insulin resistance, or metabolic syndrome.
  • the method further comprises administration of tolbutamide, acetohexamide, tolazamide, chlorpropamide, glipizide, glyburide, glimepiride, gliclazide, repaglinide, nateglinide, metformin, miglitol, acarbose, exendin, pramlintide, insulin, or combinations of two or more thereof.
  • the subject is at risk of a vascular event, for example, one or more of thrombotic disorder, myocardial infarction, angina, stroke, transient ischemic attack, thrombotic re-occlusion subsequent to a coronary intervention procedure and/or a disorder in which at least one major coronary artery exhibits greater than 50% stenosis.
  • the vascular event is a cardiovascular event or a cerebrovascular event.
  • a reduction of the occurrence or severity of the vascular event occurs, relative to a subject who is at risk of a vascular event who has not been administered the compound.
  • methods of decreasing the HbAIc value in a subject comprise administering to a subject, such as a subject in need thereof, an amount of a compound, such as a cytokine inhibitor, effective to decrease the HbAIc value in the subject relative to the level prior to the administration of the compound, wherein the cytokine inhibitor is as described herein, or a stereoisomer, tautomer, solvate, prodrug, or pharmaceutically acceptable salt thereof.
  • the subject has a HbAIc value above about 8%, above about 7.5%, or above about 7%.
  • the HbAIc level is decreased to between about 4% and about 6.5%.
  • the subject suffers from, or is at risk for a cytokine-mediated disorder as described herein. In other embodiments, the subject suffers from, or is at risk of suffering from, diabetes, insulin resistance or metabolic syndrome.
  • the method further comprises administration of tolbutamide, acetohexamide, tolazamide, chlorpropamide, glipizide, glyburide, glimepiride, gliclazide, repaglinide, nateglinide, metformin, " miglitol, acarbose, exendin, pramlintide, insulin, or combinations of two or more thereof.
  • the subject is at risk of a vascular event, for example, one or more of thrombotic disorder, myocardial infarction, angina, stroke, transient ischemic attack, thrombotic re-occlusion subsequent to a coronary intervention procedure and/or a disorder in which at least one major coronary artery exhibits greater than 50% stenosis.
  • the vascular event is a cardiovascular event or a cerebrovascular event.
  • a reduction of the occurrence or severity of the vascular event occurs, relative to a subject who is at risk of a vascular event who has not been administered the compound.
  • methods for decreasing the insulin level in a subject comprise administering to a subject, such as a subject in need thereof, an amount of a compound, such as a cytokine inhibitor, effective to decrease the insulin-level in the subject relative to the level prior to the administration of the compound, wherein the compound is as described herein, or a stereoisomer, tautomer, solvate, prodrug, or pharmaceutically acceptable salt thereof.
  • a compound such as a cytokine inhibitor
  • the subject has a fasting insulin level prior to administration of above about 100 pmol/1, above about 150 pmol/1, above about 200 pmol/1, above about 250 pmol/1, above about 300 pmol/1, above about 350 pmol/1, above about 400 pmol/1, or above about 500 pmol/1.
  • the subject has a postprandial insulin level of above about 400 pmol/1, above about 500 pmol/1, above about 600 pmol/1, above about 700 pmol/1, or above about 800 pmol/1.
  • the insulin level is reduced by about 10%, about 20%, about 30%, or about 40%.
  • the subject suffers from, or is at risk for a cytokine-mediated disorder as described herein. In yet other embodiments, the subject suffers from, or is at risk of suffering from diabetes, insulin resistance or metabolic syndrome.
  • the method further comprises administration of tolbutamide, acetohexamide, tolazamide, chlorpropamide, glipizide, glyburide, glimepiride, gliclazide, repaglinide, nateglinide, metformin, miglitol, acarbose, exendin, pramlintide, insulin, or a combination of two or more thereof.
  • the subject is at risk of a vascular event, for example, one or more of thrombotic disorder, myocardial infarction, angina, stroke, transient ischemic attack, thrombotic re-occlusion subsequent to a coronary intervention procedure and/or a disorder in which at least one major coronary artery exhibits greater than 50% stenosis.
  • the vascular event is a cardiovascular event or a cerebrovascular event.
  • a reduction of the occurrence or severity of the vascular event occurs, relative to a subject who is at risk of a vascular event who has not been administered the compound.
  • the methods comprise administering to a subject, such as a subject in need thereof, an amount of a compound, such as a cytokine inhibitor, effective to decrease the HOMA Insulin Resistance Index in the subject relative to the Index prior to the administration of the compound, wherein the compound is as described herein, or a stereoisomer, tautomer, solvate, prodrug, or pharmaceutically acceptable salt thereof.
  • a compound such as a cytokine inhibitor
  • the Insulin Resistance Index is reduced to below about 2.5, below about 2.0, or below about 1.8.
  • the Insulin Resistance Index is reduced by about 10%, about 20%, or about 30%.
  • the subject is in need of a decreased HOMA Insulin Resistance Index because, e.g., the subject suffers from, or is at risk for a cytokine-mediated disorder as described herein. In others, the subject suffers from, or is at risk of suffering from diabetes, insulin resistance or metabolic syndrome.
  • the method further comprises administration of tolbutamide, acetohexamide, tolazamide, chlorpropamide, glipizide, glyburide, glimepiride, gliclazide, repaglinide, nateglinide, metformin, miglitol, acarbose, exendin, pramlintide, insulin, or a combination of two or more thereof.
  • the subject is at risk of a vascular event, for example, one or more of thrombotic disorder, myocardial infarction, angina, stroke, transient ischemic attack, thrombotic re-occlusion subsequent to a coronary intervention procedure and/or a disorder in which at least one major coronary artery exhibits greater than 50% stenosis.
  • the vascular event is a cardiovascular event or a cerebrovascular event.
  • a reduction of the occurrence or severity of the vascular event occurs, relative to a subject who is at risk of a vascular event who has not been administered the compound.
  • the methods comprise administering to a subject, such as a subject in need thereof, an amount of a compound, such as a cytokine inhibitor, effective to increase the indirect bilirubin-level in the subject relative to the level prior to the administration of the compound, wherein the compound is as described herein, or a stereoisomer, tautomer, solvate, prodrug, or pharmaceutically acceptable salt thereof.
  • the indirect bilirubin level is increased to about 0.4 mg/dl, to about 0.5 mg/dl, to about 0.6 mg/dl, or to about 0.7 mg/dl.
  • the indirect bilirubin level is increased by about 10%, about 20%, or about 30%. In other embodiments, the bilirubin level is increased without causing jaundice. In certain embodiments, the subject is in need of increased indirect bilirubin-level because, e.g., the subject suffers from, or is at risk for a cytokine-mediated disorder as described herein.
  • the subject is at risk of a vascular event
  • the vascular event is one or more of thrombotic disorder, myocardial infarction, angina, stroke, transient ischemic attack, thrombotic re-occlusion subsequent to a coronary intervention procedure and a disorder in which at least one major coronary artery exhibits greater than 50% stenosis.
  • the vascular event is a cardiovascular event or a cerebrovascular event.
  • a reduction of the occurrence or severity of the vascular event occurs, relative to a subject who is at risk of a vascular event who has not been administered the compound.
  • compounds described herein possess inhibitory effects on the procoagulant and profibrinolytic responses during human endotoxemia.
  • the invention therefore also provides a method of anticoagulant and fibrinolytic therapy for a disease or condition relating to blood coagulation or fibrinolysis, comprising administering to a subject in need thereof a pharmaceutically effective amount of a compound as described herein, for example, a cytokine inhibitor.
  • This administration may be of benefit given either prophylactically to subjects at risk or therapeutically to subjects who have developed complications related to these pathways.
  • Compounds disclosed herein may be used in combination therapy with one or more other anticoagulant or fibrinolytic agents.
  • these include recombinant tissue plasminogen activator (rtPA), streptokinase (SK), urokinase (UK), proUK, heparin, enoxoparin, dalteparin, coumarin anticoagulants, aspirin, dipyrimidamole, aggrennox, ticlopidine, clopidogrel (Plavix), abciximab, RheoPro, integrilin, aggrestat, and the like.
  • rtPA tissue plasminogen activator
  • SK streptokinase
  • UK urokinase
  • proUK proUK
  • heparin heparin
  • enoxoparin dalteparin
  • coumarin anticoagulants aspirin, dipyrimidamole, aggrennox, ticlopidine
  • a method comprising administering to a subject a combination of a compound, as described herein, for example, a cytokine inhibitor, and one or more ingredients A, in an amount effective to control, treat or prevent obesity or obesity-related conditions or disorders in a subject in need thereof, wherein ingredient(s) A is selected from agents useful in the treatment of obesity or an obesity— related condition or disorder.
  • a compound as described herein, for example, a cytokine inhibitor
  • ingredients A in an amount effective to control, treat or prevent obesity or obesity-related conditions or disorders in a subject in need thereof, wherein ingredient(s) A is selected from agents useful in the treatment of obesity or an obesity— related condition or disorder.
  • the obesity-related disorder is selected from overeating, binge eating, bulimia, diabetes, elevated plasma insulin concentrations, insulin resistance, metabolic syndrome, dyslipidemias, hyperlipidemia, lipodystrophy, osteoarthritis, arthritis deformans, lumbodynia, emmeniopathy, obstructive sleep apnea, cholelithiasis, gallstones, nonalcoholic steatohepatitis, heart disease, abnormal heart rhythms and abnormal heart arrhythmias, myocardial infarction, congestive heart failure, coronary heart disease, coronary artery disease, angina pectoris, hypertension, sudden death, stroke, cerebral infarction, cerebral thrombosis, transient ischemic attack, polycystic ovary disease, craniopharyngioma, Pickwickian syndrome, fatty liver, Prader-Willi Syndrome, Frohlich's syndrome, GH-deficiency, normal variant short stature, Turner's syndrome, pediatric
  • the subject desires to lose body weight relative to the subject's body weight prior to administration of the combination.
  • the method additionally comprises treatment of the subject with lipoplasty, gastric bypass, laparoscopic adjustable gastric binding, biliopancreatic diversion or vertical banded gastroplasty.
  • ingredient(s) A useful in the treatment of obesity or an obesity- related condition or disorder include an insulin sensitizer, an insulin or insulin mimetic, a sulfonylurea, an oglucosidase inhibitor, a cholesterol lowering agent, a PPAR ⁇ agonist, a CB receptor ligand, a serotonergic agent, an adrenoceptor agonist, a pancreatic lipase inhibitor, an ApoB/MTP inhibitor, a MCH receptor antagonist, an amylin and/or calcitonin receptor agonist, an NPY antagonist, an orexin antagonist, a GLP-I agonist, an MC agonist, a ghrelin antagonist, a leptin agonist, a CCK agonist, a PYY agonist, a CNTF, a GH secretagogue, a GH secretagogue receptor modulator, a DP-IV inhibitor, a H3 antagonist or inverse
  • ingredient(s) A is an insulin sensitizer, an insulin or insulin mimetic, a sulfonylurea, an ⁇ -glucosidase inhibitor, or a glucose transporter inhibitor.
  • ingredient(s) A is a cholesterol lowering agent, or a PP AR ⁇ agonist.
  • ingredient(s) A is a CB receptor ligand, a serotonergic agent, an adrenoceptor agonist, a pancreatic lipase inhibitor, an ApoB/MTP inhibitor, a DP-IV inhibitor, a H3 antagonist or inverse agonist, a 5HT agonist, a serotonin transport or reuptake inhibitor, a dopamine agonist, a NE transport inhibitor, a CETP inhibitor, a squalene synthase inhibitor, a PDE inhibitor, or an acyl-estrogen.
  • ingredient(s) A is a MCH receptor antagonist, an NPY antagonist, an orexin antagonist, a GLP-I agonist, an MC agonist, a ghrelin antagonist, a leptin agonist, a CCK agonist, a PYY agonist, a CNTF, a GH secretagogue, or a GH secretagogue receptor modulator.
  • ingredient(s) A is rimonabant, sibutramine, fluoxetine, phentermine, bupropion, radafaxine, orlistat, cetilistat, oxyntomodulin, or oleoyl-estrone.
  • Typical examples of ingredient A, and combinations of any two or more thereof, that may be combined with compounds described herein, for the treatment or prevention of obesity and/or obesity-related disorders, either administered separately or in the same pharmaceutical compositions, include, but are not limited to:
  • insulin sensitizers including (i) peroxisome proliferator activated receptors
  • PPAR 7 agonists such as glitazones (e.g.isaglitazone; pioglitazone; rosiglitazone; rivoglitazone, netoglitazone), naveglitazar, farglitazar, metaglidasen, GW6779542, CSO38, MBX2044, AZD6610, PLX204, LBM642, AMG131, AVE0847, AVE5376, ONO5129, TAK654, CLX0921, and the like); (ii) biguanides such as metformin and phenformin;
  • insulin or insulin mimetics such as insulin aspart, insulin glulisine, insulin glargine, insulin lispro, insulin detemir, NN5401, NN9101, NN344, AT1391, DTYOOl, betaRx, insulin zinc suspension (lente and ultralente); insulintropin (by "insulin” is meant a polypeptide or its equivalent useful in regulation of blood glucose levels. A general description of such insulins is provided in Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th Ed., Pergamon Press (1990). Such insulins can be fast acting, intermediate acting, or long acting. Various derivatives of insulin exist and are useful in this invention. Such compositions can be administered by any standard route, including oral, nasal, pulmonary, or transdermal administration.);
  • sulfonylureas such as acetohexamide; chlorpropamide; glibenclamide; glipizide; glyburide; glimepiride; gliclazide; glipe ⁇ tide; gliquidone; glisolamide; tolazamide; and tolbutamide;
  • ⁇ f-glucosidase inhibitors such as alglucosidase alfa, voglibose, celgosivir, miglitol, acarbose, and the like;
  • cholesterol lowering agents such as (i) 3-hydroxy-3-methylglutaryl-
  • Coenzyme A HMG-CoA reductase inhibitors (atorvastatin, pitavastatin, fluvastatin, rosuvastatin, pravastatin, simvastatin, lovastatin and other statins); (ii) bile acid absorbers/sequestrants, such as colesevelam, colestipol, cholestyramine, dialkylaminoalcyl derivatives of a cross-inked dextran, and the like; (ii) nicotinyl alcohol, nicotinic acid or a salt thereof; (iii) PP ARa agonists such as fenofibric acid derivatives (ciprofibrate, gemfibrozil, clofibrate, fenofibrate and benzafibrate), GW677954, CS038, ABT335, LY674, GFT14, PLX204, Ki l l, naveglitazar, LBM64
  • PPAR ⁇ agonists such as GW677954, CS068, RWJ800025, GW501516, and CKD501;
  • CB receptor ligands such as CB-I receptor antagonists or inverse agonists, for example rimonabant, surinabant,, AVEl 625, CP945598, and SLV-319, and those disclosed in U.S. Pat. Nos. 6,344,474, 6,028,084, 5,747,524, 5,596,106, 5,532,237, 4,973,587, 5,013,837, 5,081,122, 5,112,820, 5,292,736, 5,624,941, PCT Application Nos.
  • CB-I receptor antagonists or inverse agonists for example rimonabant, surinabant,, AVEl 625, CP945598, and SLV-319, and those disclosed in U.S. Pat. Nos. 6,344,474, 6,028,084, 5,747,524, 5,596,106, 5,532,237, 4,973,587, 5,013,837, 5,081,122, 5,112,820, 5,292,736, 5,
  • anti-obesity serotonergic agents such as fenfluramine, dexfenfluramine, phentermine, DOVl 02677, zimeldine, and sibutramine;
  • adrenoceptor agonists including /33-adrenoreceptor agonists, such as solabregon, YMl 78, amibregon, tesofensince, fenfluramine, amphetamine, phenmetrazine, phentermine, and N5984;
  • pancreatic lipase inhibitors such as orlistat, cetilistat, and GT389255;
  • apolipoprotein-B secretion/mi crosomal triglyceride transfer protein apo-
  • B/MTP inhibitors such as ISIS301012, ISIS301012, JTT130, and SLx4090;
  • MCH melanin-concentrating hormone
  • MCHlR and MCH2R antagonists for example, 856464, and AMG076, and those described in U.S. Patent Application Publication Nos. 2005/0009815, 2005/0026915, 2004/0152742, 2004/0209865; PCT Patent Application Publication Nos. WO 01/82925, WO 01/87834, WO 02/06245, WO 02/04433, and WO 02/51809; and Japanese Patent Application No. JP 13226269;
  • neuropeptide Y (NPY) antagonists such as NPYl antagonists, for example, BIBP3226, Jl 15814, BIBO3304, LY357897, CP671906, GI264879A, and those disclosed in U.S. Pat. No. 6,001,836 and PCT Application Nos.
  • NPY5 antagonists for example, S2367, FMS586, GW569180A, GW594884A, GW587081, GW548118., FR226928, FR240662, FR252384, 1229U91, GI264879A, CGP71683A, LY377897, PD160170, SR120562A, SR120819A and JCF104, and those disclosed in U.S. Pat. Nos.
  • WO 97/19682 WO 97/20820, WO 97/20821, WO 97/20822, WO 97/20823, WO 98/27063, WO 00/64880, WO 00/68197, WO 00/69849, WO 01/09120, WO 01/14376, WO 01/85714, WO 01/85730, WO 01/07409, WO 01/02379, WO 01/23388, WO 01/23389, WO 01/44201, WO 01/62737, WO 01/62738, WO 01/09120, WO 02/22592, WO 0248152, and WO 02/49648; .
  • peptide YY (PYY) agonists such as PYY, PYY 3-36, peptide YY analogs, and PYY agonists, for example, AC162352, N-Acetyl [Leu(28,31)]NPY 24-36, and PYY(3-36)NH 2 , cyclo-(28/32)-Ac-[Lys28- Glu32]-(25-36)-pNPY, TASP-V, pancreatic peptide (PP), 122U91, and those disclosed in U.S. Pat. Publication No. 2002/0141985 and PCT Application Publication No. WO 2005/077094, WO 03/026591, WO 03/057235, and WO 03/027637;
  • orexin antagonists such as orexin-1 receptor antagonists, for example
  • GLP-I glucagon-like peptide (GLP)-I agonists including GLP-I, GLP-I analogs and derivatives, such as exenatide, exenatide-LAR, liraglutide, CJC 1134PC, LY548806, 716155, and AVEOOlO;
  • melanocortin (MC) agonists including MC4 agonists and MC4R agonists, such as Melanotan II, PTl 5, BL3020, API 030, or those described in PCT Application Nos. WO 99/64002, WO 00/74679, WO 01/991752, WO 01/74844, WO 02/12166, WO 02/11715, WO 02/12178, WO 03/007949, WO 02/068388, WO 02/068387, - WO 02/067869, WO 03/040117, WO 03/066587, WO 03/068738, WO 03/094918, and WO 03/031410;
  • ghrelin receptor antagonists such as NOXB 1 1 , CYT009GhrQb, TZP300,
  • leptin agonists including recombinant human leptin and recombinant methionyl human leptin, and leptin derivatives, such as OB3, and those disclosed in U.S. Pat. Nos. 5,552,524, 5,552,523, 5,552,522, 5,521,283, 6,777,388 and 6,936,439, and PCT Application Nos.
  • cholecystokinin (CCK) agonists such as ARR15849, GI181771,
  • ciliary neurotrophic factors including CNTF, CNTF modulators, and CNTF derivatives, such as Axokine and NT501, and those disclosed in U.S. Pat. Nos. 6,680,291 and 6,767,894 and in PCT Application Nos. WO 94/09134, WO 98/22128, and WO 99/43813;
  • growth hormone (GH) secretagogues growth hormone secretagogues, growth hormone secretagogue receptor modulators, such as SUN 11031, RC 1291, tesamorelin, sermorelin, examorelin, NN703, hexarelin, MK677, SM-130686, CP-424,391, L-692,429 and L-163,255;
  • dipeptidyl peptidase IV (DP-IV or DPP-IV) inhibitors such as denagliptin, sitagliptin, SYR322, RO0730699, TS021, ALS20426, vidagliptin, GRC8200, MP513, PHX1149, PSN9301, TA6666, saxagliptin, SSR162369, R1438, KRP104, 825964, and the compounds disclosed in PCT Application Nos.
  • WO 03/004498 WO 03/004496; EP 1 258 476; WO 02/083128; WO 02/062764; WO 03/000250; WO 03/002530; WO 03/002531; WO 03/002553; WO 03/002593; WO 03/000180; and WO 03/000181 ;
  • H3 histamine receptor-3 (H3) antagonists/inverse agonists, such as
  • 5HT 5-hydroxytryptamine
  • 5HT2C serotonin receptor 2C
  • lorcaserin vabicaserin
  • APD356 5-hydroxytryptamine receptor 2C
  • WO 02/36596 WO 02/48124, WO 02/10169, WO 01/66548, WO 02/44152, WO 02/51844, WO 02/40456, and WO 02/40457; and 5HT6 agonists, such as PRX07034; [00140] (20) serotonin transport or serotonin reuptake inhibitors such as nefazodone, citalopram, dapoxetine, duloxetine, desvenlafaxine, fluvoxamine, escitalopram, sibutramine, venlafaxine, vilazodone, DOV21947, LUAA21004, BGC201259, NS2359, UK416244, DOV102677, SEP225289, OPC14523, SLV314, WLlOI l, WL1017, zimeldine, fluoxetine, paroxetine, fenfluramine, imipramine and sertraline, and those disclosed in U.S. Pat. No
  • dopamine agonists for example dopamine D2 agonists, such as, ropinirole, bifeprunox, aripiprazole, pergolide, talipexole, ACP 104, quinagolide, nolomirole, NHOOl, SLV308, piribedil, lisuride, bromocriptine, aplindore, tesofensine, and preclamol;
  • dopamine D2 agonists such as, ropinirole, bifeprunox, aripiprazole, pergolide, talipexole, ACP 104, quinagolide, nolomirole, NHOOl, SLV308, piribedil, lisuride, bromocriptine, aplindore, tesofensine, and preclamol;
  • norepinephrine (NE) transport inhibitors such as lisdexamfetamine, atomoxetine, duloxetine, SLE381, desvenlafaxine, amfebutamone, sibutramine, venlafaxine, DOC21947, radafaxine, bupropion, DOV216303, reboxetine, AD337, NS2359, DOV102677, SEP225289, Xen2174, indeloxazine, protriptyline, and S33005;
  • DAG diacylglycerdl acyltransferase
  • glucose transporter inhibitors for example, sodium glucose co transporter
  • (SGLT) inhibitors such as, KGT1251, 189075, AVE2268, and SGLOOlO;
  • CETP cholesterol ester transfer protein
  • glucocorticoid antagonists for example, mifepristone, Org34517, and
  • PDE3B PDE3B inhibitors
  • tetomilast for example, tetomilast, tadalafil, atopik, vardenafil, tipelikast, HT0712, QAD171A, SK3530, oglemilast, acanafil, cilostazol, roflumilast, parogrelil, udenafil, EHT0202, dasantafil, MEM1414, SLx2101, CC10004, 256066, cilomilast, vinpocetine, ibudilast, pimobendan, ND7001, LAS37779, K123, UK357903, ND1251, tofimilast, UKl 69003, senazodan, trapidil, arofylline, theophylline, doxofylline, olprinone, pentoxifylline, zaprinast, sildenafil, amrinone
  • antiplatelet agents such as, limaprost, clopidogrel, felbinac, eptifibatide,
  • angiotensin converting enzyme (ACE) inhibitors such as peridopril, enalapril, ramipril, fosinopril, quinapril, lisinopril, imidapril, benazepril, ilepatril, captopril, trandolapril, temcapil, cilazapril, MC4232, CHF1521, omapatrilat, spirapril, moexipril, zofenopril, delapril, alacepril, S5590, and fasidotril;
  • ACE angiotensin converting enzyme
  • angiotensin II (All) receptor antagonists for example, losartan, candesartan, temisartan, coaprovel, , imidapril, azilsartan. valsartan, irbesartan, olmesartan, CYT006AngQb, TAK491, eprosartan, VNP489, CGP63170, fimesartan, pratosartan, and saralasin;
  • thyroid hormone ⁇ agonists such as thyroid hormone, levothyroxine,
  • cyclo-oxygenase (COX)-2 inhibitors such as etoricoxib, GW406381 , meloxicam, lumiracoxib, diclofenac, valdecoxib, parecoxib, PMIOOl, 6444784, SVT2016, nimesulfide, CS706, cimicoxib, LR3001, LAS34475, P54, rofecoxib, celecoxib, and arcoxia;
  • monoamine reuptake inhibitors such as those disclosed in PCT
  • metabotropic glutamate 5 (mGlu5) receptor antagonists such as
  • acyl-estrogens such as oleoyl-estrone, disclosed in del Mar-Grasa, M. et al., Obesity Research, 9:202-9 (2001);
  • FAS fatty acid synthase
  • urocortin binding protein antagonists and urocortin ligands such as urocortin II;
  • [00170] (50) neuromedin U receptor agonists; [00171] (51) topiramate, oxyntomodulin, tagatose, CP741952, zonisamide, IDl 101,
  • BDC03 BDC03, S2367, AOD9604, fluasterone, GT389255, QCBT16, MK0916, MK0493, MK0364, PD6735, c2735, and adiponectin.
  • Obesity and weight loss treatments that can be used in conjunction with compounds described herein also include surgery.
  • the weight loss surgical procedure is liposuction ⁇ r lipoplasty.
  • Surgical obesity treatments include gastric bypass, laparoscopic adjustable gastric binding, biliopancreatic diversion or vertical banded gastroplasty.
  • a method comprising administering a compound, such as a cytokine inhibitor, and one or more ingredients A to a subject in need thereof, in an amount effective to increase or enhance the effectiveness of the ingredient A when used alone, wherein ingredient A is selected from agents useful in the treatment of obesity an obesity— related condition or disorder, and wherein the compound is as described herein, or is a mixture of any two or more thereof and/or a stereoisomer, tautomer, solvate, prodrug, or pharmaceutically acceptable salt thereof.
  • the effectiveness enhancement is obtained by allowing administration of lower dosages of one or more of the ingredients A used in combination, relative to the use of either agent alone.
  • a method comprising administering to a subject a compound as described herein, for example, a cytokine inhibitor, and ingredient(s) A, in an amount effective to reduce the risk of metabolic disorders in a subject in need thereof relative to the subject's risk prior to administration of the compound and ingredient(s) A, wherein ingredient(s) A is selected from agents useful in the treatment of obesity or an obesity-related condition or disorder.
  • the reduction in risk of metabolic disorders is obtained by reducing the body weight of the subject, relative to the subject's body weight prior to administration of the combination of the cytokine inhibitor and ingredient(s) A.
  • methods of treating a cancer comprise administering to a subject in need of such treatment a composition comprising a therapeutically effective amount of a compound, such as a cytokine inhibitor, as described herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
  • a compound such as a cytokine inhibitor, as described herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
  • the method of treating cancer further comprises treating the subject with surgery, radiation, cryotherapy, or one or more antiproliferative agents or a combination thereof.
  • the antiproliferative agent is an alkylating agent, platinum agent, antimetabolite, topoisomerase inhibitor, antitumor antibiotic, antimitotic agent, aromatase inhibitor, thymidylate synthase inhibitor, DNA antagonist, farnesyltransferase inhibitor, pump inhibitor, histone acetyltransferase inhibitor, metalloproteinase inhibitor, ribonucleoside reductase inhibitor, endothelin A receptor antagonist, retinoic acid receptor agonist, immunomodulator, hormonal or antihormonal agent, photodynamic agent, angiogenesis inhibitor, or a tyrosine kinase inhibitor.
  • the alkylating agent is busulfan, procarbazine, ifosfamide, altretamine, hexamethylmelamine, estramustine phosphate, thiotepa, mechlorethamine, dacarbazine, streptozocin, lomustine, temozolomide, cyclophosphamide, semustine, or chlorambucil.
  • platinum agents examples include spiroplatin, lobaplatin (Aeterna), tetraplatin, satraplatin (Johnson Matthey), ormaplatin, iproplatin, miriplatin (Sumitomo), nexplatin (AnorMED), polymer platinate (Access), oxaliplatin, or carboplatin.
  • the antimetabolite is azacytidine, trimetrexate, floxuridine, deoxycoformycin, 2-chlorodeoxyadenosine, pentostatin, 6-mercaptopurine, hydroxyurea, 6- thioguanine, decitabine (SuperGen), cytarabine, clofarabine (Bioenvision), 2-fluorodeoxy cytidine, irofulven (MGI Pharma), methotrexate, tomudex, ethynylcytidine (Taiho), fludarabine, gemcitabine, raltitrexed, or capecitabine.
  • the topoisomerase inhibitor is amsacrine, exatecan mesylate (Daiichi), epirubicin, quinamed (ChemGenex), etoposide, gimatecan (Sigma-Tau), teniposide, mitoxantrone, diflomotecan (Beaufour-Ipsen), 7-ethyl- 10-hydroxy-camptothecin, dexrazoxanet (TopoTarget), elsamitrucin (Spectrum), pixantrone (Novuspha ⁇ na), edotecarin (Merck & Co), becatecarin (Exelixis), karenitecin (BioNumerik), BBR-3576 (Novuspharma), belotecan (Chong Kun Dang), rubitecan (SuperGen), irinotecan (CPT-11), or topotecan.
  • the antitumor antibiotic is dactinomycin (actinomycin D), azonafide, valrubicin, anthrapyrazole, daunorubicin (daunomycin), oxantrazole, therarubicin, losoxantrone, idarubicin, bleomycinic acid, rubidazone, sabarubicin (Menarini), plicamycinp, 13-deoxydoxorubicin hydrochloride (Gem Pharmaceuticals), porfiromycin, epirubicin, mitoxantrone (novantrone) or amonaf ⁇ de.
  • antimitotic agents are colchicines, ABT-751 (Abbott), vinblastine, xyotax (Cell Therapeutics), vindesine, IDN 5109 (Bayer), dolastatin 10 (NCI), A 105972 (Abbott), rhizoxin (Fujisawa), A 204197 (Abbott), mivobulin (Warner-Lambert), synthadotin (BASF), cemadotin (BASF), indibulin (ASTAMedica), RPR 109881A (Aventis), TXD 258 (Aventis), combretastatin A4 (BMS), epothilone B (Novartis), isohomohalichondrin-B (PharmaMar), T 900607 (Tularik), ZD 6126 (AstraZeneca), batabulin(Tularik), cryptophycin 52 (Eli Lilly), vinflunine (Fabre), hydravin (Prescient NeuroPharma
  • the aromatase inhibitor is aminoglutethimide, atamestane (BioMedicines), formestane, fadrozole, letrozole, exemestane, or anastrazole.
  • the thymidylate synthase inhibitor is pemetrexed (Eli Lilly), nolatrexed (Eximias), ZD-9331 (BTG), doxifluridine (Nippon Roche), or 5,10-methylenetetrahydrofolate (BioKeys).
  • the DNA antagonist is trabectedin (PharmaMar), edotreotide (Novartis), glufosfamide (Baxter International), mafosfamide (Baxter International), apaziquone (Spectrum Pharmaceuticals), or thymectacin (NewBiotics).
  • the farnesyltransferase inhibitor is arglabin (NuOncology Labs), tipifarnib (Johnson & Johnson), lonafarnib (Schering-Plough), perillyl alcohol (DOR BioPharma), or sorafenib (Bayer).
  • Examples of pump inhibitors are zosuquidar trihydrochloride (Eli Lilly), tariquidar (Xenova), biricodar dicitrate (Vertex), or MS-209 (Schering AG).
  • Examples of histone acetyltransferase inhibitors include tacedinaline (Pfizer), pivaloyloxymethyl butyrate (Titan), AP-CANC-03 and AP-CANC-04 (Aton Pharma), depsipeptide (Fujisawa), or MS-275 (Schering AG).
  • the metalloproteinase inhibitor is neovastat (Aeterna Laboratories), metastat (CollaGenex), or marimastat (British Biotech).
  • the ribonucleoside reductase inhibitor is gallium maltolate (Titan), tezacitabine (Aventis), triapine (Vion), or didox (Molecules for Health).
  • the endothelin A receptor antagonist is atrasentan (Abbott), bosentan (Roche), ambrisentan (BASF), sitaxsentan (Encysive), clazosentan (Roche), darusentan (Knoll), and ZD-4054 (AstraZeneca).
  • the retinoic acid receptor agonist is fenretinide (Johnson & Johnson), alitretinoin (Ligand), tazarotene (Allergan), tetrinoin (Roche), isotretinoin (Roche), 13-cis-retinoic acid (UCSD), or LGD-1550 (Ligand).
  • the immuno-modulator is interferon, Roferon-A (Roche), dexosome therapy (Anosys), oncophage (Antigenics), pentrix (Australian Cancer Technology), GMK vaccine (Progenies), CD 154 cell therapy (Tragen), adenocarcinoma vaccine (Biomira), transvax (Intercell), avicine (AVI BioPharma), norelin (Biostar), IRX-2 (Immuno-Rx), BLP-25 liposome vaccine (Biomira), PEP-005 (Peplin Biotech), multiganglioside vaccine (Progenies), synchrovax vaccine (CTL Immuno), b-alethine (Dovetail), melanoma vaccine (CTL Imrnuno), vasocare (Vasogen), rituximab (Genentech/Biogen pou), or p21 RAS vaccine (GemVax).
  • the hormonal agent is an estrogen, dexamethasone, a conjugated estrogen, prednisone, ethinyl estradiol, methylprednisolone, chlortrianisen, prednisolone, idenestrol, aminoglutethimide, hydroxyprogesterone caproate, leuprolide, medroxyprogesterone, octreotide, testosterone, mitotane, testosterone propionate, fluoxymesterone, methyltestosterone, 2-methoxyestradiol (EntreMed), diethylstilbestrol, arz ⁇ xifene (Eli Lilly), megestrol, tamoxifen, bicalutamide, toremof ⁇ ne, fiutamide, goserelin, nilutamide, or leuporelin.
  • the photodynamic agent is talaporfin (Light Sciences), Pd-bacteriopheophorbide (Yeda), theralux • (Theratechnologies), lutetium texaphyrin (Pharmacyclics), motexafin, gadolinium (Pharrhacyclics), or hypericin.
  • the angiogenesis inhibitor is neovastat (AEterna Zentaris), ATN-224 (Attenuon), sorafenib (Bayer), thalidomide, bevacizumab (Genentech), ranibizumab (Genentech), benefin (Lane Labs), L-651582 (Merck & Co), vatalanib (Novartis), or sutent (Sugen).
  • tyrosine kinase inhibitors include imatinib (Novartis), leflunomide (Sugen/Pharmacia), kahalide F (PharmaMar) iressa (AstraZeneca), lestaurtinib (Cephalon), erlotinib (Oncogene Science), canertinib (Pfizer), tandutinib (Millenium), squalamine (Genaera), midostaurin (Novartis), phenoxodiol, SU6668 (Pharmacia), cetuximab (ImClone), rhu-Mab (Genentech), ZD6474 (AstraZeneca), MDX- H210 (Medarex), vatalanib (Novartis), omnitarg (Genentech), lapatinib (GlaxoSmithKline), panitumumab (Abgenix), IMC-ICl 1 (Im
  • the antiproliferative agent is melphalan, carmustine, cisplatin, 5-fluorouracil, mitomycin C, adriamycin (doxorubicin), bleomycin, or paclitaxel (Taxol®).
  • the cancer is osteosarcoma, Kaposi's sarcoma, colorectal cancer, brain cancer, epithelial cell-derived neoplasia (epithelial carcinoma), basal cell carcinoma, adenocarcinoma, gastrointestinal cancer, lip cancer, mouth cancer, esophageal cancer, small bowel cancer, stomach cancer, gastric cancer, colon cancer, liver cancer, bladder cancer, pancreas cancer, ovarian cancer, cervical cancer, lung cancer, breast cancer, skin cancer, squamus cell cancer, basal cell cancer, prostate cancer, renal cell carcinoma; leukemia, lymphoma, erythroblastoma, glioblastoma, glioma, meningioma, astrocytoma, myoblastoma, multiple myeloma, acute myelogenous leukemia, myelodysplastic syndrome, non-Hodgkins lymphoma, or follicular lymphoma.
  • the cancer is acral lentiginous melanoma, actinic keratoses, adenocarcinoma, adenoid cycstic carcinoma, adenomas, adenosarcoma, adeno squamous carcinoma, astrocytic tumors, bartholin gland carcinoma, basal cell carcinoma, bronchial gland carcinomas, capillary carcinoids, carcinoma, carcinosarcoma, cavernous, cholangiocarcinoma, chondosarcoma, choriod plexus papilloma/carcinoma, clear cell carcinoma, cystadenoma, endodermal sinus tumor, endometrial hyperplasia, endometrial stromal sarcoma, endometrioid adenocarcinoma, ependymal, epitheloid, Ewing's sarcoma, fibrolamellar, focal nodular hyperplasia,
  • the cancer is leukemia, erythroblastoma, multiple myeloma, acute myelogenous leukemia, myelodysplastic syndrome, non-Hodgkin's lymphoma or follicular lymphoma. In some embodiments, the cancer is follicular lymphoma, acute myelogenous leukemia, multilple myeloma or non-hodgkin's lymphoma.
  • the cancer is brain cancer, glioblastoma, meningioma, astocytoma, medulloblastoma, neuroblastoma or retinoblastoma. In some such embodiments, the cancer is glioma or glioblastoma.
  • the cancer is osteosarcoma, Kaposi's sarcoma, chondosarcoma, Ewing's sarcoma or myoblastoma. In some such embodiments, the cancer is osteosarcoma bone cancer.
  • the cancer is breast, lung, kidney or prostate cancer metastasis.
  • the neoplasm is bone metastasis.
  • methods of treating, modifying or managing pain comprise administering to a patient in need of such treatment, modification or management, a composition comprising a therapeutically effective amount of a compound, such as a cytokine inhibitor, as described herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
  • a compound such as a cytokine inhibitor, as described herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
  • the composition further comprises an antidepressant, antihypertensive, anxiolytic, calcium channel blocker, a-adrenergic receptor agonist, a-adrenergic receptor antagonist, ketamine, anesthetic, muscle relaxant, non-narcotic analgesic, opioid analgesic, NSAID, immunomodulatory agent, immunosuppressive agent, corticosteroid, anticonvulsant, hyperbaric oxygen, a2d ligand, NMDA receptor antagonist, or a combination of any two or more thereof.
  • an antidepressant antihypertensive, anxiolytic, calcium channel blocker, a-adrenergic receptor agonist, a-adrenergic receptor antagonist, ketamine, anesthetic, muscle relaxant, non-narcotic analgesic, opioid analgesic, NSAID, immunomodulatory agent, immunosuppressive agent, corticosteroid, anticonvulsant, hyperbaric oxygen, a2d ligand,
  • the antidepressant is nortriptyline, amitriptyline, imipramine, doxepin, clomipramine, fluoxetine, sertraline, nefazodone, venlafaxine, trazodone, or bupropion.
  • the anti-hypertensive is nifedipine, terazosin, prazosin, losartan, verapamil, telmisartan, fosinopril, bosentan, or olmesartan.
  • the anxiolytic is fluoxetine, paroxetine, sertraline, or venlafaxine.
  • Examples of calcium channel blockers include nifedipine, verapamil and clonidine.
  • the a-adrenergic receptor agonist is clonidine or midodrine.
  • the a-adrenergic receptor antagonist is terazosin, prazosin, or doxasozin.
  • the anesthetic is procaine, lidocaine, mepivacaine, articaine, prilocaine, etidocaine, bupivacaine, or ropivacaine.
  • opioid analgesic include hydromorphone, oxycodone, morphine sulfate, meperidine, and fentanyl transdermal patch.
  • the NSAID is a COX-2 inhibitor, salicylic acid acetate, ibuprofen, ketoprofen, naproxen sodium, ketorolac, diclofenac, indometacin, or acetaminophen.
  • the COX-2 inhibitor is rofecoxib, celecoxib, or valdecoxib.
  • the corticosteroid is prednisone, dexamethasone or hydrocortisone.
  • the anticonvulsant is carbamazepine, oxcarbazepine, gabapentin, pregabalin, phenytoin, sodium valproate, clonazepam, topiramate, lamotrigine, zonisamide, tiagabine, famotodine, phenobarbital, diphenylhydantoin, mephenytoin, ethotoin, mephobarbital, primidone, ethosuximide, methsuximide, phensuximide, trimethadione, benzodiazepine, phenacemide, acetazolamide, progabide, divalproex sodium, magnesium sulfate injection, metharbital, paramethadione, clobazam, sulthiame, dilantin, diphenylan, or L-5-hydroxytryptophan.
  • the NMDA receptor antagonist is dextromethorphan, dextrorphan, ketamine, memantine, amantadine, agmatine, aptiganel, gavestinel, selfotel, 7-chlorokynurate, remacemide, riluzole, pyrroloquinoline quinone or cis-4-(phosphonomethyl)-2-piperidinecarboxylic acid.
  • the a2d ligand is gabapentin, pregabalin, [(lR,5R,6S)-6-(Aminomethyl)bicyclo[3.2.0]hept-6- yl]acetic acid, S-O-Aminomethyl-cyclohexylmethyl ⁇ H-tl ⁇ -oxadiazol-S-one and C-[I- (lH-Tetrazol-5-ylmethyl)-cycloheptyl]-methylamine, (3S,4S)-(l-Aminomethyl-3,4-dimethyl- cyclopentyl)-acetic acid, (la,3a,5a)(3-amino-methyl-bicyclo[3.2.0]hept-3-yl)-acetic acid, (3S,5R)-3-Aminomethyl-5-methyl-octanoic acid, (3S,5R)-3-amino-5-methyl-heptanoic acid, (3S,5R)-3-amino-5-methyl-methyl
  • the composition further comprises acetylsalicylic acid, diclofenac, ibuprofen, indometacin, flufenamic acid, mefenamic acid, morphine, pethidine, methadone, fentanyl, buprenorphine, tramadol, gabapentin, pregabalin, carbamazepine, lamotrigin, topiramate, phenyloin, levitiracetam, procaine, lidocaine, mepivacaine, articaine, prilocaine, etidocaine, bupivacaine, ropivacaine, amitryptiline, paroxetine, citalopram, bupropione, duxoletine, ketamine, memantine, 2,3 -benzodiazepines, or a combination of any two or more thereof.
  • the pain is acute pain, chronic pain, pain resulting from soft tissue and peripheral damage from acute trauma; neuropathic pain; post-stroke pain; postherpetic neuralgia, occipital neuralgia, trigeminal neuralgia, segmental or intercostal neuralgia and other neuralgias; pain associated with osteoarthritis and rheumatoid arthritis; musculoskeletal pain; spinal pain, central nervous system pain; lower back pain, sciatica, dental pain, myofascial pain syndromes, episiotomy pain, gout pain, and pain resulting from burns; deep and visceral pain; muscle pain, eye pain, inflammatory pain, orofacial pain; abdominal pain, gynecological pain; somatogenic pain; pain associated with nerve and root damage; pain associated with limb amputation, tic douloureux, neuroma, or vasculitis; diabetic neuropathy, chemotherapy-induced-neuropathy, acute herp
  • the musculo-skeletal pain is pain associated with strains, sprains or broken bones.
  • the central nervous system pain is pain due to spinal cord or brain stem damage.
  • the deep and visceral pain is heart pain.
  • the orofacial pain is odontalgia.
  • the gynecological pain is dysmenorrhoea, labour pain and pain associated with endometriosis.
  • the pain associated with nerve and root damage is pain associated with peripheral nerve disorders.
  • the peripheral nerve disorder is nerve entrapment or brachial plexus avulsions.
  • the headache is migraine with aura, migraine without aura, vascular headaches, acute or chronic tension headache, sinus headache or cluster headache.
  • the chronic non-neuropathic pain is pain associated with HIV, anthralgia, vasculitis or fibromyalgia.
  • the complex regional pain syndrome is type I or type II.
  • the pain is nociceptive pain or neuropathic pain.
  • the nociceptive pain is associated with chemical or thermal bum, cut of the skin, contusion of the skin, osteoarthritis, rheumatoid arthritis, systemic lupus erthrematosis (SLE), tendonitis, or myofascial pain.
  • the neuropathic pain is diabetic neuropathy, post herpetic neuralgia, trigeminal neuralgia, post-stroke pain, complex regional pain syndrome, sympathetic maintained pain syndrome, reflex sympathetic dystrophy, reflex neurovascular dystrophy, reflex dystrophy, spinal cord injury pain, Sudeck atrophy of bone, algoneurodystrophy, shoulder hand syndrome, post-traumatic dystrophy, pain related to cancer or metastases, phantom limb pain, fibromyalgia, chronic fatigue syndrome, radiculopathy, luetic neuropathy, or painful neuropathic condition induced by a drug.
  • the cancer is osteosarcoma, colorectal cancer, brain cancer, epithelial call-derived neoplasia (epithelial carcinoma), basal cell carcinoma, adenocarcinoma, gastrointestinal cancer, lip cancer, mouth cancer, esophageal cancer, small bowel cancer, stomach cancer, colon cancer, liver cancer, bladder cancer, pancreas cancer, ovarian cancer, cervical cancer, lung cancer, breast cancer, skin cancer, squamus cell and/or basal cell cancers, prostate cancer, renal cell carcinoma, and other known cancers that affect epithelial cells throughout the body; leukemia; lymphoma; or angiogenesis including neoplasia.
  • the metastases are breast, lung, kidney or prostate cancer metastases.
  • the methods comprise administering to a subject in need of such treatment a composition comprising a therapeutically effective amount of a compound, such as a cytokine inhibitor as described herein, or a stereoisomer, tautomer, solvate, prodrug, or pharmaceutically acceptable salt thereof.
  • a compound such as a cytokine inhibitor as described herein, or a stereoisomer, tautomer, solvate, prodrug, or pharmaceutically acceptable salt thereof.
  • the pemphigus is pemphigus vulgaris, pemphigus vegetans, pemphigus foliaceus, pemphigus erythematosus, bullous pemphigoid, paraneoplastic pemphigus, cicatricial pemphigoid, bullous impetigo, or staphylococcal scalded-skin syndrome.
  • methods comprising administering to a subject in need thereof a combination of (i) an effective amount of a compound of the invention and (ii) an effective amount of one or more therapeutic ingredients A useful in the treatment of pemphigus as described herein, wherein the effective amount of ingredients A is less than the effective amount of ingredient(s) A when used alone.
  • kits for reduce the number and/or severity of clinical indicia of pemphigus comprise administering to a subject exhibiting one or more clinical indicia of pemphigus an amount of a compound of the invention, such as a cytokine inhibitor, effective to reduce the number and/or severity of clinical indicia of pemphigus relative to those present in the subject prior to the administration of the cytokine inhibitor, wherein the clinical indicia of pemphigus include the percentage of total body surface area (BSA) affected by pemphigus, pemphigus lesion thickness, the number of new pemphigus lesions, the number of active pemphigus lesions (including blisters and erosions), the healing time of active lesions (for example, time to 80% healing), serum anti-desmoglein- 1 (DSGl) antibody levels, serum anti-DSG3 antibody levels, serum TNFa-levels, serum IL-6 levels, skin TNFa-mRNA levels, skin
  • BSA total body surface area
  • the methods additionally comprise administering to the subject an effective amount of one or more ingredient(s) A, useful in the treatment of pemphigus, as described herein.
  • the effective amount of ingredient(s) A is less than the effective amount of ingredient A when used alone.
  • the methods further comprise administering to the subject an ingredient A, wherein the ingredient A is an antiinflammatory agent, an immunosuppressant, an anti-infective, an antibiotic, a gold salt, an alkylating agent, an immunoglobulin, or a combination of two or more thereof.
  • the ingredient A is an antiinflammatory agent, an immunosuppressant, an anti-infective, an antibiotic, a gold salt, an alkylating agent, an immunoglobulin, or a combination of two or more thereof.
  • the anti-inflammatory may be a corticosteroid, a COX-2 inhibitor, a non-steroidal antiinflammatory drug (NSAID), a TNFa antagonist, or an IL-I . antagonist.
  • the corticosteroid can be prednisone, prednisolone, or methylprednisolone. Corticosteroids such as these may also be administered with either chlorambusil or mycophenylate mofetil.
  • the TNFa antagonist is infliximab, etanercept, or adalimumab.
  • the IL-I antagonist is anakinra.
  • the immunosuppressant is mycophenylate mofetil, cyclosporin, azathioprine, methotrexate, alefacept, rituximab, anti-interferon gamma, or cyclophosphamide.
  • the anti-infective is dapsone, or hydroxychloroquine.
  • the gold salt is myochrysine, or solganal.
  • the alkylating agent is lukeran.
  • the antibiotic is tetracycline, minocycline, or doxycycline.
  • the method further comprises administration of nicotinamide, or niacinamide.
  • the methods of the invention further comprise administering plasmapher sis therapy or photophoresis therapy to the subject.
  • the dosage of ingredient(s) A is reduced by from about 10% to about 90% in comparison to the dosage used to achieve the same therapeutic effect with ingredient(s) A alone. In some embodiments, the dosage is reduced by at least about 10%, about 20%, about 30%, about 40%, about 50%, or about 60%.
  • ingredient(s) A is a corticosteroid, for example, prednisone or prednisolone. In some other embodiments, ingredient(s) A comprises a corticosteroid and either chlorambusil or mycophenylate mofetil.
  • the dosage of prednisone is reduced to less than about 70 mg/day, less than about 50 mg/day, less than about 30 mg/day, less than about 20 mg/day, less than about 15 mg/ day, or less than about 10 mg/day.or
  • the cytokine inhibitor is administered orally or topically.
  • ingredient(s) A is a corticosteroid or antibiotic and is administered orally, topically, in a mouthwash or in a mouth spray.
  • the pharmaceutical combinations of ingredient A and compound(s) described herein may be administered in any conventional dosage form in any conventional manner, including any of the routes described herein.
  • routes of administration include, but are not limited to, intravenous, intramuscular, subcutaneous, intrasynovial, by infusion, sublingual, transdermal, oral, topical and by inhalation. Typical modes of administration are oral, topical or intravenous.
  • the pharmaceutical combinations of ingredient A and the compound as described herein may be administered separately, or in a combination formulation with other ingredients or adjuvants that enhance stability of the inhibitors, facilitate administration of pharmaceutical compositions containing them, provide increased dissolution or dispersion, increase inhibitory activity, provide adjunct therapy, or provide like advantages.
  • Such combination therapies typically utilize lower dosages of the conventional therapeutics, and avoid the possible toxicity and adverse side effects incurred when those agents are used as monotherapies.
  • Pharmaceutical combinations of ingredient A and the compound may therefore be physically combined with the conventional therapeutics or other adjuvants into a single pharmaceutical composition.
  • the ingredient A and/or the compound may be used in the combination as a salt, solvate, tautomer and/or prodrug and as a single stereoisomer or mixtures of stereoisomers, including racemates.
  • ingredient A and the compound as described herein may be used in the combinations according to the invention are variable.
  • Ingredient(s) A and the compound are optionally present in the form of their solvates or hydrates.
  • the weight ratios which may be used within the scope of the present invention vary on the basis of the different molecular weights of the various compounds and their different potencies. Determination of ratios by weight is dependent on the particular ingredient A and the compound, and are within the skill in the art.
  • references to a certain element such as hydrogen or H is meant to include all isotopes of that element.
  • an R group is defined to include hydrogen or H, it also includes deuterium and tritium.
  • isotopically labeled compounds are within the scope of the invention.
  • substituted refers to an organic group as defined below (e.g., an alkyl group) in which one or more bonds to a hydrogen atom contained therein are replaced by a bond to non-hydrogen or non-carbon atoms.
  • Substituted groups also include groups in which one or more bonds to a carb ⁇ n(s) or hydrogen(s) atom are replaced by one or more bonds, including double or triple bonds, to a heteroatom.
  • a substituted group will be substituted with one or more substituents, unless otherwise specified.
  • a substituted group is substituted with 1, 2, 3, 4, 5, or 6 substituents. Examples of substituent .
  • halogens i.e., F, Cl, Br 3 and I
  • hydroxyls alkoxy, alkenoxy, alkynoxy, aryloxy, aralkyloxy, heterocyclyloxy, and heterocyclylalkoxy groups
  • carbonyls oxo
  • carboxyls esters; urethanes; oximes; hydroxyl amines; alkoxyamines; aralkoxyamines; thiols; sufides; sulfoxides; sulfones; sulfonyls; sulfonamides; amines; N-oxides; hydrazines; hydrazides; hydrazones; azides; amides; ureas; amidines; guanidines; enamines; imides; isocyanates; isothiocyanates; cyanates; thiocyanates; imines; nitriles (i.e. CN); and the like.
  • Substituted ring groups such as substituted cycloalkyl, aryl, heterocyclyl and heteroaryl groups also include rings and fused ring systems in which a bond to a hydrogen atom is replaced with a bond to a carbon atom. Therefore, substituted cycloalkyl, aryl, heterocyclyl and heteroaryl groups may also be substituted with substituted or unsubstituted alkyl, alkenyl, and alkynyl groups as defined below.
  • Alkyl groups include straight chain and branched alkyl groups having from 1 to about 20 carbon atoms, and typically from 1 to 12 carbons or, in some embodiments, from 1 to 8, 1 to 6, or 1 to 4 carbon atoms.
  • Alkyl groups further include cycloalkyl groups as defined below.
  • straight chain alkyl groups include those with from 1 to 8 carbon atoms such as methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, n-heptyl, and n- octyl groups.
  • branched alkyl groups include, but are not limited to, isopropyl, iso-butyl, sec-butyl, tert-butyl, neopentyl, isopentyl, and 2,2-dimethylpropyl groups.
  • Representative substituted alkyl groups may be substituted one or more times with substituents such as those listed above.
  • Cycloalkyl groups are cyclic alkyl groups such as, but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl groups.
  • the cycloalkyl group has 3 to 10 or 3 to 8 ring members, whereas in other embodiments the number of ring carbon atoms range from 3 to 5, 3 to 6, or 3 to 7.
  • Cycloalkyl groups further include mono-, bicyclic and polycyclic ring systems, such as, for example bridged cycloalkyl groups as described below, and fused rings, such as, but not limited to, decalinyl, and the like.
  • polycyclic cycloalkyl groups have three rings. Substituted cycloalkyl groups may be substituted one or more times with non- hydrogen and non-carbon groups as defined above. However, substituted cycloalkyl groups also include rings that are substituted with straight or branched chain alkyl groups as defined above. Representative substituted cycloalkyl groups may be mono-substituted or substituted more than once, such as, but not limited to, 2,2-, 2,3-, 2,4- 2,5- or 2,6-disubstituted cyclohexyl groups, which may be substituted with substituents such as those listed above.
  • Bridged cycloalkyl groups are cycloalkyl groups in which two or more hydrogen atoms are replaced by an alkylene bridge, wherein the bridge can contain 2 to 6 carbon atoms if two hydrogen atoms are located on the same carbon atom, or 1 to 5 carbon atoms if the two hydrogen atoms are located on adjacent carbon atoms, or 2 to 4 carbon atoms if the two hydrogen atoms are located on carbon atoms separated by 1 or 2 carbon atoms.
  • Bridged cycloalkyl groups can be bicyclic, such as, for example bicyclo[2.1.l]hexane, or tricyclic, such as, for example, adamantyl.
  • Representative bridged cycloalkyl groups include bicyclo[2.1.l]hexyl, bicyclo[2.2.1]heptyl, bicyclo[3.2.1]octyl, bicyclo[2.2.2]octyl, bicyclo[3.2.2]nonyl, bicyclo[3.3.1]nonyl, bicyclo[3.3.2]decanyl, adamantyl, noradamantyl, bomyl, or norbornyl groups.
  • Substituted bridged cycloalkyl groups may be substituted one or more times with non-hydrogen and non-carbon groups as defined above.
  • Representative substituted bridged cycloalkyl groups may be mono-substituted or substituted more than once, such as, but not limited to, mono-, di- or tri-substituted adamantyl groups, which may be substituted with substituents such as those listed above.
  • Cycloalkylalkyl groups are alkyl groups as defined above in which a hydrogen or carbon bond of an alkyl group is replaced with a bond to a cycloalkyl group as defined above.
  • cycloalkylalkyl groups have from 4 to 20 carbon atoms, 4 to 16 carbon atoms, and typically 4 to 10 carbon atoms.
  • Substituted cycloalkylalkyl groups may be substituted at the alkyl, the cycloalkyl or both the alkyl and cycloalkyl portions of the group.
  • Representative substituted cycloalkylalkyl groups may be mono-substituted or substituted more than once, such as, but not limited to, mono-, di- or tri-substituted with substituents such as those listed above.
  • Alkenyl groups include straight and branched chain and cycloalkyl groups as defined above, except that at least one double bond exists between two carbon atoms.
  • alkenyl groups have from 2 to about 20 carbon atoms, and typically from 2 to 12 carbons or, in some embodiments, from 2 to 8,'2 to 6, or 2 to 4 carbon atoms.
  • alkenyl groups include cycloalkenyl groups having from 4 to 20 carbon atoms, 5 to 20 carbon atoms, 5 to 10 carbon atoms, or even 5, 6, 7 or 8 carbon atoms.
  • Representative substituted alkenyl groups may be mono- substituted or substituted more than once, such as, but not limited to, mono-, di- or tri- substituted with substituents such as those listed above.
  • Cycloalkenylalkyl groups are alkyl groups as defined above in which a hydrogen or carbon bond of the alkyl group is replaced with a bond to a cycloalkenyl group as defined above. Substituted cycloalkenylalkyl groups may be substituted at the alkyl, the cycloalkenyl or both the alkyl and cycloalkenyl portions of the group. Representative substituted cycloalkenylalkyl groups may be substituted one or more times with substituents such as those listed above. [00208] Alkynyl groups include straight and branched chain alkyl groups, except that at least one triple bond exists between two carbon atoms.
  • Representative substituted alkynyl groups may be mono-substituted or substituted more than once, such as, but not limited to, mono-, di- or tri-substituted with substituents such as those listed above.
  • Aryl groups are cyclic aromatic hydrocarbons that do not contain heteroatoms.
  • Aryl groups include monocyclic, bicyclic and polycyclic ring systems.
  • aryl groups include, but are not limited to, phenyl, azulenyl, heptalenyl, biphenylenyl, indacenyl, fluorenyl, phenanthrenyl, triphenylenyl, pyrenyl, naphthacenyl, chrysenyl, biphenyl, anthracenyl, indenyl, indanyl, pentaienyl, and naphthyl groups.
  • aryl groups contain 6-14 carbons, and in others from 6 to 12 or even 6 to 10 carbon atoms in the ring portions of the groups.
  • aryl groups includes groups containing fused rings, such as fused aromatic-aliphatic ring systems (e.g., indanyl, tetrahydronaphthyl, and the like), it does not include aryl groups that have other groups, such as alkyl or halo groups, bonded to one of the ring members. Rather, groups such as tolyl are referred to as substituted aryl groups.
  • Representative substituted aryl groups may be mono-substituted or substituted more than once.
  • monosubstituted aryl groups include, but are not limited to, 2-, 3-, 4-, 5-, or 6-substituted phenyl or naphthyl groups, which may be substituted with substituents such as those listed above.
  • Aralkyl groups are alkyl groups as defined above in which a hydrogen or carbon bond of an alkyl group is replaced with a bond to an aryl group as defined above.
  • aralkyl groups contain 7 to 20 carbon atoms, 7 to 14 carbon atoms or 7 to 10 carbon atoms. Substituted aralkyl groups may be substituted at the alkyl, the aryl, or both the alkyl and the aryl portions of the group.
  • Representative aralkyl groups include but are not limited to benzyl and phenethyl groups and fused (cycloalkylaryl)alkyl groups such as 4- ethyl-indanyl.
  • Heterocyclyl groups include aromatic (also referred to as heteroaryl) and non- aromatic ring compounds containing 3 or more ring members, of which one or more is a heteroatom such as, but not limited to, N, O, and S.
  • heterocyclyl groups include 3 to 20 ring members, whereas other such groups have 3 to 6, 3 to 10, 3 to 12, or 3 to 15 ring members.
  • Heterocyclyl groups encompass unsaturated, partially saturated and saturated ring systems, such as, for example, imidazolyl, imidazolinyl and imidazolidinyl groups.
  • heterocyclyl group includes fused ring species including those comprising fused aromatic and non-aromatic groups, such as, for example, benzotriazolyl, 2,3-dihydrobenzo[l,4]dioxinyl, and benzo[l,3]dioxolyl.
  • the phrase also includes bridged polycyclic ring systems containing a heteroatom such as, but not limited to, quinuclidyl.
  • the phrase does not include heterocyclyl groups that have other groups, such as alkyl, oxo or halo groups, bonded to one of the ring members. Rather, these are referred to as "substituted heterocyclyl groups".
  • Heterocyclyl groups include, but are not limited to, aziridinyl, azetidinyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, thiazolidinyl, tetrahydrothiophenyl, teteahydrofuranyl, dioxolyl, furanyl, thiophenyl, pyrrolyl, pyrrolinyl, imidazolyl, imidazolinyl, pyrazolyl, pyrazolinyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, thiazolyl, thiazolinyl, isothiazolyl, thiadiazolyl, oxadiazolyl, piperidyl, piperazinyl, morpholinyl, thiomorpholinyl, tetrahydropyranyl, tetrahydrothiopyranyl, o
  • substituted heterocyclyl groups may be mono- substituted or substituted more than once, such as, but not limited to, pyridyl or morpholinyl groups, which are 2-, 3-, 4-, 5-, or 6-substituted, or disubstituted with various substituents such as those listed above.
  • Heteroaryl groups are aromatic ring compounds containing 5 or more ring members, of which one or more is a heteroatom such as, but not limited to, N, O, and S.
  • Heteroaryl groups include, but are not limited to, groups such as pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, thiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiophenyl, benzothiophenyl, furanyl, benzofuranyl, indolyl, azaindolyl (pyrrolopyridyl), indazolyl, benzimidazolyl, imidazopyridyl (azabenzimidazolyl), pyrazolopyridyl, triazolopyridyl, benzotriazolyl, benzoxazolyl
  • heteroaryl groups includes fused ring compounds such as indolyl and 2,3-dihydro indolyl, the phrase does not include heteroaryl groups that have other groups bonded to one of the ring members, such as alkyl groups. Rather, heteroaryl groups with such substitution are referred to as "substituted heteroaryl groups”. Representative substituted heteroaryl groups may be substituted one or more times with various substituents such as those listed above.
  • Heterocyclylalkyl groups are alkyl groups as defined above in which a hydrogen or carbon bond of an alkyl group is replaced with a bond to a heterocyclyl group as defined above. Substituted heterocyclylalkyl groups may be substituted at the alkyl, the heterocyclyl or both the alkyl and heterocyclyl portions of the group.
  • heterocyclyl alkyl groups include, but are not limited to, 4-ethyl-morpholinyl, 4- propylmorpholinyl, furan-2-yl methyl, furan-3-yl methyl, pyridine-3-yl methyl, tetrahydrofuran-2-yl ethyl, and indol-2-yl propyl.
  • Representative substituted heterocyclylalkyl groups may be substituted one or more times with substituents such as those listed above.
  • Heteroaralkyl groups are alkyl groups as defined above in which a hydrogen or carbon bond of an alkyl group is replaced with a bond to a heteroaryl group as defined above. Substituted heteroaralkyl groups may be substituted at the alkyl, the heteroaryl, or both the alkyl and heteroaryl portions of the group. Representative substituted heteroaralkyl groups may be substituted one or more times with substituents such as those listed above. [00215] Alkoxy groups are hydroxyl groups (-OH) in which the bond to the hydrogen atom is replaced by a bond to a carbon atom of a substituted or unsubstituted alkyl group as defined above.
  • linear alkoxy groups include but are not limited to methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, and the like.
  • branched alkoxy groups include but are not limited to isopropoxy, sec-butoxy, tert-butoxy, isopentoxy, isohexoxy, and the like.
  • cycloalkoxy groups include but are not limited to cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, and the like.
  • Representative substituted alkoxy groups may be substituted one or more times with substituents such as those listed above.
  • aryloxy and arylalkoxy refer to, respectively, a substituted or unsubstituted aryl group bonded to an oxygen atom and a substituted or unsubstituted aralkyl group bonded to the oxygen atom at the alkyl. Examples include but are not limited to phenoxy, naphthyloxy, and benzyloxy. Representative substituted aryloxy and arylalkoxy groups may be substituted one or more times with substituents such as those listed above.
  • Alkyl, alkenyl, and alkynyl groups may be divalent as well as monovalent.
  • alkyl, alkenyl, or alkynyl group will be readily apparent from the context to those of skill in the art.
  • the aikyl group in an aralkyl group is divalent.
  • divalency is expressly indicated by appending the suffix "ene” or "ylene” to terms defined herein.
  • alkylene refers to divalent alkyl groups
  • alkenylene refers to divalent alkene groups.
  • carboxylate refers to a -COOH group.
  • R 30 is a substituted or unsubstituted alkyl, cycloalkyl, alkenyl, alkynyl, aryl, aralkyl, heterocyclylalkyl or heterocyclyl group as defined herein.
  • amide (or “amido”) includes C- and N-amide groups, i.e.,
  • R 31 and R 32 are independently hydrogen, or a substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heterocyclylalkyl or heterocyclyl group as defined herein.
  • Amido groups therefore include but are not limited to carbamoyl groups (-C(O)NH2) and formamide groups (-NHC(O)H).
  • Urethane groups include N- and O-urethane groups, i.e., -NR 33 C(O)OR 34 and
  • R 33 and R 34 are independently hydrogen, or a substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heterocyclylalkyl, or heterocyclyl group as defined herein.
  • amine refers to -NHR 35 and -NR 36 R 37 groups, wherein R 35 , R 36 and R 37 are independently hydrogen, or a substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heterocyclylalkyl or heterocyclyl group as defined herein.
  • the amine is NH 2 , methylamino, dimethylamino, ethylamino, diethylamino, propylamino, isopropylamino, phenylamino, or benzylamino.
  • sulfonamido includes S- and N-sulfonamide groups, i.e.,
  • R 38 and R 39 are independently hydrogen, or a substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heterocyclylalkyl, or heterocyclyl group as defined herein.
  • Sulfonamido groups therefore include but are not limited to sulfamoyl groups (-SO 2 NH 2 ).
  • thiol refers to -SH groups
  • sulfides include -SR 40 groups
  • sulfoxides include -S(O)R 41 groups
  • sulfones include -SO 2 R 42 groups
  • sulfonyls include -SO 2 OR 43 .
  • R 40 , R 41 , R 42 , and R 43 are each independently a substituted or unsubstituted alkyl, cycloalkyl, alkenyl, alkynyl, aryl aralkyl, heterocyclyl or heterocyclylalkyl group as defined herein.
  • urea refers to -NR 4 ⁇ C(O)-NR 45 R 46 groups.
  • R 44 , R 45 , and R 46 groups are independently hydrogen, or a substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heterocyclyl, or heterocyclylalkyl group as defined herein.
  • amidine refers to -C(NR 47 )NR 48 R 49 and -NR 47 C(NR 48 )R 49 , wherein R 47 , R 48 , and R 49 are each independently hydrogen, or a substituted or unsubstituted alkyl, cycloalkyl, alkenyl, alkynyl, aryl aralkyl, heterocyclyl or heterocyclylalkyl group as defined herein.
  • guanidine refers to -NR 50 C(NR 5 ⁇ NR 52 R 53 , wherein R 50 , R 51 , R 52 and R 53 are each independently hydrogen, or a substituted or unsubstituted alkyl, cycloalkyl, alkenyl, alkynyl, aryl aralkyl, heterocyclyl or heterocyclylalkyl group as defined herein.
  • R 54 , R 55 , R 56 and R 57 are each independently hydrogen, a substituted or unsubstituted alkyl, cycloalkyl, alkenyl, alkynyl, aryl aralkyl, heterocyclyl or heterocyclylalkyl group as defined herein.
  • imide refers to -C(O)NR 58 C(O)R 59 , wherein R 5S and R 59 are each independently hydrogen, or a substituted or unsubstituted alkyl, cycloalkyl, alkenyl, alkynyl, aryl aralkyl, heterocyclyl or heterocyclylalkyl group as defined herein.
  • the term "imine” refers to -CR 60 (NR 61 ) and -N(CR 60 R 61 ) groups, wherein R 60 and R 61 are each independently hydrogen or a substituted or unsubstituted alkyl, cycloalkyl, alkenyl, alkynyl, aryl aralkyl, heterocyclyl or heterocyclylalkyl group as defined herein, with the proviso that R 60 and R 61 are not both simultaneously hydrogen.
  • protected with respect to hydroxyl groups, amine groups, carboxy groups, and sulfhydryl groups refers to forms of these functionalities which are protected from undesirable reaction by means of protecting groups.
  • Protecting groups are known to those skilled in the art and can be added or removed using well-known procedures, such as those set forth in Protective Groups in Organic Synthesis, Greene, T.W.; Wuts, P. G. M., John Wiley & Sons, New York, NY, (3rd Edition, 1999).
  • Examples of protected hydroxyl groups include, but are not limited to, silyl ethers such as those obtained by reaction of a hydroxyl group with a reagent such as, but not limited to, t-butyldimethyl-chlorosilane, trimethylchlorosilane, triisopropylchlorosilane, triethylchlorosilane; substituted methyl and ethyl ethers such as, but not limited to methoxymethyl ether, methythiomethyl ether, benzyloxymethyl ether, t-butoxymethyl ether, 2-methoxyethoxymethyl ether, tetrahydropyranyl ethers, 1-ethoxyethyl ether, allyl ether, benzyl ether; esters such as, but not limited to, benzoylformate, formate, acetate, trichloroacetate, and trifluoroacetate.
  • a reagent such as, but not limited
  • N-Protecting groups comprise acyl groups such as formyl, acetyl, propionyl, pivaloyl, t-butylacetyl, 2-chloroacetyl, 2-bromoacetyl, trifluoroacetyl, trichloroacetyl, phthalyl, o-nitrophenoxyacetyl, a-chlorobutyryl, benzoyl, 4-chlorobenzoyl, 4-bromobenzoyl, 4-nitrobenzoyl, and the like; sulfonyl groups such as benzenesulfonyl, p-toluenesulfonyl, and the like; carbamate forming groups such as benzyl ox ycarbonyl, p-chlorobenzyloxycarbonyl, p-methoxybenzyloxycarbonyl, p-nitrobenzyloxycarbonyl, 2 ⁇ nitrobenzyloxycarbony
  • N-protecting groups are formyl, acetyl, benzoyl, pivaloyl, t-butylacetyl, phenylsulfonyl, benzyl, 9,-fluorenylmethyloxycarbonyl (Fmoc), t-butyloxycarbonyl (Boc) and benzyloxycarbonyl (Cbz).
  • Examples of protected sulfhydryl groups include, but are not limited to, thioethers such as S-benzyl thioether, S-t-butylthioether, and S-4-picolyl thioether; substituted S -methyl derivatives such as hemithio, dithio and aminothio acetals; and others.
  • thioethers such as S-benzyl thioether, S-t-butylthioether, and S-4-picolyl thioether
  • substituted S -methyl derivatives such as hemithio, dithio and aminothio acetals
  • Representative carboxy protecting groups are Ci to Cs alkyl (e.g., methyl, ethyl or tertiary butyl and the like); haloalkyl; alkenyl; cycloalkyl and substituted derivatives thereof such as cyclohexyl, cyclopentyl, and the like; cycloalkylalkyl and substituted derivatives thereof such as cyclohexylmethyl, cyclopentylm ethyl, and the like; arylalkyl, for example, phenethyl or benzyl and substituted derivatives thereof such as alkoxybenzyl or nitrobenzyl groups, and the like; arylalkenyl, for example, phenylethenyl and the like; aryl and substituted derivatives thereof, for example, 5-indanyl and the like; dialkylaminoalkyl (e.g., dimethylaminoethyl, and the like); alkano
  • alkoxycarbonylalkyl such as methoxycarbonylmethyl, cyclohexyloxycarbonylmethyl, 1-methoxycarbonyl-l -ethyl, and the like
  • alkoxycarbonyloxyalkyl such as methoxycarbonyloxymethyl, t-butyloxycarbonyloxymethyl, 1 -ethoxycarbonyloxy- 1 -ethyl, 1 -cyclohexyloxycarbonyloxy- 1 - ethyl, and the like
  • alkoxycarbonylaminoalkyl such as t-butyloxycarbonylaminomethyl, and the like
  • alkylaminocarbonylaminoalkyl such as methylaminocarbonylaminomethyl, and the like
  • alkanoylaminoalkyl such as acetylaminomethyl, and the like
  • heterocyclic such as methoxycarbonylmethyl, cyclohexyloxycarbonylmethyl, 1-meth
  • Tautomers refers to isomeric forms of a compound that are in equilibrium with each other. The concentrations of the isomeric forms will depend on the environment the compound is found in and may be different depending upon, for example, whether the compound is a solid or is in an organic or aqueous solution. For example, in aqueous solution, triazoles may exhibit the following isomeric forms, which are referred to as tautomers of each other:
  • Stereoisomers of compounds include all chiral, diastereomeric, and racemic forms of a structure, unless the specific stereochemistry is expressly indicated.
  • compounds used in the present invention include enriched or resolved optical isomers at any or all asymmetric atoms as are apparent from the depictions.
  • racemic and diastereomeric mixtures, as well as the individual optical isomers can be isolated or synthesized so as to be substantially free of their enantiomeric or diastereomeric partners, and these are all within the scope of the invention.
  • a solvate is an aggregation of a molecule and one or more molecules of solvent. Some compounds have a tendency to associate with a fixed molar ratio of solvent molecules in the solid state.
  • the solvent molecules may interact with the non- solvent molecule by dipole-dipole interactions, ion-dipole interactions, coordinate bonds, and the like.
  • the solvent is water, the solvate is referred to as a hydrate.
  • Many organic solvents can also form solvates, including, e.g., ethers such as diethyl ether and tetrahydrofuran, alcohols such as methanol and ethanol, ketones such as acetone, DMF, DMSO and others.
  • Solvates may be identified by various methods known in the art. For example, solvates in which the solvent molecules contain hydrogen may be observable by 1 H NMR. Additional methods useful in identifying solvates include thermogravimetric analysis, differential scanning calorimetry, X-ray analysis and elemental analysis. Solvates are readily formed simply by dissolving a compound in a solvent and removing the unassociated solvent by suitable techniques, e.g., evaporation, freeze drying or crystallization techniques. It is therefore well within the skill in the art to produce such solvates. Indeed, it is often the case that careful drying of a compound is necessary to remove the residual solvent that is part of a solvate. Compounds described herein may form solvates and all such solvates are within the scope of the invention.
  • prodrugs Certain compounds within the scope of the invention are derivatives referred to as “prodrugs".
  • the expression “prodrug” denotes a derivative of a known direct acting drug, e.g., esters and amides, which derivative has enhanced delivery characteristics and therapeutic value as compared to the drug, and is transformed into the active drug by an enzymatic or chemical process; see Notari, R.E., "Theory and Practice of Prodrug Kinetics," Methods in En ⁇ ymology J J 2:309-323 (1985); Bodor, N., “Novel Approaches in Prodrug Design," Drugs of the Future 5:165-182 (1981); and Bundgaard, H., “Design of Prodrugs: Bioreversible-Derivatives for Various Functional Groups and Chemical Entities,” in Design of Prodrugs (H.
  • compositions are considered within the scope of the present invention.
  • pharmaceutically acceptable salts can be formed with inorganic acids (such as hydrochloric acid, hydroboric acid, nitric acid, sulfuric acid, and phosphoric acid), organic acids (e.g., formic acid, acetic acid, trifluoroacetic acid, fumaric acid, oxalic acid, tartaric acid, lactic acid, maleic acid, citric acid, succinic acid, malic acid, methanesulfonic acid, benzenesulfonic acid, and p-toluenesulfonic acid) or acidic amino acids (such as aspartic acid and glutamic acid).
  • inorganic acids such as hydrochloric acid, hydroboric acid, nitric acid, sulfuric acid, and phosphoric acid
  • organic acids e.g., formic acid, acetic acid, trifluoroacetic acid, fumaric acid, oxalic acid, tartaric acid, lactic acid,
  • the compound of the invention when it has an acidic group, such as for example, a carboxylic acid group, it can form salts with metals, such as alkali and earth alkali metals (e.g., Na + , Li + , K + , Ca 2+ , Mg 2+ , Zn 2+ ), ammonia, organic amines (e.g., trimethylamine, triethylamine, pyridine, picoline, ethanolamine, diethanolamine, triethanolamine), or basic amino acids (e.g., arginine, lysine and ornithine).
  • alkali and earth alkali metals e.g., Na + , Li + , K + , Ca 2+ , Mg 2+ , Zn 2+
  • ammonia e.g., organic amines (e.g., trimethylamine, triethylamine, pyridine, picoline, ethanolamine, diethanolamine, triethanolamine), or basic amino acids
  • L' when L' contains a carbonyl moiety or oxygen linker, L' can be L 2 -Q, wherein L 2 is -C(O)- or O(CH2) n C(O) respectively, and Q is as defined herein.
  • L' when L' contains a protected carboxylate group (e.g. ester), this group is deprotected under basic or acidic conditions (for example, NaOH or TFA respectively), followed by coupling with HNR-Q to form compound e, wherein L 2 is C(O)NR.
  • L' when L' contains a protected amine, it can be deprotected and coupled with Q-COOH by the methods described herein, leading to compound e, wherein L 2 is C(O)NR.
  • Coupling between amine and carboxylate-containing moieties may be effected, for example, by the use of typical amide-bond-forming reagents such as DCC, EDC, CDI, BOP, PyBOP, HATU, HBTU, HCTU, TATU, TBTU, TDBTU, DEPBT 5 TSTU, and the like, or by introduction of an activating moiety on the carboxylate.
  • the activating moiety is a sufficiently reactive leaving group to allow for amide bond formation under mild conditions.
  • Typical activating moieties include F, Cl, Br, I, N 3 , N-hydroxysuccinimide, 1-hydroxybenzotriazole, l-hydroxy-7-azabenzotriazole, pentafluorophenol, pentachlorophenol, para-nitrophenol, or OC(O)-OR y , wherein R y is a C 1 . 6 alkyl group.
  • Suitable bases include sodium bicarbonate or a suitable organoamine, such as pyridine, N-methylmorpholine, diisopropylethylamine or triethylamine.
  • any suitable amide- bond forming procedure may be used, such as those described in Bodanszky, M. and Bodanszky, A., The Practice of Peptide Synthesis, Springer-Verlag (1984); or Jones, J. Amino Acid and Peptide Synthesis Ed. Steven G. Davies, Oxford Science (1992).
  • the synthesis may be continued by reducing the nitro group of compound e to the amine as in compound f.
  • Any suitable method may be used for the reduction including, for example, hydrogenation in a solvent such as MeOH, EtOH, or the like, using Raney nickel or Pd/C as a catalyst, or reaction with SnCl 2 in a solvent such as DMF at room temperature.
  • Target compounds of Formula I may be obtained by coupling compound f with a G-COOH moiety by one of the coupling methods described herein.
  • the nitro group in compound c is reduced first, followed by coupling with G-COOH, and finally conversion of L' to L 2 -Q, using the methods described herein.
  • the nitro group in compound a is reduced, followed by coupling of the amine group with G-COOH, cross-coupling with a suitable arylboronic acid to obtain compound h, and finally conversion of L' to L 2 -Q, again using the methods described herein.
  • compounds containing the alternate orientation of L 1 can also be obtained by starting from a derivatized pyridine containing a protected carboxylate instead of a nitro moiety.
  • the azide moiety is introducted by reacting a suitably derivatized bromo-pyridine or bromo-pyridazine with an organolithium reagent, followed by tosylazide.
  • a protic solvent such as, for example water, acetonitrile, or mixtures thereof, optionally in the presence of copper (Cu (0) metal, Cu (I) or Cu (!l) salts
  • L' when L' is an alkyl, cycloalkyl, aryl, heterocycyl, aralkyl or heterocyclylalkyl group, L' can be L 2 -Q, wherein L 2 is a covalent bond, and Q is as defined herein.
  • L' contains a protected carboxylate group (e.g. ester)
  • this group is deprotected under basic or acidic conditions (for example, NaOH or TFA respectively), followed by coupling with HNR-Q to form compound m, wherein L 2 is C(O)NR.
  • the nitro group of compound m is reduced to the amine as in compound n, by the methods described herein.
  • Target compounds of Formula II, wherein B and D are N are obtained by coupling compound n with a G-COOH moiety by one of the coupling methods described herein.
  • the nitro group in compound j can be reduced first, followed by coupling with G-COOH, and finally conversion of L' to L 2 -Q, using the methods described herein.
  • Reaction with (Z)-ethyl 2-formyl-3-hydroxyacrylate (J.Org.Chem., 1982, 47, 2216) leads to formation of the pyrazole intermediate q, wherein R is H, and L' is C(O)OEt.
  • Scheme 3 also shows the synthesis of intermediates of structure r which are precursors to compounds of Formula II, wherein B is CR and D is N.
  • the sequence of derivatization can also be reversed, so that G-L 2 is attached to the core ring first, followed by the synthesis steps shown in Scheme 3.
  • Scheme 4 shows additional synthesis routes towards intermediates for compounds of Formula II.
  • Compounds v can be obtained by nucleophilic aromatic substitution of fluorinated pyridine or pyridazine derivatives s by the appropriately derivatized 5-membered heterocycles.
  • compounds of structure t wherein Hal is Br, Cl, or I
  • u wherein W is a boronic acid or boronic ester derivative
  • Compounds of structure u may be obtained from compounds of structure t wherein Hal is Br.
  • the sequence of synthesis steps, as before, can be altered, so that coupling of G-L 2 is performed before attachment of the 5-membered heterocyclyl moiety.
  • pyridine precursors for the alternate orientations of L 1 can be prepared by reported methods (see for example, International Application PCT/US06/042679, J. Med. Chem., 1974, 17, 172; J. Org. Chem., 1984, 49, 193; J. Am. Chem. Soc, 1953, 75, 737; J. Med. Chem., 1977, 20, 129; J. Am. Chem. Soc, 1961, 26, 3420; J. Am. Chem. Soc, 1947, 69, 2574; J. Med. Chem., 1978, 21, 194; J. Med.
  • intermediate x was obtained by oxidation of the (lH-l,2,3-triazol-l-yl)propan-2-ol intermediate by well known methods (e.g. Dess-Martin oxidation).
  • intermediate x was prepared starting from either the corresponding chloroethanone or tosylethanone derivative (prepared from the hydroxyethanone derivative) by reaction with sodium azide to generate the azidoethanone intermediate, which was cyclized with a suitable alkyne in the presence of copper wire.
  • a "cytokine inhibitor" within the context of this invention is a compound which at a concentration of 10 ⁇ M inhibits induced cytokine release from a cell by about 50% or greater than 50%.
  • induction of TNFa release can be achieved by, but not limited to, treatment of a cell or cell line with lipopolysaccharide (LPS) or IL-Ib and is inhibited by compounds described herein.
  • LPS lipopolysaccharide
  • IL-Ib IL-Ib
  • Treating within the context of the instant invention, means an alleviation, in whole or in part, of symptoms associated with a disorder or disease, or slowing, or halting of further progression or worsening of those symptoms, or prevention or prophylaxis of the disease or disorder in a subject at risk for developing the disease or disorder.
  • a "therapeutically effective amount" of a compound of the invention refers to an amount of the compound that alleviates, in whole or in part, symptoms associated with a disorder or disease, or slows or halts further progression or worsening of those symptoms, or prevents or provides prophylaxis for the disease or disorder in a subject at risk for developing the disease or disorder.
  • the therapeutically effective amount of a compound disclosed herein may vary depending on the indication being treated, e.g., the therapeutically effective amount of a compound described herein would likely be different for treating subjects suffering from, or at risk for, cytokine- mediated disorders relative to the therapeutically effective amount of the compound for treating subjects suffering from, or at risk of, a different disorder, e.g., vascular event(s), diabetes, insulin resistance, or metabolic syndrome.
  • a different disorder e.g., vascular event(s), diabetes, insulin resistance, or metabolic syndrome.
  • the therapeutically effective amount of a compound for decreasing CRP-levels in a subject would likely be different from the therapeutically effective amount for raising HDL-levels in a subject.
  • a subject is any animal that can benefit from the administration of a compound as described herein.
  • the subject is a mammal, for example, a human, a primate, a dog, a cat, a horse, a cow, a pig, a rodent, such as for example a rat or mouse.
  • the subject is a human.
  • C-reactive protein is a plasma protein, and an acute phase protein produced by the liver.
  • CRP is a member of the class of acute phase reactants as its levels rise dramatically during inflammatory processes occurring in the body.
  • CRP is used mainly as a marker of inflammation. Measuring and charting C-reactive protein values can prove useful in determining disease progress or the effectiveness of treatments.
  • Blood usually collected in a serum-separating tube, is analysed in a medical laboratory or at the point of testing.
  • Various analytical methods are available for CRP determination, such as ELISA, immunoturbidimetiy, rapid immunodiffusion and visual agglutination. Research suggests that patients with elevated basal levels of CRP are at an increased risk for diabetes, hypertension and cardiovascular disease. It is thought that CRP levels ⁇ lmg/l represent low cardiovascular risk, while levels >3mg/l represent high risk.
  • Lipoproteins are complexes which contain both a lipid and protein. Most of the lipids in plasma are present as lipoproteins and are transported as such. Lipoproteins are characterized by their flotation constants (e.g., densities). Various classes of lipoproteins exist and include high density lipoproteins (HDL) and low density lipoproteins (LDL). The HDL fraction comprises two major fractions, namely HDL 2 (large, buoyant HDL, density 1.063 - . 1.125 g/ml) and HDL 3 (small, dense HDL, density 1.125-1.21 g/ml). LDLs are particularly rich in cholesterol esters.
  • HDL 2 large, buoyant HDL, density 1.063 - . 1.125 g/ml
  • HDL 3 small, dense HDL, density 1.125-1.21 g/ml
  • LDL and/or low levels of HDL are associated with coronary artery disease.
  • Epidemiological studies have shown that high concentrations of HDL (over 60 mg/dl) have protective value against cardiovascular diseases.
  • Low concentrations of HDL (below 40 mg/dl for men, below 50 mg/dl for women) are a positive risk factor for atherosclerotic diseases.
  • a near optimal level of LDL is considered to be between 100 to 129 mg/dl, with levels below 100 mg/dl considered optimal, while very high LDL levels (above 190 mg/dl) correspond to the highest increased risk of heart disease.
  • the second method based on density gradient ultracentrifugation, measures the amount of cholesterol across a range of densities and utilizes deconvolution to determine the amount of cholesterol in each fraction (HDL, including HDL 2 and HDL 3 , LDL, IDL, VLDL).
  • Apolipoprotein A-I is the major protein component of HDL in plasma. The protein promotes cholesterol efflux from tissues to the liver for excretion and helps to clear cholesterol from arteries.
  • Glucose or "blood sugar" is normally present in humans at concentrations of about 80-120 mg/dl and is the principal source of carbohydrate energy for man and many other organisms. Excess glucose is stored in the body (especially in the liver and muscles) as glycogen, a starch-like substance which is, essentially, polymerized glucose. Glycogen is metabolized into glucose as needed to meet bodily requirements.
  • Glucose normally stimulates both the secretion and biosynthesis of insulin.
  • basal insulin secretion namely the biological process by which insulin is released into the circulation in the absence of stimulation by levels of glucose, or other agents that promote insulin secretion, that are elevated above their "fasting" or non-fed levels.
  • the values for fasting and postprandial (after a meal) insulin are about 14 to 145 pmol/1, and 100 to 300 pmol/1 respectively in healthy people, with perhaps 3-to 4-fold higher levels in insulin-resistant people.
  • Glycosylated (or glycated) hemoglobin is a form of hemoglobin used primarily to identify the plasma glucose concentration over time.
  • the normal range (that found in healthy subjects) is 4% to 5.9%. People with diabetes mellitus often have higher levels of HbAIc. While diabetic subject treatment goals vary, many include a target range of HbAIc values.
  • a diabetic with good glucose control has a HbAIc level that is close to or within the reference range.
  • the International Diabetes Federation and American College of Endocrinology recommends HbAIc values below 6.5%, while the range recommended by the American Diabetes Association extends to 7%.
  • a very high HbAIc represents poor glucose control.
  • Insulin resistance is the condition in which normal amounts of insulin are inadequate to produce a normal insulin response from fat, muscle and liver cells. Insulin resistance in fat cells results in hydrolysis of stored triglycerides, which elevates free fatty acids in the blood plasma. Insulin resistance in muscle reduces glucose uptake whereas insulin resistance in liver reduces glucose storage, with both effects serving to elevate blood glucose. High plasma levels of insulin and glucose due to insulin resistance often leads to metabolic syndrome and type 2 diabetes.
  • Metabolic syndrome also known as Syndrome X, metabolic syndrome X, insulin resistance syndrome
  • Metabolic syndrome is a combination of medical disorders, having at least three of the following symptoms and features: fasting hyperglycemia (including diabetes mellitus type 2 or impaired fasting glucose, impaired glucose tolerance or insulin resistance), high blood pressure, central obesity (also known as visceral adiposity), decreased HDL cholesterol, and elevated triglycerides.
  • Insulin resistance can be detected by the following indications: as an increased level of blood insulin, increased blood level of glucose in response to oral glucose tolerance test (OGTT), decreased level of ph ⁇ sphorylated protein kinase B (AKT) in response to insulin administration, and the like. Insulin resistance may be caused by decreased sensitivity of the insulin receptor-related signaling system in cells and/or by loss of beta cells in the pancreas through apoptosis. There is also evidence that insulin resistance can be characterized as having an underlying inflammatory component.
  • OGTT oral glucose tolerance test
  • AKT ph ⁇ sphorylated protein kinase B
  • Bilirubin is formed when red blood cells die and their hemoglobin is broken down within the macrophages to heme and globins. The heme is further degraded to Fe 2+ , carbon monoxide and bilirubin via the intermediate compound biliverdin. Since bilirubin is poorly soluble in water, it is carried to the liver and bound to albumin. Bilirubin is made water-soluble in the liver by conjugation with glucuronic acid. Conjugated bilirubin, or bilirubinglucuronide, moves into the bile canaliculi of the liver and then to the gall bladder.
  • Bilirubin is found in blood either in the conjugated form (also called direct bilirubin), or in the unconjugated form (also called indirect bilirubin).
  • the reference range for total bilirubin is 0.3 - 1.0 mg/dl.
  • For direct bilirubin it is 0.1 - 0.3 mg/dl, while for indirect bilirubin it is 0.2 - 0.7 mg/dl.
  • the concentration of total bilirubin in the blood must exceed 2—3 mg/dl for the coloration to be easily visible.
  • Subjects who are at risk for a cardiovascular and/or cerebrovascular event are also subjects who manifest at least one symptom indicative of a vascular disorder/event.
  • Symptoms that are indicative of a coronary-related vascular event include chest pain, abnormal electrocardiograms, elevated levels of ischemic markers, necrosis markers, or thrombin/f ⁇ brin generation markers.
  • Such markers include, but are not limited to, Creatine Kinase with Muscle and/or Brain subunits (CKMB), D-Dimer, Fl .2, thrombin anti-thrombin (TAT), soluble fibrin monomer (SFM), fibrin peptide A (FPA), myoglobin, thrombin precursor protein (TPP), platelet monocyte aggregate (PMA) and troponin (cTn).
  • Subjects who are at risk also include subjects having a history of a thrombotic event (e.g., disorder), including coronary heart disease (CHD), stroke, or transient ischemic attacks (TIA).
  • a thrombotic event e.g., disorder
  • CHD coronary heart disease
  • TIA transient ischemic attacks
  • a history of CHD can include, for example, a history of MI, coronary revascularization procedure, angina with ischemic changes, or a positive coronary angiogram (e.g., showing greater than about 50% stenosis of at least one major coronary artery).
  • carcinomas Malignancies of epithelial glandular tissue such as are found in the breast, prostate, and colon, are known as adenocarcinomas.
  • Malignant growths of connective tissue e.g., muscle, cartilage, lymph tissue, and bone, are called sarcomas. Lymphomas and leukemias are malignancies arising among the white blood cells.
  • prevention or chemoprevention includes either preventing the onset of clinically evident neoplasia altogether or preventing the onset of a preclinically evident stage of neoplasia in individuals at risk. Also intended to be encompassed by this definition is the prevention of transformation into malignant cells or to arrest or reverse the progression of premalignant cells to malignant cells. This includes prophylactic treatment of those at risk of developing the neoplasia.
  • nociceptive pain includes, but is not limited to, pain associated with chemical or thermal burns, cuts of the skin, contusions of the skin, osteoarthritis, rheumatoid arthritis, tendonitis, and myofascial pain.
  • neuropathic pain includes, but is not limited to, CRPS (Complex Regional Pain Syndrome) type I, CRPS type II, reflex sympathetic dystrophy (RSD), reflex neurovascular dystrophy, reflex sympathetic dystrophy, reflex neurovascular dystrophy, reflex dystrophy, sympathetically maintained pain syndrome, causalgia, Sudeck atrophy of bone, algoneurodystrophy, shoulder hand syndrome, post-traumatic dystrophy, trigeminal neuralgia, post herpetic neuralgia, cancer and metastases related pain, phantom limb pain, fibromyalgia, chronic fatigue syndrome, spinal cord injury pain, central post-stroke pain, radiculopathy, diabetic neuropathy, ' post-stroke pain, luetic neuropathy, and other painful neuropathic conditions such as those induced by drugs such as vincristine, velcade and thalidomide.
  • the neuropathic pain can result from a mononeuropathy, polyneuropathy, complex regional pain syndromes or deafferentation
  • neuropathy includes, but is not limited to, a functional disturbance or pathological change in the nervous system, especially in the peripheral nervous system, and is characterized clinically by sensory or motor neuron abnormalities.
  • mononeuropathy indicates that a single nerve is affected, while the term polyneuropathy indicates that several nerves are affected.
  • Deafferentation indicates a loss of the sensory input from a portion of the body, and can be caused by interruption of either peripheral sensory fibers or nerves from the central nervous system.
  • the etiology of a neuropathy can be known or unknown.
  • a therapeutically effective amount of a compound as described herein used in the present invention may vary depending upon the route of administration and dosage form. Effective amounts of invention compounds typically fall in the range of about 0.001 up to 100 mg/kg/day, and more typically in the range of about 0.05 up to 10 mg/kg/day. Typically, the compound or compounds used in the instant invention are selected to provide a formulation that exhibits a high therapeutic index.
  • the therapeutic index is the dose ratio between toxic and therapeutic effects which can be expressed as the ratio between LD 50 and ED 5 0.
  • the LD50 is the dose lethal to 50% of the population and the ED 50 is the dose therapeutically effective in 50% of the population.
  • the LD 50 and ED 50 are determined by standard pharmaceutical procedures in animal cell cultures or experimental animals.
  • Treatment may also include administering the compounds or pharmaceutical formulations of the present invention in combination with other therapies.
  • Combinations of the invention may be administered simultaneously, separately or sequentially.
  • the compounds and pharmaceutical formulations of the present invention maybe administered before, during, or after surgical procedure and/or radiation therapy.
  • the compounds of the invention can also be administered in conjunction with other anti-inflammatory agents, anticancer agents and other agents described herein.
  • many types of immunomodulatory, immunosuppressive or cytostatic drugs, as described herein can be used in combination with the cytokine inhibitors.
  • the specific amount of the additional active agent will depend on the specific agent used, the type of condition being treated or managed, the severity and stage of the condition, and the amount(s) of compounds and any optional additional active agents concurrently administered to the subject.
  • one or more compounds of the invention and an additional active agent are administered to a subject, more typically a human, in a sequence and within a time interval such that the compound can act together with the other agent to provide an enhanced benefit relative to the benefits obtained if they were administered otherwise.
  • the additional active agents can be coadminstered by coformulation, administered at the same time or administered sequentially in any order at different points in time; however, if not administered at the same time, they should be administered sufficiently close in time so as to provide the desired therapeutic or prophylactic effect.
  • the compound and the additional active agents exert their effects at times which overlap.
  • Each additional active agent can be administered separately, in any appropriate form and by any suitable route.
  • the compound is administered before, concurrently or after administration of the additional active agents.
  • the compound and the additional active agents are administered less than about 1 hour apart, at about 1 hour apart, at about 1 hour to about 2 hours apart, at about 2 hours to about 3 hours apart, at about 3 hours to about 4 hours apart, at about 4 hours to about 5 hours apart, at about 5 hours to about 6 hours apart, at about 6 hours to about 7 hours apart, at about 7 hours to about 8 hours apart, at about 8 hours to about 9 hours apart, at about 9 hours to about 10 hours apart, at about 10 hours to about 11 hours apart, at about 11 hours to about 12 hours apart, no more than 24 hours apart or no more than 48 hours apart.
  • the compound and the additional active agents are administered concurrently.
  • the compound and the additional active agents are administered concurrently by coformulation.
  • the compound and the additional active agents are administered at about 2 to 4 days apart, at about 4 to 6 days apart, at about 1 week part, at about 1 to 2 weeks apart, or more than 2 weeks apart.
  • the inventive compound and optionally the additional active agents are cyclically administered to a subject.
  • Cycling therapy involves the administration of a first agent for a period of time, followed by the administration of a second agent and/or third agent for a period of time and repeating this sequential administration. Cycling therapy can provide a variety of benefits, e.g., reduce the development of resistance to one or more of the therapies, avoid or reduce the side effects of one or more of the therapies, and/or improve the efficacy of the treatment.
  • the inventive compound and optionally the additional active agent are administered in a cycle of less than about 3 weeks, about once every two weeks, about once every 10 days or about once every week.
  • One cycle can comprise the administration of an inventive compound and optionally the second active agent by infusion over about 90 minutes every cycle, about 1 hour every cycle, about 45 minutes every cycle, about 30 minutes every cycle or about 15 minutes every cycle.
  • Each cycle can comprise at least 1 week of rest, at least 2 weeks of rest, at least 3 weeks of rest.
  • the number of cycles administered is from about 1 to about 12 cycles, more typically from about 2 to about 10 cycles, and more typically from about 2 to about 8 cycles.
  • Courses of treatment can be administered concurrently to a subject, i.e., individual doses of the additional active agents are administered separately yet within a time interval such that the inventive compound can work together with the additional active agents.
  • one component can be administered once per week in combination with the other components that can be administered once every two weeks or once every three weeks.
  • the dosing regimens are carried out concurrently even if the therapeutics are not administered simultaneously or during the same day.
  • the additional active agents can act additively or, more typically, synergistically with the inventive compound.
  • the inventive compound is administered concurrently with one or more second active agents in the same pharmaceutical composition.
  • the inventive compound is administered concurrently with one or more second active agents in separate pharmaceutical compositions.
  • the inventive compound is administered prior to or subsequent to administration of a second active agent.
  • the invention contemplates administration of an inventive compound and a second active agent by the same or different routes of administration, e.g., oral and parenteral.
  • the inventive compound when administered concurrently with a second active agent that potentially produces adverse side effects including, but not limited to, toxicity, the second active agent can advantageously be administered at a dose that falls below the threshold that the adverse side effect is elicited.
  • the instant invention also provides for pharmaceutical compositions and medicaments which may be prepared by mixing one or more compounds of the invention, prodrugs thereof, pharmaceutically acceptable salts thereof, stereoisomers thereof, tautomers thereof, or solvates thereof, with pharmaceutically acceptable carriers, excipients, binders, diluents or the like to prevent and treat disorders associated with excess cytokine production.
  • the compounds and compositions of the invention may be used to prepare formulations and medicaments that prevent or treat a variety of disorders associated with excess cytokine production as disclosed herein, e.g., diseases and pathological conditions involving inflammation, pain, cancer, etc.
  • compositions can be in the form of, for example, granules, powders, tablets, capsules, syrup, suppositories, injections, emulsions, elixirs, suspensions or solutions.
  • the instant compositions can be formulated for various routes of administration, for example, by oral, parenteral, topical, rectal, nasal, vaginal administration, or via implanted reservoir.
  • Parenteral or systemic administration includes, but is not limited to, subcutaneous, intravenous, intraperitoneally, intramuscular, intra-articular, intrasynovial, intrasternal, intrathecal, intralesional and intracranial injections.
  • the following dosage forms are given by way of example and should not be construed as limiting the instant invention.
  • powders, suspensions, granules, tablets, pills, capsules, gelcaps, and caplets are acceptable as solid dosage forms. These can be prepared, for example, by mixing one or more compounds of the instant invention, or pharmaceutically acceptable salts or tautomers thereof, with at least one additive such as a starch or other additive.
  • Suitable additives are sucrose, lactose, cellulose sugar, mannitol, maltitol, dextran, starch, agar, alginates, chitins, chitosans, pectins, tragacanth gum, gum arabic, gelatins, collagens, casein, albumin, synthetic or semi-synthetic polymers or glycerides.
  • oral dosage forms can contain other ingredients to aid in administration, such as an inactive diluent, or lubricants such as magnesium stearate, or preservatives such as paraben or sorbic acid, or anti-oxidants such as ascorbic acid, tocopherol or cysteine, a disintegrating agent, binders, thickeners, buffers, sweeteners, flavoring agents or perfuming agents. Tablets and pills may be further treated with suitable coating materials known in the art.
  • suitable coating materials known in the art.
  • Liquid dosage forms for oral administration may be in the form of pharmaceutically acceptable emulsions, syrups, elixirs, suspensions, and solutions, which may contain an inactive diluent, such as water.
  • Pharmaceutical formulations and medicaments may be prepared as liquid suspensions or solutions using a sterile liquid, such as, but not limited to, an oil, water, an alcohol, and combinations of these.
  • Pharmaceutically suitable surfactants, suspending agents, emulsifying agents may be added for oral or parenteral administration.
  • suspensions may include oils.
  • oils include, but are not limited to, peanut oil, sesame oil, cottonseed oil, corn oil and olive oil.
  • Suspension preparation may also contain esters of fatty acids such as ethyl oleate, isopropyl myristate, fatty acid glycerides and acetylated fatty acid glycerides.
  • Suspension formulations may include alcohols, such as, but not limited to, ethanol, isopropyl alcohol, hexadecyl alcohol, glycerol and propylene glycol.
  • Ethers such as but not limited to, poly(ethyleneglycol), petroleum hydrocarbons such as mineral oil and petrolatum; and water may also be used in suspension formulations.
  • Injectable dosage forms generally include aqueous suspensions or oil suspensions which may be prepared using a suitable dispersant or wetting agent and a suspending agent. Injectable forms may be in solution phase or in the form of a suspension, which is prepared with a solvent or diluent. Acceptable solvents or vehicles include sterilized water, Ringer's solution, or an isotonic aqueous saline solution. Alternatively, sterile oils may be employed as solvents or suspending agents. Typically, the oil or fatty acid is nonvolatile, including natural or synthetic oils, fatty acids, mono-, di- or tri-glycerides.
  • the pharmaceutical formulation and/or medicament may be a powder suitable for reconstitution with an appropriate solution as described above.
  • these include, but are not limited to, freeze dried, rotary dried or spray dried powders, amorphous powders, granules, precipitates, or particulates.
  • the formulations may optionally contain stabilizers, pH modifiers, surfactants, bioavailability modifiers and combinations of these.
  • the pharmaceutical formulations and medicaments may be in the form of a suppository, an ointment, an enema, a tablet or a cream for release of compound in the intestines, sigmoid flexure and/or rectum.
  • Rectal suppositories are prepared by mixing one or more compounds of the instant invention, or pharmaceutically acceptable salts or tautomers of the compound, with acceptable vehicles, for example, cocoa butter or polyethylene glycol, which is present in a solid phase at normal storing temperatures, and present in a liquid phase at those temperatures suitable to release a drug inside the body, such as in the rectum.
  • Oils may also be employed in the preparation of formulations of the soft gelatin type and suppositories.
  • Water, saline, aqueous dextrose and related sugar solutions, and glycerols may be employed in the preparation of suspension formulations which may also contain suspending agents such as pectins, carbomers, methyl cellulose, hydroxypropyl cellulose or carboxymethyl cellulose, as well as buffers and preservatives.
  • suspending agents such as pectins, carbomers, methyl cellulose, hydroxypropyl cellulose or carboxymethyl cellulose, as well as buffers and preservatives.
  • Compounds of the invention may be administered to the lungs by inhalation through the nose or mouth.
  • Suitable pharmaceutical formulations for inhalation include solutions, sprays, dry powders, or aerosols containing any appropriate solvents and optionally other compounds such as, but not limited to, stabilizers, antimicrobial agents, antioxidants, pH modifiers, surfactants, bioavailability modifiers and combinations of these.
  • Formulations for inhalation administration contain as excipients, for example, lactose, polyoxyethylene-9- lauryl ether, glycocholate and deoxycholate.
  • Aqueous and nonaquous aerosols are typically used for delivery of inventive compounds by inhalation.
  • an aqueous aerosol is made by formulating an aqueous solution or suspension of the compound together with conventional pharmaceutically acceptable carriers and stabilizers.
  • the carriers and stabilizers vary with the requirements of the particular compound, but typically include nonionic surfactants (Tweens, Pluronics, or polyethylene glycol), innocuous proteins like serum albumin, sorbitan esters, oleic acid, lecithin, amino acids such as glycine, buffers, salts, sugars or sugar alcohols.
  • Aerosols generally are prepared from isotonic solutions.
  • a nonaqueous suspension e.g., in a fluorocarbon propellant
  • Aerosols containing compounds for use according to the present invention are conveniently delivered using an inhaler, atomizer, pressurized pack or a nebulizer and a suitable propellant, e.g., without limitation, pressurized dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, nitrogen, air, or carbon dioxide.
  • a suitable propellant e.g., without limitation, pressurized dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, nitrogen, air, or carbon dioxide.
  • the dosage unit may be controlled by providing a valve to deliver a metered amount.
  • Capsules and cartridges of, for example, gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch. Delivery of aerosols of the present invention using sonic nebulizers is advantageous because nebulizers minimize exposure of the agent to shear, which can result in degradation of the compound.
  • the pharmaceutical formulations and medicaments may be a spray, nasal drops or aerosol containing an appropriate solvent(s) and optionally other compounds such as, but not limited to, stabilizers, antimicrobial agents, antioxidants, pH modifiers, surfactants, bioavailability modifiers and combinations of these.
  • the compounds may be formulated in oily solutions or as a gel.
  • any suitable propellant may be used including compressed air, nitrogen, carbon dioxide, or a hydrocarbon based low boiling solvent.
  • Dosage forms for the topical (including buccal and sublingual) or transdermal administration of compounds of the invention include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, and patches.
  • the active component may be mixed under sterile conditions with a pharmaceutically-acceptable carrier or excipient, and with any preservatives, or buffers, which may be required.
  • Powders and sprays can be prepared, for example, with excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances.
  • the ointments, pastes, creams and gels may also contain excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
  • excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
  • Transdermal- patches have the added advantage of providing controlled delivery of a compound of the invention to the body.
  • dosage forms can be made by dissolving or dispersing the agent in the proper medium.
  • Absorption enhancers can also be used to increase the flux of the inventive compound across the skin. The rate of such flux can be controlled by either providing a rate controlling membrane or dispersing the compound in a polymer matrix or gel.
  • Ophthalmic formulations eye ointments, powders, solutions and the. like, are also contemplated as being within the scope of this invention.
  • the compounds of this invention can be incorporated into various types of ophthalmic formulations for delivery to the eye (e.g., topically, intracamerally, or via an implant).
  • the compounds are typically incorporated into topical ophthalmic formulations for delivery to the eye.
  • the compounds may be combined with one or more ophthalmologically acceptable preservatives, viscosity enhancers, penetration enhancers, buffers, sodium chloride, and water to form an aqueous, sterile ophthalmic suspension or solution.
  • Ophthalmic solution formulations may be prepared by dissolving a compound in a physiologically acceptable isotonic aqueous buffer.
  • the ophthalmic solution may include an ophthalmologically acceptable surfactant to assist in dissolving the compound.
  • the ophthalmic solution may contain an agent to increase viscosity, such as hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylmethylcellulose, methylcellulose, polyvinylpyrrolidone, or the like, to improve the retention of the formulation in the conjunctival sac.
  • Gelling agents can also be used, including, but not limited to, gellan and xanthan gum.
  • sterile ophthalmic ointment formulations the compound of the invention is combined with a preservative in an appropriate vehicle, such as, mineral oil, liquid lanolin, or white petrolatum.
  • a preservative in an appropriate vehicle, such as, mineral oil, liquid lanolin, or white petrolatum.
  • Sterile ophthalmic gel formulations may be prepared by suspending the invention compound in a hydrophilic base prepared from the combination of, for example, carbopol-974, or the like, according to the published formulations for analogous ophthalmic preparations. Preservatives and tonicity agents can be optionally incorporated.
  • Intrathecal administration via bolus dosage or constant infusion, allows the local administration of a compound to a region of the spinal cord, such as the dorsal horn regions, delivering the compound directly to the subarachnoid space containing the CSF (cerebrospinal fluid).
  • a region of the spinal cord such as the dorsal horn regions
  • Central delivery to the spinal cord regions can also be performed by epidural injection to a region of the spinal cord exterior to the arachnoid membrane.
  • Enhancing permeation of the active compound through meningeal membranes may be achieved by using hypertonic dosing solutions that increase permeability of meningeal membranes, or by addition of permeation enhancers, such as, but not limited to, liposomal encapsulation, surfactants, or ion-pairing agents.
  • excipients and carriers are generally known to those skilled in the art and are thus included in the instant invention. Such excipients and carriers are described, for example, in "Remingtons Pharmaceutical Sciences” Mack Pub. Co., New Jersey (1991), which is incorporated herein by reference.
  • the formulations of the invention may be designed to be short-acting, fast- releasing, long-acting, and sustained-releasing as described below.
  • the pharmaceutical formulations may also be formulated for controlled release or for slow release.
  • compositions may also comprise, for example, micelles or liposomes, or some other encapsulated form, or may be administered in an extended release form to provide a prolonged storage and/or delivery effect. Therefore, the pharmaceutical formulations and medicaments may be compressed into pellets or cylinders and implanted intramuscularly or subcutaneously as depot injections or as implants such as stents. Such implants may employ known inert materials such as silicones and biodegradable polymers.
  • the present disclosure also provides medical devices incorporating the cytokine inhibitors as described herein.
  • a representative device includes a vascular stent coated or impregnated with the cytokine inhibitors as described herein.
  • the device can be configured to be inserted into a blood vessel where it can release the cytokine inhibitors as described herein to help reduce or prevent vascular inflammation, for example vascular inflammation.
  • cytokine inhibitors as described herein, or a combination of the cytokine inhibitors with additional ingredients A, as described herein.
  • the cytokine inhibitors as described herein can be coated on the surface of the medical device or the device can be saturated with the cytokine inhibitors such that the cytokine inhibitors are released from the device, for example over a period of time.
  • Exemplary medical devices including the cytokine inhibitors as disclosed herein include, but are not limited to, vascular medical devices such as vascular stents.
  • Stents and methods for making and using stents coated or impregnated with therapeutic agents are well-known in the art: see, e.g., U.S. Application No. US20050181977 and U.S. Application No. US20050129729.
  • Specific dosages may be adjusted depending on conditions of disease, the age, body weight, general health conditions, sex, and diet of the subject, dose intervals, administration routes, excretion rate, and combinations of drugs. Any of the above dosage forms containing effective amounts are well within the bounds of routine experimentation and therefore, well within the scope of the instant invention.
  • a therapeutically effective amount of a compound of the present invention may vary depending upon the route of administration and dosage form. Effective amounts of invention compounds typically fall in the range of about 0.001 up to 100 mg/kg/day, and more typically in the range of about 0.05 up to 10 mg/kg/day. Typically, the compound or compounds of the instant invention are selected to provide a formulation that exhibits a high therapeutic index.
  • the therapeutic index is the dose ratio between toxic and therapeutic effects which can be expressed as the ratio between LD50 and ED 5 0.
  • the LD 50 is the dose lethal to 50% of the population and the ED 50 is the dose therapeutically effective in 50% of the population.
  • the LD50 and ED50 are determined by standard pharmaceutical procedures in animal cell cultures or experimental animals.
  • the cytokine inhibitors can be used in the methods and compositions of the invention either alone or together with additional treatments or active ingredients or a combination thereof. Additional treatments comprise treatment by surgery, radiation, or cryotherapy, while treatment with additional active ingredients comprises the use of antiproliferative agents. Combinations of drugs are administered in an attempt to obtain a synergistic cytotoxic effect on most cancers, e.g., carcinomas, melanomas, lymphomas and sarcomas, and to reduce or eliminate emergence of drug-resistant cells and to reduce side effects to each drug.
  • Additional treatments comprise treatment by surgery, radiation, or cryotherapy
  • additional active ingredients comprises the use of antiproliferative agents.
  • Combinations of drugs are administered in an attempt to obtain a synergistic cytotoxic effect on most cancers, e.g., carcinomas, melanomas, lymphomas and sarcomas, and to reduce or eliminate emergence of drug-resistant cells and to reduce side effects to each drug.
  • the additional active agent will depend on the specific agent used, the type of cancer being treated or managed, the severity and stage of the cancer, and the amount(s) of cytokine inhibitors and any optional additional active agents concurrently administered to the subject.
  • the additional active ingredients that can be used in combination with the cytokine inhibitors of the present invention are used at dosages well known in the art.
  • antiproliferative agents includes agents that prevent the development, maturation, or spread of cells, by acting directly on the cell, e.g., by cytostatic or cytocidal effects, and not indirectly through mechanisms such as biological response modification.
  • cytostatic or cytocidal effects e.g., by cytostatic or cytocidal effects
  • biological response modification e.g., by cytostatic or cytocidal effects
  • Typical antiproliferative agents can be categorized as alkylating agents, platinum agents, antimetabolites, topoisomerase inhibitors, antitumor antibiotics, antimitotic agents, aromatase inhibitors, thymidylate synthase inhibitors, DNA antagonists, farnesyltransferase inhibitors, pump inhibitors, histone acetyltransferase inhibitors, metalloproteinase inhibitors, ribonucleoside reductase inhibitors, endothelin A receptor antagonists, retinoic acid receptor agonists, immunomodulators, hormonal or antihormonal agents, photodynamic agents, angiogenesis inhibitors, tyrosine kinase inhibitors, and the like. Some antiproliferative agents operate through multiple or unknown mechanisms and can thus be classified into more than one category.
  • a family of antiproliferative agents which may be used in combination with the present invention includes alkylating-type agents.
  • the alkylating agents are believed to act by alkylating and cross-linking guanine and possibly other bases in DNA, arresting cell division.
  • Typical alkylating agents include nitrogen mustards, ethyleneimine compounds, alkyl sulfates, cisplatin, and various nitrosoureas.
  • a disadvantage with these compounds is that they not only attack malignant cells, but also other cells which are naturally dividing, such as those of bone marrow, skin, gastro-intestinal mucosa, and fetal tissue.
  • Suitable alkylating-type agents include, but are not limited to, busulfan, procarbazine, ifosfamide, altretamine, hexamethylmelamine, estramustine phosphate, thiotepa, mechlorethamine, dacarbazine, streptozocin, lomustine, temozolomide, cyclophosphamide, semustine, and chlorambucil.
  • a family of antiproliferative agents which may be used in combination with the present invention includes platinum agents.
  • Suitable platinum agents that may be used in the present invention include, but are not limited to spiroplatin, lobaplatin (Aeterna), tetraplatin, satraplatin (Johnson Matthey), ormaplatin, iproplatin, miriplatin (Sumitomo), nexplatin (AnorMED), polymer platinate (Access), oxaliplatin, or carboplatin.
  • An additional family of antiproliferative agents which may be used in combination with the present invention includes antimetabolite-type agents.
  • Antimetabolites are typically reversible or irreversible enzyme inhibitors, or compounds that otherwise interfere with the replication, translation or transcription of nucleic acids.
  • Suitable antimetabolite agents include, but are not limited to azacytidine, trimetrexate, floxuridine, deoxycoformycin, 2-chlorodeoxyadenosine, pentostatin, 6-mercaptopurine, hydroxyurea, 6-thioguanine, decitabine (SuperGen), cytarabine, clofarabine (Bioenvision), 2-fluorodeoxy cytidine, irofulven (MGI Pharma), methotrexate, tomudex, ethynylcytidine (Taiho), fiudarabine, gemcitabine, raltitrexed, or capecitabine.
  • topoisomerase inhibitors Another family of antiproliferati ve agents which may be used in combination with the present invention includes topoisomerase inhibitors.
  • Suitable topoisom erase agents include, but are not limited to amsacrine, exatecan mesylate (Daiichi), epirubicin, quinamed (ChemGenex), etoposide, gimatecan (Sigma-Tau), teniposide, mitoxantrone, diflomotecan (Beaufour-Ipsen), 7-ethyl-10-hydroxy-camptothecin, dexrazoxanet (TopoTarget), elsamitrucin (Spectrum), pixantrone (Novuspharma), edotecarin (Merck & Co), becatecarin (Exelixis), karenitecin (BioNiimerik), BBR-3576 (Novuspharma), belotecan (Chong Kun Dang), rubitecan
  • antibiotic-type antiproliferative agents Another family of antiproliferative agents which may be used in combination with the present invention includes antibiotic-type antiproliferative agents.
  • Suitable antibiotic-type antiproliferative agents include, but are not limited to dactinomycin (actinomycin D), azonafide, valrubicin, anthrapyrazole, daunorubicin (daunomycin), oxantrazole, therarubicin, losoxantrone, idarubicin, bleomycinic acid, rubidazone, sabarubicin (Menarini), plicamycinp, 13-deoxydoxorubicin hydrochloride (Gem Pharmaceuticals), porfiromycin, epirubicin, mitoxantrone (novantrone) or amonafide.
  • Suitable antimitotic antiproliferative agents that may be used in the present invention include, but are not limited to colchicines, ABT-751 (Abbott), vinblastine, xyotax (Cell Therapeutics), vindesine, IDN 5109 (Bayer), dolastatin 10 (NCI), A 105972 (Abbott), rhizoxin (Fujisawa), A 204197 (Abbott), mivobulin (Warner-Lambert), synthadotin (BASF), cemadotin (BASF), indibulin (ASTAMedica), RPR 109881 A (Aventis), TXD 258 (Aventis), combretastatin A4 (BMS), epothilone B (Novartis), isohomohalichondrin-B (PharmaMar), T 900607 (Tularik), ZD 6
  • aromatase inhibitors include, but are not limited to aminoglutethimide, atamestane (BioMedicines), formestane, fadrozole, letrozole, exemestane, or anastrazole.
  • An additional family of antiproliferative agents which may be used in combination with the present invention includes the thymidylate synthase inhibitors.
  • Suitable thymidylate synthase inhibitors that may be used in the present invention include, but are not limited to, pemetrexed (Eli Lilly), nolatrexed (Eximias), ZD-9331 (BTG), doxifluridine (Nippon Roche), or 5,10-methylenetetrahydrofolate (BioKeys).
  • DNA antagonists include, but are not limited to trabectedin (PharmaMar), edotreotide (Novartis), glufosfamide (Baxter International), mafosfamide (Baxter International), apaziquone (Spectrum Pharmaceuticals), or thymectacin (NewBiotics).
  • Another family of antiproliferative agents which may be used in combination with the present invention includes farnesyltransferase inhibitors.
  • Suitable farnesyltransferase inhibitors include, but are not limited to arglabin (NuOncology Labs), tipifarnib (Johnson & Johnson), lonafarnib (Schering-Plough), perillyl alcohol (DOR BioPharma), or sorafenib (Bayer).
  • An additional family of antiproliferative agents which may be used in combination with the present invention includes pump inhibitors.
  • Suitable pump inhibitors - that may be used in the present invention include, but are not limited to zosuquidar trihydrochloride (Eli Lilly), tariquidar (Xenova), biricodar dicitrate (Vertex), or MS-209 (Schering AG).
  • An alternative family of antiproliferative agents which may be used in combination with the present invention includes histone acetyltransferase inhibitors.
  • Suitable histone acetyltransferase inhibitors include, but are not limited to tacedinaline (Pfizer), pivaloyloxymethyl butyrate (Titan), AP-CANC-03 and AP-CANC-04 (Aton Pharma), depsipeptide (Fujisawa), or MS-275 (Schering AG).
  • Another family of antiproliferative agents which may be used in combination with the present invention includes metalloproteinase inhibitors.
  • Suitable metalloproteinase inhibitors that may be used in the present invention include, but are not limited to neovastat (Aeterna Laboratories), metastat (CollaGenex), or marimastat (British Biotech).
  • the family of antiproliferative agents which may be used in combination with the present invention includes ribonucleoside reductase inhibitors.
  • ribonucleoside reductase inhibitors include, but are not limited to gallium maltolate (Titan), tezacitabine (Aventis), triapine (Vion), or didox (Molecules for Health).
  • Another family of antiproliferative agents which may be used in combination with the present invention includes endothelin A receptor antagonists.
  • Suitable endothelin A receptor antagonists that maybe used in the present invention include, but are not limited to atrasentan (Abbott), bosentan (Roche), ambrisentan (BASF), sitaxsentan (Encysive), clazosentan (Roche), darusentan (Knoll), and ZD-4054 (AstraZeneca).
  • retinoic acid receptor agonists include compounds which are natural and synthetic analogues of retinol (Vitamin A).
  • the retinoids bind to one or more retinoic acid receptors to initiate diverse processes such as reproduction, development, bone formation, cellular proliferation and differentiation, apoptosis, hematopoiesis, immune function and vision.
  • Retinoids are required to maintain normal differentiation and proliferation of almost all cells and have been shown to reverse/suppress carcinogenesis in a variety of in vitro and in vivo experimental models of cancer, see (Moon et al., Ch.
  • Suitable retinoic acid receptor agonists that may be used in the present invention include, but are not limited to fenretinide (Johnson & Johnson), alitretinoin (Ligand), tazarotene (Allergan), tetrinoin (Roche), isotretinoin (Roche), 13-cis-retinoic acid (UCSD), or LGD-1550 (Ligand).
  • Suitable immunomodulators that may be used in the present invention include, but are not limited to interferon, Roferon-A (Roche), dexosome therapy (Anosys), oncophage (Antigenics), pentrix (Australian Cancer Technology), GMK vaccine (Progenies), CD 154 cell therapy (Tragen), adenocarcinoma vaccine (Biomira), transvax (Intercell), avicine (AVI BioPharma), norelin (Biostar), IRX-2 (Immuno-Rx), BLP-25 liposome vaccine (Biomira), PEP-005 (Peplin Biotech), multiganglioside vaccine (Progenies), synchrovax vaccine (CTL Immuno), D-alethine (Dovetail), melanoma vaccine (CTL Immuno), vasocare (Vasogen), rituximab (
  • hormonal agents include, but are not limited to an estrogen, dexamethasone, a conjugated estrogen, prednisone, ethinyl estradiol, methylprednisolone, chlortrianisen, prednisolone, idenestrol, aminoglutethimide, hydroxyprogesterone caproate, leuprolide, medroxyprogesterone, octreotide, testosterone, mitotane, testosterone propionate, fiuoxymesterone, methyltestosterone, 2-methoxyestradiol (EntreMed), diethylstilbestrol, arzoxifene (Eli Lilly), megestrol, tamoxifen, bicalutamide, toremofine, flutamide, goserelin, nilutamide, or leuporel
  • photodynamic agents include, but are not limited to talaporfin (Light Sciences), Pd-bacteriopheophorbide (Yeda), theralux (Theratechnologies), lutetium texaphyrin (Pharmacyclics), motexafin, gadolinium (Pharmacyclics), or hypericin.
  • angiogenesis inhibitors include, but are not limited to neovastat (AEterna Zentaris), ATN-224 (Attenuon), sorafenib (Bayer), thalidomide, bevacizumab (Genentech), ranibizumab (Genentech), benefin (Lane Labs), L-651582 (Merck & Co), vatalanib (Novartis), or sutent (Sugen).
  • Tyrosine Kinase Inhibitors Another family of antiproliferative agents which may be used in combination with the present invention includes Tyrosine Kinase Inhibitors.
  • Suitable Tyrosine Kinase Inhibitors include, but are not limited to imatinib (Novartis), leflunomide (Sugen/Pharmacia), kahalide F (PharmaMar) iressa (AstraZeneca), lestaurtinib (Cephalon), erlotinib (Oncogene Science), canertinib (Pfizer), tandutinib (Millenium), squalamine (Genaera), midostaurin (Novartis), phenoxodiol, SU6668 (Pharmacia), cetuximab (ImClone), rhu-Mab (Genentech), ZD6474 (AstraZeneca), MDX- H210 (Medarex), vatalanib (
  • Additional anti-pro liferative agents which may be used in combination with the present invention include melphalan, carmustine, cisplatin, 5-fluorouracil, mitomycin C, adriamycin (doxorubicin), bleomycin, paclitaxel (Taxol ® ), and the like.
  • the cytokine inhibitors of the invention can be used in methods and compositions together with additional active ingredients or agents.
  • the additional active agents are capable of relieving pain, inhibiting inflammatory reactions, providing a sedative effect or an antineuralgic effect, or ensuring patient comfort.
  • additional active agents include, but are not limited to, opioid analgesics, non-narcotic analgesics, anti-infiammatories, COX-2 inhibitors, ⁇ -adrenergic receptor agonists or antagonists, k ⁇ tamine, anesthetic agents, NMDA antagonists, ⁇ 2 ⁇ ligands, immunomodulatory agents, immunosuppressive agents, antidepressants, anticonvulsants, antihypertensives, anxiolytics, calcium channel blockers, muscle relaxants, corticosteroids, hyperbaric oxygen, other therapeutics known to relieve pain, and pharmaceutically acceptable salts, solvates, hydrates, stereoisomers, prodrugs and pharmacologically active metabolites thereof.
  • Opioids can be used to treat severe pain.
  • opioid analgesics include, but are not limited to, oxycodone (OxyContinTM), morphine sulfate (MS ContinTM, DuramorphTM, AstramorphTM), meperidine (DemerolTM), and fentanyl transdermal patch (DuragesicTM) and other known conventional medications [See, e.g., Physicians 1 Desk Reference, 594-595, 2851 and 2991 (57 th ed., 2003)].
  • Oxycodone (OxyContinTM) is a long- acting form of an opioid and may be used usually in initial and later stages of CRPS.
  • Morphine sulfate may be used for analgesia due to reliable and predictable effects, safety profile, and ease of reversibility with naloxone. Morphine sulfate is sold in the United States under the trade name MS ContinTM, DuramorphTM, or AstramorphTM [See, e.g., Physicians' Desk Reference, 594-595 (57 th ed., 2003)].
  • Fentanyl transdermal patch (DuragesicTM) is a potent narcotic analgesic with much shorter half-life than morphine sulfate.
  • Meperidine (DemerolTM) and hydromorphone (DilaudidTM) may also be used for pain management [See, e.g., Physicians 1 Desk Reference, 2991 (57 th ed., 2003)].
  • Non-narcotic analgesics and antiinflammatories are preferably used for treatment of pain during pregnancy and breastfeeding.
  • Antiinflammatories such as nonsteroidal anti-inflammatory drugs (NSAIDs) and cbx-2 inhibitors typically inhibit inflammatory reactions and pain by decreasing the activity of cyclo-oxygenase, which is responsible for prostaglandin synthesis.
  • NSAIDs may provide pain relief in the early stage of pain syndrome.
  • anti-inflammatories include, but are not limited to, salicylic acid acetate (AspirinTM), ibuprofen (MotrinTM, AdvilTM), ketoprofen (OruvailTM), rofecoxib (VioxxTM), naproxen sodium (AnaproxTM, NaprelanTM, NaprosynTM), ketorolac (AcularTM), and other known conventional medications.
  • a specific cox-2 inhibitor is celecoxib (CelebrexTM) [See, e.g., Physicians' Desk Reference, 1990, 1910-1914 and 2891 (57 th ed., 2003); Physicians' Desk Reference for Nonprescription Drugs and Dietary Supplements, 511, 667 and 773 (23 rd ed., 2002)].
  • Antidepressants increase the synaptic concentration of serotonin and/or norepinephrine in the CNS by inhibiting their reuptake by presynaptic neuronal membrane. Some antidepressants also have sodium channel blocking ability to reduce the firing rate of injured peripheral afferent fibers.
  • antidepressants include, but are not limited to, nortriptyline (PamelorTM), amitriptyline (ElavilTM), imipramine (Tofranil.), doxepin (SinequanTM), clomipramine (AnafranilTM), fluoxetine (ProzacTM), sertraline (ZoloftTM), nefazodone (SerzoneTM), venlafaxine (EffexorTM), trazodone (DesyrelTM), bupropion (WellbutrinTM) and other known conventional medications [See, e.g., Physicians' Desk Reference, 329, 1417, 1831 and 3270 (57 th ed., 2003)].
  • Anticonvulsant drugs may also be used in embodiments of the invention.
  • anticonvulsants include, but are not limited to, carbamazepine, oxcarbazepine, gabapentin (NeurontinTM), phenytoin, sodium valproate, clonazepam, topiramate, lamotrigine, zonisamide, and tiagabine [See, e.g., Physicians' Desk Reference, 2563 (57 th ed., 2003)].
  • Corticosteroids e.g., prednisone, dexamethasone or hydrocortisone
  • orally active .class Ib anti-arrhythmic agents e.g., mexiletine
  • calcium channel blockers e.g., nifedipine
  • beta-blockers e.g., propranolol
  • ⁇ -blockers e.g., phenoxybenzamine
  • ⁇ .2- adrenergic agonists e.g., clonidine
  • cytokine inhibitor See, e.g., Physicians' Desk Reference, 1979, 2006 and 2190 (57 th ed., 2003)].
  • the specific amount of the additional active agent will depend on the specific agent used, the type of pain being treated or managed, the severity and stage of pain, and the amount(s) of cytokine inhibitors and any optional additional active agents concurrently administered to the patient.
  • Hydromorphone (DilaudidTM) is typically administered in an initial dose of about 2 mg orally, or about 1 mg intravenously to manage moderate to severe pain [See, e.g., Physicians' Desk Reference, 2991 (57 th ed., 2003)].
  • Morphine sulphate (DuramorphTM, AstramorphTM, MS ContinTM) is typically administered in an initial dose of about 2 mg IV/SC/IM, depending on whether a patient has already taken narcotic analgesics [See, e.g., Physicians' Desk Reference, 594-595 (57 th ed., 2003)].
  • Oxycodone is a long-acting form of an opioid and may be used in initial and later stages of pain syndrome.
  • Oxycodone (OxyContinTM) is usually administered in an amount of about 10-160 mg twice a day [See, e.g., Physicians' Desk Reference, 2851 (57 th ed., 2003)].
  • Meperidine (DemerolTM) is typically administered in an amount of about 50-150 mg PO/IV/IM/SC every 3-4 hours.
  • a typical pediatric dose of meperidine (DemerolTM) is 1-1.8 mg/kg (0.5-0.8 mg/lb) PO/IV/IM/SC every 3-4 hours [See, e.g., Physicians' Desk Reference, 2991 (57 th ed., 2003)].
  • Fentanyl transdermal patch (DuragesicTM) is available as a transdermal dosage form.
  • a typical adult dose is about 25 mcg/h (10 cm 2 ), 50 mcg/h (20 cm 2 ), 75 mcg/h (75 cm 2 ), or 100 mcg/h (100 cm 2 ) [See, e.g., Physicians' Desk Reference, 1775 (57 th ed., 2003)].
  • Non-narcotic analgesics and anti-inflammatories such as NSAIDs and cox-2 inhibitors may be used to treat patients suffering from mild to moderate pain.
  • Ibuprofen MotrinTM, AdvilTM
  • Naproxen sodium may also be used for relief of mild to moderate pain in an amount of about 275 mg thrice a day or about 550 mg twice a day [See, e.g., Physicians' Desk Reference, 1417,2193 and 2891 (57 th ed., 2003)].
  • Antidepressants e.g., nortriptyline (PamelorTM) may also be used in the invention to treat patients suffering from chronic and/or neuropathic pain.
  • the oral adult dose is typically in an amount of about 25-100 mg, and usually does not exceed 200 mg/d.
  • a typical pediatric dose is about 0.1 mg/kg PO as initial dose, increasing, as tolerated, up to about 0.5-2 mg/d.
  • Amitriptyline (EtrafonTM) is typically used for neuropathic pain in an adult dose of about 25-100 mg PO [See, e.g., Physicians' Desk Reference, 1417 and 2193 (57 th ed., 2003)].
  • Anticonvulsants such as gabapentin (NeurontinTM) may also be used to treat patients suffering from chronic and neuropathic pain.
  • gabapentin is orally administered in an amount of about 100-1,200 mg three times a day [See, e.g., Physicians' Desk Reference, 2563 (57 th ed., 2003)].
  • Carbamazepine (TegretolTM) is used to treat pain associated with true trigeminal neuralgia.
  • the oral adult dose is typically in an amount of about 100 mg twice a day as initial dose, increasing, as tolerated, up to about 2,400 mg/d [See, e.g., Physicians' Desk Reference, 2323-25 (57 th ed., 2003)].
  • agents which may be used in combination with the novel compounds of the invention include, but are not limited to, anti -inflammatory agents, immunosuppressants, anti-infectives, antibiotics, gold salts, alkylating agents, immunoglobulins, or a combination of two or more thereof.
  • anti-inflammatory agents include corticosteroids, COX-2 inhibitors, non-steroidal anti-inflammatory drugs (NSAID), TNFa antagonists, and IL-I antagonists.
  • the corticosteroid can be prednisone, prednisolone, or methylprednisolone. Corticosteroids such as these may also be administered with either chlorambusil or mycophenylate mofetil.
  • TNFa antagonists examples include infliximab, etanercept, and adalimumab.
  • An example of an IL-I antagonist is anakinra.
  • immunosuppressants are mycophenylate mofetil, cyclosporin, azathioprine, methotrexate, alefacept, rituximab, anti-interferon gamma, and cyclophosphamide, while anti-infectives include dapsone and hydroxychloroquine.
  • the gold salt can be myochrysine, or solganal.
  • An example of an alkylating agent is lukeran.
  • Antibiotics useful in combinations are tetracycline, minocycline, and doxycycline, sometimes in combination with nicotinamide, or niacinamide.
  • Treatment of pemphigus can also include plasmapherisis therapy or photophoresis therapy to the subject.
  • DEPBT (3-(Diethoxyphosphoryloxy)-l,2,3-benzotriazin-4(3H)- one)
  • HATU 2-(7-Aza-lH-benzotriazole-l-yl)-l ,1 ,3,3- tetramethyluronium hexafluorophosphate
  • HBTU 2-( 1 H-Benzotriazole- 1 -yl)- 1 , 1 ,3 ,3-tetramethyluronium hexafluorophosphate
  • HCTU 2-(6-Chloro- 1 H-benzotriazole- 1 -yl)- 1 , 1 ,3 ,3 - tetramethylaminium hexafluorophosphate
  • HOBt Hydroxybenzotriazole
  • HPLC High Pressure Liquid Chromatography hr: Hour(s)
  • IC50 value The concentration of an inhibitor that causes a 50 % reduction in a measured activity.
  • PE Petroleum ether
  • TATU O-CV-Azabenzotriazole-l-yO-N.N.N ⁇ N'- tetramethyluronium tetrafluoroborate
  • TDBTU 2-(l H-Benzotriazole-l -yl)-l ,1 ,3,3-tetramethyluronium tetrafluoroborate
  • TDBTU N,N,N',N'-Tetramethyl-O-(3,4-dihydro-4-oxo- 1 ,2,3- benzotriazin-3-yl)uranium tetrafluoroborate
  • TFA Trifluoroacetic acid
  • THF Tetrahydrofuran
  • TSTU O-(N-Succinimidyl)- 1,1,3,3 -tetramethyl uranium tetrafluoroborate
  • Methyl S-cyano-S-morpholinobenzoate Methyl 3-carbamoyl-5- morpholinobenzoate A (257 mg, 0.97 mmol) was dissolved in DCM (15 ml) in a 100 ml round-bottomed flask. Pyridine (851 ⁇ l, 9.7 mmol) and phosphorous oxychloride (445 ⁇ l, 4.9 mmol) were added and the solution was allowed to sit at r.t. for 1 hr.
  • the organic fractions were dried over MgSO 4 .
  • the drying agent was removed by filtration, and the filtrate was concentrated under vacuum to give the benzyl alcohol intermediate.
  • the intermediate was taken up into a THF/DCM mixture (50 ml of a 3:1 mixture) and was cooled to 0 0 C.
  • phosphorous tribromide (2.12 ml of a 1.0 M solution in DCM) was added and the reaction was stirred at 0 0 C for 1 hr and then at r.t. for 4 hr.
  • the mixture was added to 200 ml of water and was extracted with DCM.
  • the organic fractions were dried with MgSO 4 .
  • the drying agent was removed by filtration, and the filtrate was concentrated under vacuum.
  • Ethyl 3,5-difluoro-2-methoxybenzoate To the mixture of 3,5-difiuoro-2- methoxybenzoic acid (18.8 g, 100 mmol) in EtOH (200 ml) in an ice-bath, was added SOCl 2 (35.7 g, 300 mmol) dropwise. After the addition was complete, the reaction mixture was heated to reflux overnight. TLC was used to detect completion of the reaction. The mixture was evaporated to give ethyl 3,5-difluoro-2-methoxybenzoate as a white solid (21.5 g, 99.5%), which was used as such in the next step.
  • the compound was dissolved in toluene (12 ml) and excess sodium azide (600 mg, 9.2 mmol), catalytic tetrabutylammonium chloride (20 mg, 0.09 mmol), and water (3 ml) were added and the mixture was vigorously stirred. Progress of the reaction was followed by IR, by tracking of the disappearance of the COCl carbonyl stretch at 1752 cm "1 . Typically the reaction took less then 60 min to completion. The aqueous layer was removed, the toluene layer was washed with water and dried with MgSO 4 . This toluene solution of the intermediate azide b was heated to 105°C until the evolving of gas seized.
  • Methyl 3-amino-5-tert-butylbenzoate Methyl 3-(tert- butoxycarbonylamino)-5-tert-butylbenzoate (Intermediate A-c) (1.14 g, 3.71 mmol) was dissolved in TFA and stirred for 10 min at r.t. The solvent was evaporated and the intermediate was suspended in a minimum amount of water. Sulfuric acid (250 ⁇ ) was added and the mixture was cooled in an ice/water bath. An aqueous sodium nitrite solution (14.15 mmol dissolved in minimum amount of water) was added dropwise and the reaction was mixed at 0 0 C for 30 min. The reaction mixture was added to boiling 10% aq.
  • Methyl 3-tert-butyl-5-methoxybenzoate 190 mg, 0.912 mmol
  • K 2 CO 3 440 mg, 3.184 mmol
  • MeI 456 mg, 3.213 mmol
  • acetone 5 ml
  • the reaction mixture was evaporated, and the residue was triturated with diethylether.
  • the ether solution was evaporated to give the target product as a red oil, which was used in the next step without purification.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

La présente invention concerne des composés à faible masse moléculaire utiles en tant qu'inhibiteurs des cytokines, et des compositions à base de ceux-ci. L'invention concerne également des procédés destinés à la préparation de ces agents et leur utilisation pour empêcher et pour traiter les troubles médiés par les cytokines. En particulier, les composés de l'invention sont utiles en tant qu'agents anti-inflammatoires, anti-douleur ou anticancéreux.
PCT/US2007/018049 2006-08-17 2007-08-16 Dérivés hétéroaryles en tant qu'inhibiteurs des cytokines WO2008021388A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US83879506P 2006-08-17 2006-08-17
US60/838,795 2006-08-17
US89147007P 2007-02-23 2007-02-23
US60/891,470 2007-02-23

Publications (1)

Publication Number Publication Date
WO2008021388A1 true WO2008021388A1 (fr) 2008-02-21

Family

ID=39082322

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/018049 WO2008021388A1 (fr) 2006-08-17 2007-08-16 Dérivés hétéroaryles en tant qu'inhibiteurs des cytokines

Country Status (5)

Country Link
AR (1) AR062427A1 (fr)
CL (1) CL2007002375A1 (fr)
PE (1) PE20080906A1 (fr)
TW (1) TW200815422A (fr)
WO (1) WO2008021388A1 (fr)

Cited By (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2455176A (en) * 2007-11-01 2009-06-03 Acucela Inc Amine derivatives useful for treating ophthalmic diseases and disorders
US7608628B2 (en) 2005-12-12 2009-10-27 Astrazeneca Ab Alkylsulphonamide quinolines
WO2010094695A1 (fr) 2009-02-17 2010-08-26 Boehringer Ingelheim International Gmbh Dérivés pyrimido-[5,4-d]-pyrimidine pour l'inhibition des tyrosine-kinases
WO2010034838A3 (fr) * 2008-09-29 2010-11-18 Boehringer Ingelheim International Gmbh Nouveaux composés chimiques
EP2349279A1 (fr) * 2008-10-28 2011-08-03 The Board of Trustees of The Leland Stanford Junior University Modulateurs d'aldéhyde déshydrogénase et procédés d'utilisation de ceux-ci
JP2011524365A (ja) * 2008-06-11 2011-09-01 アイアールエム・リミテッド・ライアビリティ・カンパニー マラリアの処置に有用な化合物および組成物
WO2011117382A1 (fr) 2010-03-26 2011-09-29 Boehringer Ingelheim International Gmbh Pyridyltriazoles
WO2011117381A1 (fr) 2010-03-26 2011-09-29 Boehringer Ingelheim International Gmbh Inhibiteurs de kinase b-raf
WO2012008549A1 (fr) * 2010-07-15 2012-01-19 武田薬品工業株式会社 Composé hétérocyclique
US8134007B2 (en) 2007-05-03 2012-03-13 Pfizer Inc. Pyridine derivatives
US8168793B2 (en) 2005-07-26 2012-05-01 Portela & Ca., S.A. Nitrocatechol derivatives as COMT inhibitors
JP2012513409A (ja) * 2008-12-23 2012-06-14 アボット・ラボラトリーズ 抗ウイルス化合物
US8524746B2 (en) 2007-01-31 2013-09-03 Bial-Portela & Ca., S.A. Dosage regimen for COMT inhibitors
US8536203B2 (en) 2006-04-10 2013-09-17 Bial-Portela & Ca, S.A. Pharmaceutical compounds
JP2013539775A (ja) * 2010-10-15 2013-10-28 エフ．ホフマン−ラ ロシュ アーゲー Ｎ−ピリジン−３−イル又はｎ−ピラジン−２−イルカルボキサミド類
US8653087B2 (en) 2008-09-08 2014-02-18 Boehringer Ingelheim International Gmbh Pyrido [5, 4-D] pyrimidines as cell proliferation inhibitors
US8710055B2 (en) 2010-12-21 2014-04-29 Boehringer Ingelheim International Gmbh Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors
US8889665B2 (en) 2007-07-02 2014-11-18 Boehringer Ingelheim International Gmbh Chemical compounds
US8906942B2 (en) 2008-09-08 2014-12-09 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldhehyde dehydrogenase activity and methods of use thereof
US20150105456A1 (en) 2007-03-08 2015-04-16 The Board Of Trustees Of The Leland Stanford Junior University Mitochondrial Aldehyde Dehydrogenase-2 Modulators and Methods of Use Thereof
US9132094B2 (en) 2009-04-01 2015-09-15 Bial—Portela & Ca, S.A. Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making thereof
CN104926738A (zh) * 2015-06-08 2015-09-23 南京农业大学 一类1,2,3-三唑-4-酰肼衍生物在制备农用杀菌剂中的应用
US9186361B2 (en) 2013-03-15 2015-11-17 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
US9233961B2 (en) 2013-03-15 2016-01-12 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
JP2016502975A (ja) * 2012-12-10 2016-02-01 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ＲＯＲｃモジュレーターとしてのベンジルスルホンアミド誘導体
US9249138B2 (en) 2008-12-23 2016-02-02 Abbvie Inc. Anti-viral compounds
US9278922B2 (en) 2009-04-15 2016-03-08 Abbvie Inc. Anti-viral compounds
US9296754B2 (en) 2013-03-15 2016-03-29 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
US9303034B2 (en) 2013-12-19 2016-04-05 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
CN105873438A (zh) * 2014-01-31 2016-08-17 日产化学工业株式会社 液体农药组合物
US9475773B2 (en) 2013-04-19 2016-10-25 Astrazeneca Ab NK3 receptor antagonist compound (NK3RA) for use in a method for the treatment of polycystic ovary syndrome (PCOS)
US9630955B2 (en) 2011-12-13 2017-04-25 BIAL—Portela & Cª., S.A Chemical compound useful as intermediate for preparing a catechol-O-methyltransferase inhibitor
US9670162B2 (en) 2013-03-14 2017-06-06 The Board Of Trustees Of The Leland Stanford Junio Mitochondrial aldehyde dehyrogenase-2 modulators and methods of use thereof
WO2017108737A1 (fr) 2015-12-23 2017-06-29 Chiesi Farmaceutici S.P.A. Dérivés de 1-(3-tert-butyl-phényl)-3-(4-([1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tétrahydro-naphthalèn-1-yl)-urée et leur utilisation en tant qu'inhibiteur de p38 mapk
KR101761715B1 (ko) 2009-12-08 2017-07-26 꼼미사리아 아 레네르지 아또미끄 에 오 에네르지 알떼르나띠브스 1종 이상의 금속 원소가 착화될 수 있는 트리아졸기에 기초한 화합물 및 이 화합물에 기초한 배위 착물
WO2017152117A1 (fr) * 2016-03-03 2017-09-08 Cornell University Inhibiteurs ire1-alpha à petites molécules
US9845316B2 (en) 2008-03-17 2017-12-19 BIAL—Portela & CA., S.A. Crystal forms of 5-[3-(2,5-dichloro-4, 6-dimethyl-1-oxy-pyridine-3-yl)[1,2,4]oxadiazol-5-yl]-3-nitrobenzene-1,2-diol
US10065944B2 (en) 2011-02-11 2018-09-04 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
US10357468B2 (en) 2014-11-28 2019-07-23 Bial—Portela & Ca, S.A. Medicaments for slowing Parkinson's disease
CN110095463A (zh) * 2019-03-15 2019-08-06 中国人民解放军陆军军医大学第二附属医院 一种乳糜定性检测的试剂盒
JP2019529579A (ja) * 2016-10-03 2019-10-17 シギロン セラピューティクス， インコーポレイテッドＳｉｇｉｌｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 化合物、デバイスおよびその使用
US10457659B2 (en) 2011-04-29 2019-10-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
CN111220737A (zh) * 2018-11-27 2020-06-02 罗欣药业(上海)有限公司 一种分离依折麦布及其光学异构体的方法
CN113661163A (zh) * 2019-02-28 2021-11-16 国立大学法人大阪大学 用于修饰蛋白质和/或肽的分子
US11291659B2 (en) 2017-10-05 2022-04-05 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
WO2022188792A1 (fr) * 2021-03-12 2022-09-15 四川科伦博泰生物医药股份有限公司 Composé hétérocyclique ayant une activité inhibitrice de protéine kinase, composition pharmaceutique le comprenant, son procédé de préparation et son utilisation
US11571429B2 (en) * 2017-05-23 2023-02-07 Upexmed Co. Ltd. Method and compounds for treating peripheral neuropathy
US11697666B2 (en) 2021-04-16 2023-07-11 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
US11767337B2 (en) 2020-02-18 2023-09-26 Gilead Sciences, Inc. Antiviral compounds
US12030903B2 (en) 2020-02-18 2024-07-09 Gilead Sciences, Inc. Antiviral compounds
US12054507B2 (en) 2020-02-18 2024-08-06 Gilead Sciences, Inc. Antiviral compounds
WO2024159284A1 (fr) * 2023-01-30 2024-08-08 Eurofarma Laboratórios S.A. Hydrazides inhibiteurs de nav 1.7 et/ou de nav 1.8, leurs procédés d'obtention, compositions, utilisations, méthodes de traitement et trousses
US12116380B2 (en) 2021-08-18 2024-10-15 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115089590B (zh) * 2022-06-13 2023-05-12 同济大学 环戊基三唑嘧啶类药物作为药物成分在肝炎药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6448274B2 (en) * 2000-05-25 2002-09-10 Merck Frosst Canada & Co. Fluoroalkoxy-substituted benzamide dichloropyridinyl N-oxide PDE4 inhibitor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6448274B2 (en) * 2000-05-25 2002-09-10 Merck Frosst Canada & Co. Fluoroalkoxy-substituted benzamide dichloropyridinyl N-oxide PDE4 inhibitor

Cited By (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168793B2 (en) 2005-07-26 2012-05-01 Portela & Ca., S.A. Nitrocatechol derivatives as COMT inhibitors
US9550759B2 (en) 2005-07-26 2017-01-24 Bial—Portela & Ca, S.A. Nitrocatechol derivatives as COMT inhibitors
US10336740B2 (en) 2005-07-26 2019-07-02 Bial—Portela & Ca, S.A. Nitrocatechol derivatives as COMT inhibitors
US8907099B2 (en) 2005-07-26 2014-12-09 Bial-Portela & Ca, S.A. Nitrocatechol derivatives as COMT inhibitors
US7608628B2 (en) 2005-12-12 2009-10-27 Astrazeneca Ab Alkylsulphonamide quinolines
US8071621B2 (en) 2005-12-12 2011-12-06 Astrazeneca Ab Alkylsulphonamide quinolines
US9446012B2 (en) 2006-04-10 2016-09-20 Bial—Portela & Ca, S.A. Pharmaceutical compounds
US8536203B2 (en) 2006-04-10 2013-09-17 Bial-Portela & Ca, S.A. Pharmaceutical compounds
US9745290B2 (en) 2007-01-31 2017-08-29 Bial—Portela & Ca, S.A. Dosage regimen for COMT inhibitors
US8524746B2 (en) 2007-01-31 2013-09-03 Bial-Portela & Ca., S.A. Dosage regimen for COMT inhibitors
US20150105456A1 (en) 2007-03-08 2015-04-16 The Board Of Trustees Of The Leland Stanford Junior University Mitochondrial Aldehyde Dehydrogenase-2 Modulators and Methods of Use Thereof
US9102651B2 (en) 2007-03-08 2015-08-11 The Board of Trustees-Leland Stanford Junior University Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
US9315484B2 (en) 2007-03-08 2016-04-19 The Board of Trustees—Leland Stanford Junior University Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
US8134007B2 (en) 2007-05-03 2012-03-13 Pfizer Inc. Pyridine derivatives
US8889665B2 (en) 2007-07-02 2014-11-18 Boehringer Ingelheim International Gmbh Chemical compounds
US9056849B2 (en) 2007-11-01 2015-06-16 Acucela Inc. Amine derivative compounds for treating ophthalmic diseases and disorders
US8716529B2 (en) 2007-11-01 2014-05-06 Acucela Inc. Amine derivative compounds for treating ophthalmic diseases and disorders
US8450527B2 (en) 2007-11-01 2013-05-28 Acucela Inc. Amine derivative compounds for treating ophthalmic diseases and disorders
US9452153B2 (en) 2007-11-01 2016-09-27 Acucela Inc. Amine derivative compounds for treating ophthalmic diseases and disorders
US8076516B2 (en) 2007-11-01 2011-12-13 Acucela, Inc. Amine derivative compounds for treating ophthalmic diseases and disorders
GB2455176A (en) * 2007-11-01 2009-06-03 Acucela Inc Amine derivatives useful for treating ophthalmic diseases and disorders
US9845316B2 (en) 2008-03-17 2017-12-19 BIAL—Portela & CA., S.A. Crystal forms of 5-[3-(2,5-dichloro-4, 6-dimethyl-1-oxy-pyridine-3-yl)[1,2,4]oxadiazol-5-yl]-3-nitrobenzene-1,2-diol
JP2011524365A (ja) * 2008-06-11 2011-09-01 アイアールエム・リミテッド・ライアビリティ・カンパニー マラリアの処置に有用な化合物および組成物
US9345693B2 (en) 2008-09-08 2016-05-24 The Board of Trustees-Leland Stanford Junior University Modulators of aldehyde dehydrogenase activity and methods of use thereof
US8906942B2 (en) 2008-09-08 2014-12-09 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldhehyde dehydrogenase activity and methods of use thereof
US8653087B2 (en) 2008-09-08 2014-02-18 Boehringer Ingelheim International Gmbh Pyrido [5, 4-D] pyrimidines as cell proliferation inhibitors
JP2012504114A (ja) * 2008-09-29 2012-02-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規化合物
CN102227421A (zh) * 2008-09-29 2011-10-26 贝林格尔.英格海姆国际有限公司 抗增殖化合物
US8778929B2 (en) 2008-09-29 2014-07-15 Boehringer Ingelheim International Gmbh Substituted heteroaryl inhibitors of B-RAF
WO2010034838A3 (fr) * 2008-09-29 2010-11-18 Boehringer Ingelheim International Gmbh Nouveaux composés chimiques
EP2349279A4 (fr) * 2008-10-28 2013-12-25 Univ Leland Stanford Junior Modulateurs d'aldéhyde déshydrogénase et procédés d'utilisation de ceux-ci
US8772295B2 (en) 2008-10-28 2014-07-08 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase and methods of use thereof
EP2349279A1 (fr) * 2008-10-28 2011-08-03 The Board of Trustees of The Leland Stanford Junior University Modulateurs d'aldéhyde déshydrogénase et procédés d'utilisation de ceux-ci
US9370506B2 (en) 2008-10-28 2016-06-21 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase and methods of use thereof
US9163017B2 (en) 2008-12-23 2015-10-20 Abbvie Inc. Anti-viral compounds
US9249138B2 (en) 2008-12-23 2016-02-02 Abbvie Inc. Anti-viral compounds
JP2012513409A (ja) * 2008-12-23 2012-06-14 アボット・ラボラトリーズ 抗ウイルス化合物
US8569316B2 (en) 2009-02-17 2013-10-29 Boehringer Ingelheim International Gmbh Pyrimido [5,4-D] pyrimidine derivatives for the inhibition of tyrosine kinases
WO2010094695A1 (fr) 2009-02-17 2010-08-26 Boehringer Ingelheim International Gmbh Dérivés pyrimido-[5,4-d]-pyrimidine pour l'inhibition des tyrosine-kinases
US9132094B2 (en) 2009-04-01 2015-09-15 Bial—Portela & Ca, S.A. Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making thereof
US10583130B2 (en) 2009-04-01 2020-03-10 Bial-Portela & Ca, S.A. Pharmaceutical formulations compromising nitrocatechol derivatives and methods of making thereof
US10071085B2 (en) 2009-04-01 2018-09-11 Bial—Portela & Ca, S.A. Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making thereof
US9278922B2 (en) 2009-04-15 2016-03-08 Abbvie Inc. Anti-viral compounds
KR101761715B1 (ko) 2009-12-08 2017-07-26 꼼미사리아 아 레네르지 아또미끄 에 오 에네르지 알떼르나띠브스 1종 이상의 금속 원소가 착화될 수 있는 트리아졸기에 기초한 화합물 및 이 화합물에 기초한 배위 착물
US9290507B2 (en) 2010-03-26 2016-03-22 Boehringer Ingelheim International Gmbh B-RAF kinase inhibitors
JP2013523615A (ja) * 2010-03-26 2013-06-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ピリジルトリアゾール
US8865703B2 (en) 2010-03-26 2014-10-21 Boehringer Ingelheim International Gmbh Pyridyltriazoles
WO2011117382A1 (fr) 2010-03-26 2011-09-29 Boehringer Ingelheim International Gmbh Pyridyltriazoles
WO2011117381A1 (fr) 2010-03-26 2011-09-29 Boehringer Ingelheim International Gmbh Inhibiteurs de kinase b-raf
WO2012008549A1 (fr) * 2010-07-15 2012-01-19 武田薬品工業株式会社 Composé hétérocyclique
JPWO2012008549A1 (ja) * 2010-07-15 2013-09-09 武田薬品工業株式会社 複素環化合物
US8937055B2 (en) 2010-07-15 2015-01-20 Takeda Pharmaceutical Company Limited Heterocyclic ring compound having muscle cell or adipocyte differentiation regulating action
JP2013539775A (ja) * 2010-10-15 2013-10-28 エフ．ホフマン−ラ ロシュ アーゲー Ｎ−ピリジン−３−イル又はｎ−ピラジン−２−イルカルボキサミド類
US8710055B2 (en) 2010-12-21 2014-04-29 Boehringer Ingelheim International Gmbh Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors
US12129247B2 (en) 2011-02-11 2024-10-29 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
US10065944B2 (en) 2011-02-11 2018-09-04 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
US10457659B2 (en) 2011-04-29 2019-10-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
US9630955B2 (en) 2011-12-13 2017-04-25 BIAL—Portela & Cª., S.A Chemical compound useful as intermediate for preparing a catechol-O-methyltransferase inhibitor
JP2016502975A (ja) * 2012-12-10 2016-02-01 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ＲＯＲｃモジュレーターとしてのベンジルスルホンアミド誘導体
US10227304B2 (en) 2013-03-14 2019-03-12 The Board Of Trustees Of The Leland Stanford Junior University Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
US9670162B2 (en) 2013-03-14 2017-06-06 The Board Of Trustees Of The Leland Stanford Junio Mitochondrial aldehyde dehyrogenase-2 modulators and methods of use thereof
US9296754B2 (en) 2013-03-15 2016-03-29 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
US9186361B2 (en) 2013-03-15 2015-11-17 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
US9233961B2 (en) 2013-03-15 2016-01-12 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
US9475773B2 (en) 2013-04-19 2016-10-25 Astrazeneca Ab NK3 receptor antagonist compound (NK3RA) for use in a method for the treatment of polycystic ovary syndrome (PCOS)
US10596175B2 (en) 2013-12-19 2020-03-24 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
US11123348B2 (en) 2013-12-19 2021-09-21 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
US10085989B2 (en) 2013-12-19 2018-10-02 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
US9700559B2 (en) 2013-12-19 2017-07-11 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
US9303034B2 (en) 2013-12-19 2016-04-05 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
CN105873438A (zh) * 2014-01-31 2016-08-17 日产化学工业株式会社 液体农药组合物
US10357468B2 (en) 2014-11-28 2019-07-23 Bial—Portela & Ca, S.A. Medicaments for slowing Parkinson's disease
CN104926738B (zh) * 2015-06-08 2017-05-24 南京农业大学 一类1,2,3‑三唑‑4‑酰肼衍生物在制备农用杀菌剂中的应用
CN104926738A (zh) * 2015-06-08 2015-09-23 南京农业大学 一类1,2,3-三唑-4-酰肼衍生物在制备农用杀菌剂中的应用
WO2017108737A1 (fr) 2015-12-23 2017-06-29 Chiesi Farmaceutici S.P.A. Dérivés de 1-(3-tert-butyl-phényl)-3-(4-([1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tétrahydro-naphthalèn-1-yl)-urée et leur utilisation en tant qu'inhibiteur de p38 mapk
US10988461B2 (en) 2016-03-03 2021-04-27 Cornell University Small molecule IRE1-α inhibitors
WO2017152117A1 (fr) * 2016-03-03 2017-09-08 Cornell University Inhibiteurs ire1-alpha à petites molécules
US10125123B2 (en) 2016-03-03 2018-11-13 Cornell University Small molecule IRE1-α inhibitors
JP2019529579A (ja) * 2016-10-03 2019-10-17 シギロン セラピューティクス， インコーポレイテッドＳｉｇｉｌｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 化合物、デバイスおよびその使用
US11945786B2 (en) 2016-10-03 2024-04-02 Sigilon Therapeutics, Inc. Compounds, devices, and uses thereof
US11571429B2 (en) * 2017-05-23 2023-02-07 Upexmed Co. Ltd. Method and compounds for treating peripheral neuropathy
US10537560B2 (en) 2017-10-05 2020-01-21 Fulcrum Therapeutics. Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
US11291659B2 (en) 2017-10-05 2022-04-05 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
US11479770B2 (en) 2017-10-05 2022-10-25 Fulcrum Therapeutics, Inc. Use of p38 inhibitors to reduce expression of DUX4
CN111220737A (zh) * 2018-11-27 2020-06-02 罗欣药业(上海)有限公司 一种分离依折麦布及其光学异构体的方法
CN113661163A (zh) * 2019-02-28 2021-11-16 国立大学法人大阪大学 用于修饰蛋白质和/或肽的分子
EP3932912A4 (fr) * 2019-02-28 2022-09-07 Osaka University Molécule pour modification par une protéine et/ou un peptide
CN110095463A (zh) * 2019-03-15 2019-08-06 中国人民解放军陆军军医大学第二附属医院 一种乳糜定性检测的试剂盒
CN110095463B (zh) * 2019-03-15 2021-10-22 中国人民解放军陆军军医大学第二附属医院 一种乳糜定性检测的试剂盒
US11767337B2 (en) 2020-02-18 2023-09-26 Gilead Sciences, Inc. Antiviral compounds
US12030903B2 (en) 2020-02-18 2024-07-09 Gilead Sciences, Inc. Antiviral compounds
US12054507B2 (en) 2020-02-18 2024-08-06 Gilead Sciences, Inc. Antiviral compounds
WO2022188792A1 (fr) * 2021-03-12 2022-09-15 四川科伦博泰生物医药股份有限公司 Composé hétérocyclique ayant une activité inhibitrice de protéine kinase, composition pharmaceutique le comprenant, son procédé de préparation et son utilisation
US11697666B2 (en) 2021-04-16 2023-07-11 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
US12116380B2 (en) 2021-08-18 2024-10-15 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
WO2024159284A1 (fr) * 2023-01-30 2024-08-08 Eurofarma Laboratórios S.A. Hydrazides inhibiteurs de nav 1.7 et/ou de nav 1.8, leurs procédés d'obtention, compositions, utilisations, méthodes de traitement et trousses

Also Published As

Publication number Publication date
CL2007002375A1 (es) 2008-04-04
PE20080906A1 (es) 2008-07-05
TW200815422A (en) 2008-04-01
AR062427A1 (es) 2008-11-05

Similar Documents

Publication Publication Date Title
WO2008021388A1 (fr) Dérivés hétéroaryles en tant qu'inhibiteurs des cytokines
WO2007075896A2 (fr) Inhibiteurs de cytokine heterocycliques
WO2007056016A2 (fr) Inhibiteurs de cytokine bisamide
WO2008089034A2 (fr) Inhibiteurs de cytokine
US10822343B2 (en) Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor4 (PAR4) inhibitors for treating platelet aggregation
US9896452B2 (en) Substituted prolines/piperidines as orexin receptor antagonists
CA2722075C (fr) Inhibiteur d'enzyme d'allongement d'acide gras a longue chaine incluant un derive arylsulfonyle en tant que principe actif
WO2006091862A2 (fr) Inhibiteurs des cytokines et utilisation therapeutique
CN112384500B (zh) 免疫调节剂及其组合物和制备方法
EP2035005A2 (fr) Thérapie à base d'inhibiteurs de cytokine
TW200815412A (en) A pharmaceutical combination comprising 3-or 4-monosubstituted phenol and thiophenol derivatives
WO2004037817A1 (fr) Composes de n-oxyde
EA021938B1 (ru) Хинолины и их аналоги в качестве модуляторов сиртуина
EP1765327A2 (fr) Composes, compositions et procedes associes
EA011439B1 (ru) Конденсированные производные пиримидина и их композиции, применимые в качестве модуляторов cxcr3 рецепторов для профилактики и лечения воспалительных и иммунорегуляторных расстройств и заболеваний
CN102417508A (zh) 作为新陈代谢调节剂的稠合芳基和杂芳基衍生物以及预防和治疗与其相关的病症
WO2015123355A1 (fr) Prolines/pipéridines substituées en tant qu'antagonistes du récepteur de l'orexine
US9085570B2 (en) Substituted benzamides and their uses
US9440982B2 (en) Substituted prolines/piperidines as orexin receptor antagonists
CA3172387A1 (fr) Composes a base d'indazole et procedes d'utilisation associes
JPWO2004069798A1 (ja) ピペリジン誘導体を有効成分とするメラニン凝集ホルモン受容体拮抗剤
MX2014015691A (es) Derivados de 1- [m-carboxamido (hetero) aril-metil]-heterociclil-c arboxamida.
WO2019133445A1 (fr) Aminothiazoles utilisés en tant qu'inhibiteurs de vanin-1
US9446047B2 (en) Substituted 2,3-dihydro-1H-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis
CN102690278B (zh) 新颖嘧啶并环化合物作为细胞因子抑制剂

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07811340

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC

122 Ep: pct application non-entry in european phase

Ref document number: 07811340

Country of ref document: EP

Kind code of ref document: A1